1	Th	NN	O	th	npadvmod	19	SENT_1	[p1l672t81r703b102],
2	e	SYM	O	e	dep	11	SENT_1	[p1l709t88r718b102],
3	N	NN	O	n	nn	11	SENT_1	[p1l736t83r759b102],
4	E	NN	O	e	nn	11	SENT_1	[p1l768t83r785b102],
5	W	NN	O	w	nn	11	SENT_1	[p1l791t83r821b102],
6	E	NN	O	e	nn	11	SENT_1	[p1l840t83r857b102],
7	N	NN	O	n	nn	11	SENT_1	[p1l865t83r889b102],
8	G	NN	O	g	nn	11	SENT_1	[p1l896t83r918b102],
9	L	NN	O	l	nn	11	SENT_1	[p1l924t83r941b102],
10	A	NN	O	a	nn	11	SENT_1	[p1l947t83r968b102],
11	ND	NN	O	nd	dep	1	SENT_1	[p1l975t83r1060b109],
12	]	CD	NUMBER	]	num	13	SENT_1	[p1l975t83r1060b109],
13	O	NN	O	o	dep	11	SENT_1	[p1l1067t83r1088b102],
14	U	NNP	O	U	nn	18	SENT_1	[p1l1095t83r1117b102],
15	R	NNP	O	R	nn	18	SENT_1	[p1l1125t83r1146b102],
16	N	NNP	O	N	nn	18	SENT_1	[p1l1154t83r1177b102],
17	A	NNP	O	A	nn	18	SENT_1	[p1l1183t83r1203b102],
18	L	NN	O	l	dep	13	SENT_1	[p1l1211t83r1227b102],
19	of	IN	O	of	dep	23	SENT_1	[p1l1247t81r1275b108],
20	M	NN	O	m	nn	22	SENT_1	[p1l1287t83r1314b102],
21	E	NN	O	e	nn	22	SENT_1	[p1l1322t83r1339b102],
22	D	NN	O	d	pobj	19	SENT_1	[p1l1347t83r1368b102],
23	I	PRP	O	I	_	0	SENT_1	[p1l1376t83r1386b102],
24	C	NN	O	c	prep	23	SENT_1	[p1l1393t83r1411b102],
25	I	PRP	O	I	dep	26	SENT_1	[p1l1419t83r1429b102],
26	NE	NNS	O	ne	dep	24	SENT_1	[p1l1437t83r1486b102],

1	|	RB	O	|	dep	2	SENT_2	[p1l235t184r238b384],
2	CORRESPONDENCE	NNP	O	CORRESPONDENCE	_	0	SENT_2	[p1l762t257r1397b289],
3	|	IN	O	|	dep	2	SENT_2	[p1l1921t184r1924b384],

1	Treatment	NN	O	treatment	_	0	SENT_3	[p1l728t632r1005b676],
2	of	IN	O	of	_	0	SENT_3	[p1l1024t627r1084b676],
3	Lung	NN	O	lung	nn	4	SENT_3	[p1l1098t632r1227b691],
4	Cancer	NN	O	cancer	prep_of	1	SENT_3	[p1l1246t632r1431b676],

1	To	TO	O	to	dep	20	SENT_4	[p1l9t872r121b927],
2	THE	DT	O	the	det	3	SENT_4	[p1l154t873r318b927],
3	EDITOR	NN	O	editor	pobj	1	SENT_4	[p1l359t872r695b928],
4	:	:	O	:	_	0	SENT_4	[p1l359t872r695b928],
5	In	IN	O	in	_	0	SENT_4	[p1l733t857r821b927],
6	the	DT	O	the	det	7	SENT_4	[p1l858t849r991b928],
7	study	NN	O	study	prep_in	20	SENT_4	[p1l1029t849r1258b950],
8	by	IN	O	by	_	0	SENT_4	[p1l1291t849r1388b950],
9	Mok	NNP	PERSON	Mok	nn	13	SENT_4	[p1l1417t849r1613b928],
10	et	FW	O	et	nn	13	SENT_4	[p1l1645t866r1722b928],
11	al.	FW	O	al.	nn	13	SENT_4	[p1l1752t849r1849b928],
12	(	FW	O	(	nn	13	SENT_4	[p1l1896t855r2128b950],
13	Sept.	NNP	DATE	Sept.	prep_by	7	SENT_4	[p1l1896t855r2128b950],
14	3	CD	DATE	3	num	15	SENT_4	[p1l12t983r56b1056],
15	issue	NN	O	issue	dep	7	SENT_4	[p1l95t978r396b1073],
16	)	CD	NUMBER	)	number	17	SENT_4	[p1l95t978r396b1073],
17	,1	CD	NUMBER	,1	dep	15	SENT_4	[p1l95t978r396b1073],
18	the	DT	O	the	det	19	SENT_4	[p1l434t977r566b1056],
19	authors	NNS	O	author	nsubj	20	SENT_4	[p1l602t977r924b1056],
20	state	VBP	O	state	_	0	SENT_4	[p1l964t994r1162b1056],
21	that	IN	O	that	complm	24	SENT_4	[p1l1199t977r1371b1056],
22	gefitinib	NN	O	gefitinib	nsubj	24	SENT_4	[p1l1402t977r1774b1078],
23	was	VBD	O	be	cop	24	SENT_4	[p1l1807t1004r1969b1056],
24	superior	JJ	O	superior	ccomp	20	SENT_4	[p1l2009t1004r2132b1056, p1l10t1106r266b1206],
25	to	TO	O	to	_	0	SENT_4	[p1l297t1122r377b1184],
26	carboplatin	NN	O	carboplatin	nn	28	SENT_4	[p1l413t1105r1373b1206],
27	—	CD	NUMBER	—	num	28	SENT_4	[p1l413t1105r1373b1206],
28	paclitaXel	NN	O	paclitaxel	prep_to	24	SENT_4	[p1l413t1105r1373b1206],
29	,	,	O	,	_	0	SENT_4	[p1l413t1105r1373b1206],
30	despite	IN	O	despite	_	0	SENT_4	[p1l1413t1105r1706b1206],
31	a	DT	O	a	det	36	SENT_4	[p1l1739t1132r1783b1184],
32	median	JJ	O	median	amod	36	SENT_4	[p1l1815t1105r2133b1184],
33	progression	NN	O	progression	nn	36	SENT_4	[p1l10t1233r718b1334],
34	—	CD	NUMBER	—	num	36	SENT_4	[p1l10t1233r718b1334],
35	free	JJ	O	free	amod	36	SENT_4	[p1l10t1233r718b1334],
36	survival	NN	O	survival	prep_despite	24	SENT_4	[p1l754t1233r1086b1312],
37	(	IN	O	(	_	0	SENT_4	[p1l1124t1233r1282b1325],
38	the	DT	O	the	det	42	SENT_4	[p1l1124t1233r1282b1325],
39	main	JJ	O	main	amod	42	SENT_4	[p1l1316t1234r1538b1312],
40	end	NN	O	end	nn	42	SENT_4	[p1l1573t1233r1726b1312],
41	point	NN	O	point	nn	42	SENT_4	[p1l1759t1234r2011b1334],
42	)	NN	O	)	prep_(	36	SENT_4	[p1l1759t1234r2011b1334],
43	of	IN	O	of	_	0	SENT_4	[p1l2052t1233r2152b1312],
44	5.7	CD	DURATION	5.7	num	45	SENT_4	[p1l13t1369r134b1440],
45	months	NNS	NUMBER	month	prep_of	42	SENT_4	[p1l182t1361r509b1440],
46	and	CC	O	and	_	0	SENT_4	[p1l558t1361r715b1440],
47	5.8	CD	DURATION	5.8	num	48	SENT_4	[p1l765t1367r888b1440],
48	months	NNS	NUMBER	month	prep_of	42	SENT_4	[p1l937t1361r1289b1457],
49	,	,	O	,	_	0	SENT_4	[p1l937t1361r1289b1457],
50	respectively	RB	O	respectively	advmod	24	SENT_4	[p1l1342t1361r1855b1462],
51	.	.	O	.	_	0	SENT_4	[p1l1342t1361r1855b1462],

1	Their	PRP$	O	they	poss	2	SENT_5	[p1l1904t1361r2136b1440],
2	conclusion	NN	O	conclusion	nsubjpass	4	SENT_5	[p1l12t1489r473b1568],
3	was	VBD	O	be	auxpass	4	SENT_5	[p1l499t1516r661b1568],
4	based	VBN	O	base	ccomp	57	SENT_5	[p1l696t1489r940b1568],
5	on	IN	O	on	_	0	SENT_5	[p1l972t1515r1078b1568],
6	a	DT	O	a	det	7	SENT_5	[p1l1108t1516r1153b1568],
7	comparison	NN	O	comparison	prep_on	4	SENT_5	[p1l1183t1490r1693b1590],
8	of	IN	O	of	_	0	SENT_5	[p1l1724t1489r1824b1568],
9	the	DT	O	the	det	11	SENT_5	[p1l1837t1489r1970b1568],
10	12month	JJ	O	12month	amod	11	SENT_5	[p1l2005t1495r2132b1567, p1l11t1617r290b1696],
11	rates	NNS	O	rate	prep_of	7	SENT_5	[p1l318t1634r514b1696],
12	of	IN	O	of	_	0	SENT_5	[p1l544t1617r643b1696],
13	progression	NN	O	progression	prep_of	11	SENT_5	[p1l650t1617r1336b1718],
14	—	CD	NUMBER	—	num	16	SENT_5	[p1l650t1617r1336b1718],
15	free	JJ	O	free	amod	16	SENT_5	[p1l650t1617r1336b1718],
16	survival	NN	O	survival	dobj	4	SENT_5	[p1l1365t1617r1685b1696],
17	(	CD	PERCENT	(	number	18	SENT_5	[p1l1717t1623r1999b1709],
18	24.9	CD	PERCENT	24.9	num	19	SENT_5	[p1l1717t1623r1999b1709],
19	%	NN	PERCENT	%	dep	16	SENT_5	[p1l1717t1623r1999b1709],
20	vs.	CC	O	vs.	_	0	SENT_5	[p1l2022t1644r2128b1696],
21	6.7	CD	PERCENT	6.7	num	22	SENT_5	[p1l12t1750r270b1841],
22	%	NN	PERCENT	%	dobj	4	SENT_5	[p1l12t1750r270b1841],
23	)	CD	NUMBER	)	dep	22	SENT_5	[p1l12t1750r270b1841],
24	,	,	O	,	_	0	SENT_5	[p1l12t1750r270b1841],
25	but	CC	O	but	_	0	SENT_5	[p1l312t1745r452b1824],
26	this	DT	O	this	det	27	SENT_5	[p1l482t1745r642b1824],
27	comparison	NN	O	comparison	nsubjpass	30	SENT_5	[p1l680t1746r1190b1846],
28	was	VBD	O	be	auxpass	30	SENT_5	[p1l1220t1772r1382b1824],
29	not	RB	O	not	neg	30	SENT_5	[p1l1420t1762r1563b1824],
30	planned	VBN	O	plan	ccomp	57	SENT_5	[p1l1591t1745r1941b1846],
31	and	CC	O	and	_	0	SENT_5	[p1l1975t1745r2133b1824],
32	its	PRP$	O	its	poss	33	SENT_5	[p1l11t1874r109b1952],
33	results	NNS	O	result	nsubj	35	SENT_5	[p1l144t1873r426b1952],
34	strictly	RB	O	strictly	advmod	35	SENT_5	[p1l463t1873r759b1974],
35	depended	VBD	O	depend	ccomp	57	SENT_5	[p1l789t1873r1202b1974],
36	on	IN	O	on	_	0	SENT_5	[p1l1236t1899r1342b1952],
37	the	DT	O	the	det	38	SENT_5	[p1l1375t1873r1507b1952],
38	time	NN	O	time	prep_on	35	SENT_5	[p1l1542t1874r1734b1952],
39	of	IN	O	of	_	0	SENT_5	[p1l1769t1873r1868b1952],
40	evaluation	NN	O	evaluation	prep_of	38	SENT_5	[p1l1883t1873r2132b1952, p1l11t2002r228b2080],
41	(	CD	NUMBER	(	num	40	SENT_5	[p1l266t2008r460b2102],
42	e.g.	FW	O	e.g.	dobj	35	SENT_5	[p1l266t2008r460b2102],
43	,	,	O	,	_	0	SENT_5	[p1l266t2008r460b2102],
44	in	IN	O	in	_	0	SENT_5	[p1l498t2002r581b2079],
45	a	DT	O	a	det	46	SENT_5	[p1l614t2028r659b2080],
46	comparison	NN	O	comparison	prep_in	35	SENT_5	[p1l692t2002r1201b2102],
47	of	IN	O	of	_	0	SENT_5	[p1l1235t2001r1335b2080],
48	rates	NNS	O	rate	prep_of	46	SENT_5	[p1l1350t2018r1552b2080],
49	at	IN	O	at	_	0	SENT_5	[p1l1588t2018r1667b2080],
50	4	CD	DURATION	4	num	51	SENT_5	[p1l1694t2007r1743b2080],
51	months	NNS	NUMBER	month	prep_at	35	SENT_5	[p1l1776t2001r2128b2097],
52	,	,	O	,	_	0	SENT_5	[p1l1776t2001r2128b2097],
53	the	DT	O	the	det	54	SENT_5	[p1l12t2129r142b2208],
54	result	NN	O	result	nsubj	57	SENT_5	[p1l169t2129r407b2208],
55	would	MD	O	would	aux	57	SENT_5	[p1l424t2129r685b2208],
56	have	VB	O	have	aux	57	SENT_5	[p1l711t2129r898b2208],
57	been	VBN	O	be	_	0	SENT_5	[p1l925t2129r1123b2208],
58	in	IN	O	in	_	0	SENT_5	[p1l1150t2130r1231b2207],
59	favor	NN	O	favor	prep_in	57	SENT_5	[p1l1258t2129r1467b2208],
60	of	IN	O	of	_	0	SENT_5	[p1l1491t2129r1590b2208],
61	carboplatin	NN	O	carboplatin	nn	64	SENT_5	[p1l1599t2129r2137b2230],
62	—	CD	NUMBER	—	num	64	SENT_5	[p1l1599t2129r2137b2230],
63	paclitaxel	NN	O	paclitaxel	nn	64	SENT_5	[p1l10t2257r474b2358],
64	)	NN	O	)	prep_of	59	SENT_5	[p1l10t2257r474b2358],
65	.	.	O	.	_	0	SENT_5	[p1l10t2257r474b2358],

1	Furthermore	RB	O	furthermore	advmod	20	SENT_6	[p1l138t2385r710b2481],
2	,	,	O	,	_	0	SENT_6	[p1l138t2385r710b2481],
3	the	DT	O	the	det	4	SENT_6	[p1l768t2385r900b2464],
4	validity	NN	O	validity	nsubjpass	20	SENT_6	[p1l947t2385r1266b2486],
5	of	IN	O	of	_	0	SENT_6	[p1l1313t2385r1413b2464],
6	the	DT	O	the	det	7	SENT_6	[p1l1446t2385r1578b2464],
7	results	NNS	O	result	prep_of	4	SENT_6	[p1l1630t2385r1912b2464],
8	that	WDT	O	that	nsubjpass	10	SENT_6	[p1l1966t2385r2138b2464],
9	were	VBD	O	be	auxpass	10	SENT_6	[p1l7t2540r205b2593],
10	achieved	VBN	O	achieve	rcmod	7	SENT_6	[p1l238t2513r598b2592],
11	with	IN	O	with	_	0	SENT_6	[p1l626t2513r817b2592],
12	the	DT	O	the	det	13	SENT_6	[p1l851t2513r981b2592],
13	use	NN	O	use	prep_with	10	SENT_6	[p1l1014t2540r1153b2592],
14	of	IN	O	of	_	0	SENT_6	[p1l1187t2513r1285b2592],
15	a	DT	O	a	det	18	SENT_6	[p1l1299t2540r1344b2592],
16	Cox	NN	ORGANIZATION	cox	nn	18	SENT_6	[p1l1375t2519r1537b2592],
17	proportionalhazards	NNS	O	proportionalhazard	nn	18	SENT_6	[p1l1565t2513r2132b2614, p1l11t2641r349b2720],
18	model	NN	O	model	prep_of	13	SENT_6	[p1l400t2641r668b2720],
19	was	VBD	O	be	auxpass	20	SENT_6	[p1l711t2668r874b2720],
20	conditioned	VBN	O	condition	_	0	SENT_6	[p1l926t2641r1438b2720],
21	by	IN	O	by	_	0	SENT_6	[p1l1487t2641r1585b2742],
22	the	DT	O	the	det	24	SENT_6	[p1l1629t2641r1761b2720],
23	proportional	JJ	O	proportional	amod	24	SENT_6	[p1l1810t2667r2132b2742, p1l12t2769r261b2848],
24	hazard	NN	O	hazard	agent	20	SENT_6	[p1l304t2769r624b2848],
25	:	:	O	:	_	0	SENT_6	[p1l304t2769r624b2848],
26	this	DT	O	this	det	27	SENT_6	[p1l672t2769r832b2848],
27	assumption	NN	O	assumption	nsubjpass	30	SENT_6	[p1l877t2770r1381b2870],
28	was	VBD	O	be	auxpass	30	SENT_6	[p1l1421t2796r1583b2848],
29	not	RB	O	not	neg	30	SENT_6	[p1l1629t2786r1772b2848],
30	verified	VBN	O	verify	parataxis	20	SENT_6	[p1l1806t2769r2134b2848],
31	nor	CC	O	nor	_	0	SENT_6	[p1l11t2923r157b2976],
32	were	VBD	O	be	parataxis	20	SENT_6	[p1l208t2924r410b2976],
33	the	DT	O	the	det	34	SENT_6	[p1l469t2897r602b2976],
34	results	NNS	O	result	nsubj	35	SENT_6	[p1l660t2897r942b2976],
35	reported	VBD	O	report	ccomp	32	SENT_6	[p1l1003t2897r1392b2998],
36	.	.	O	.	_	0	SENT_6	[p1l1003t2897r1392b2998],

1	The	DT	O	the	det	2	SENT_7	[p1l1453t2897r1613b2976],
2	conclusion	NN	O	conclusion	nsubj	19	SENT_7	[p1l1673t2897r2133b2976],
3	that	IN	O	that	complm	12	SENT_7	[p1l12t3025r187b3104],
4	6	CD	DURATION	6	number	6	SENT_7	[p1l235t3031r282b3104],
5	to	TO	DURATION	to	dep	6	SENT_7	[p1l336t3042r419b3104],
6	22	CD	DURATION	22	num	7	SENT_7	[p1l472t3031r574b3103],
7	months	NNS	NUMBER	month	nsubj	12	SENT_7	[p1l628t3025r960b3104],
8	of	IN	O	of	_	0	SENT_7	[p1l1016t3025r1117b3104],
9	gefitinib	NN	O	gefitinib	nn	10	SENT_7	[p1l1151t3025r1531b3126],
10	treatment	NN	O	treatment	prep_of	7	SENT_7	[p1l1586t3042r2018b3104],
11	is	VBZ	O	be	cop	12	SENT_7	[p1l2065t3026r2132b3104],
12	superior	JJ	O	superior	dep	2	SENT_7	[p1l13t3154r375b3254],
13	to	TO	O	to	_	0	SENT_7	[p1l413t3170r496b3232],
14	carboplatin	NN	O	carboplatin	nn	16	SENT_7	[p1l538t3153r1521b3254],
15	—	CD	NUMBER	—	num	16	SENT_7	[p1l538t3153r1521b3254],
16	paclitaXel	NN	O	paclitaxel	prep_to	12	SENT_7	[p1l538t3153r1521b3254],
17	could	MD	O	could	aux	19	SENT_7	[p1l1563t3153r1801b3232],
18	be	VB	O	be	cop	19	SENT_7	[p1l1843t3153r1941b3232],
19	due	JJ	O	due	_	0	SENT_7	[p1l1983t3153r2133b3232],
20	to	TO	O	to	_	0	SENT_7	[p1l12t3299r92b3361],
21	a	DT	O	a	det	23	SENT_7	[p1l133t3309r177b3361],
22	selection	NN	O	selection	nn	23	SENT_7	[p1l217t3282r595b3361],
23	effect	NN	O	effect	prep_to	19	SENT_7	[p1l635t3282r898b3361],
24	.	.	O	.	_	0	SENT_7	[p1l635t3282r898b3361],

1	Enzo	NNP	PERSON	Enzo	nn	2	SENT_8	[p1l20t3427r226b3499],
2	Ballatori	NNP	PERSON	Ballatori	_	0	SENT_8	[p1l267t3419r646b3513],
3	,	,	O	,	_	0	SENT_8	[p1l267t3419r646b3513],
4	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_8	[p1l690t3419r919b3499],
5	.	.	O	.	_	0	SENT_8	[p1l690t3419r919b3499],

1	Via	NNP	O	Via	nn	4	SENT_9	[p1l8t3573r111b3628],
2	Pillino	NNP	O	Pillino	nn	4	SENT_9	[p1l142t3567r344b3628],
3	2	CD	NUMBER	2	num	4	SENT_9	[p1l369t3573r402b3627],
4	Spinetoli	NNP	LOCATION	Spinetoli	_	0	SENT_9	[p1l12t3654r325b3733],
5	,	,	O	,	_	0	SENT_9	[p1l12t3654r325b3733],
6	Italy	NNP	LOCATION	Italy	appos	4	SENT_9	[p1l358t3654r492b3734],

1	Sonia	NNP	PERSON	Sonia	nn	2	SENT_10	[p2l13t36r253b109],
2	Fatigoni	NNP	PERSON	Fatigoni	_	0	SENT_10	[p2l295t37r666b135],
3	,	,	O	,	_	0	SENT_10	[p2l295t37r666b135],
4	M.D.	NNP	PERSON	M.D.	nn	8	SENT_10	[p2l711t37r917b109],
5	Fausto	NNP	PERSON	Fausto	nn	8	SENT_10	[p2l20t165r307b238],
6	Roila	NNP	PERSON	Roila	nn	8	SENT_10	[p2l349t158r579b252],
7	,	,	O	,	_	0	SENT_10	[p2l349t158r579b252],
8	M.D.	NNP	O	M.D.	appos	2	SENT_10	[p2l624t165r829b238],

1	Santa	NNP	LOCATION	Santa	nn	6	SENT_11	[p2l12t299r197b355],
2	Maria	NNP	LOCATION	Maria	nn	6	SENT_11	[p2l227t300r412b355],
3	Hospital	NNP	LOCATION	Hospital	nn	6	SENT_11	[p2l443t294r722b373],
4	Terni	NNP	LOCATION	Terni	nn	6	SENT_11	[p2l8t382r194b447],
5	,	,	O	,	_	0	SENT_11	[p2l8t382r194b447],
6	Italy	NNP	LOCATION	Italy	_	0	SENT_11	[p2l227t376r362b456],
7	roi	NN	O	rous	nn	10	SENT_11	[p2l15t462r732b536],
8	|	CD	NUMBER	|	num	10	SENT_11	[p2l15t462r732b536],
9	a.	NN	O	a.	nn	10	SENT_11	[p2l15t462r732b536],
10	fausto	NN	O	fausto	dep	6	SENT_11	[p2l15t462r732b536],
11	@	IN	O	@	_	0	SENT_11	[p2l15t462r732b536],
12	|	CD	NUMBER	|	num	13	SENT_11	[p2l15t462r732b536],
13	ibero	NN	O	ibero	prep_@	10	SENT_11	[p2l15t462r732b536],
14	.	.	O	.	_	0	SENT_11	[p2l15t462r732b536],

1	it	PRP	O	it	nsubj	2	SENT_12	[p2l15t462r732b536],
2	1	LS	NUMBER	1	_	0	SENT_12	[p2l13t567r61b617],
3	.	.	O	.	_	0	SENT_12	[p2l13t567r61b617],

1	Mok	NN	O	mok	nn	2	SENT_13	[p2l137t559r286b618],
2	TS	NN	O	t	_	0	SENT_13	[p2l310t564r412b630],
3	,	,	O	,	_	0	SENT_13	[p2l310t564r412b630],
4	Wu	NNP	O	Wu	nn	5	SENT_13	[p2l444t564r553b618],
5	Y	NN	O	y	appos	2	SENT_13	[p2l581t564r701b630],
6	.	.	O	.	_	0	SENT_13	[p2l581t564r701b630],

1	—	NN	O	—	_	0	SENT_14	[p2l581t564r701b630],
2	.	.	O	.	_	0	SENT_14	[p2l581t564r701b630],

1	L	NN	O	l	_	0	SENT_15	[p2l581t564r701b630],
2	,	,	O	,	_	0	SENT_15	[p2l581t564r701b630],
3	Thongprasert	NNP	O	Thongprasert	nn	4	SENT_15	[p2l733t559r1186b635],
4	S	NNP	O	S	appos	1	SENT_15	[p2l1214t564r1265b630],
5	,	,	O	,	_	0	SENT_15	[p2l1214t564r1265b630],
6	et	FW	O	et	nn	7	SENT_15	[p2l1300t572r1359b617],
7	al.	FW	O	al.	appos	4	SENT_15	[p2l1386t559r1460b618],
8	.	.	O	.	_	0	SENT_15	[p2l1386t559r1460b618],

1	Gefitinib	NN	O	gefitinib	_	0	SENT_16	[p2l1494t559r1796b618],
2	or	CC	O	or	_	0	SENT_16	[p2l1828t578r1895b618],
3	carboplatin-paclitaxel	NN	O	carboplatin-paclitaxel	conj_or	1	SENT_16	[p2l1924t559r2133b618, p2l9t644r561b719],
4	in	IN	O	in	_	0	SENT_16	[p2l592t645r656b702],
5	pulmonary	JJ	O	pulmonary	amod	6	SENT_16	[p2l686t644r1052b719],
6	adenocarcinoma	NN	O	adenocarcinoma	prep_in	1	SENT_16	[p2l1080t644r1644b703],
7	.	.	O	.	_	0	SENT_16	[p2l1080t644r1644b703],

1	N	NN	O	n	nn	3	SENT_17	[p2l1679t649r1734b703],
2	Engl	NNP	O	Engl	nn	3	SENT_17	[p2l1765t644r1912b720],
3	J	NNP	O	J	nsubj	4	SENT_17	[p2l1936t649r1965b712],
4	Med	VBD	O	med	_	0	SENT_17	[p2l1993t644r2134b703],
5	2009	CD	DATE	2009	dobj	4	SENT_17	[p2l11t743r555b809],
6	;	:	O	;	_	0	SENT_17	[p2l11t743r555b809],
7	361:947	CD	NUMBER	361:947	number	8	SENT_17	[p2l11t743r555b809],
8	—	CD	NUMBER	—	dep	5	SENT_17	[p2l11t743r555b809],
9	57	CD	NUMBER	57	dep	8	SENT_17	[p2l11t743r555b809],
10	.	.	O	.	_	0	SENT_17	[p2l11t743r555b809],

1	To	TO	O	to	_	0	SENT_18	[p2l9t999r121b1054],
2	THE	DT	O	the	det	3	SENT_18	[p2l159t1000r323b1054],
3	EDITOR	NN	O	editor	prep_to	27	SENT_18	[p2l368t999r704b1055],
4	:	:	O	:	_	0	SENT_18	[p2l368t999r704b1055],
5	The	DT	O	the	det	7	SENT_18	[p2l746t976r906b1055],
6	primary	JJ	O	primary	amod	7	SENT_18	[p2l947t977r1297b1077],
7	analysis	NN	O	analysis	dep	3	SENT_18	[p2l1334t976r1674b1077],
8	of	IN	O	of	_	0	SENT_18	[p2l1719t976r1819b1055],
9	the	DT	O	the	prep_of	7	SENT_18	[p2l1843t976r1975b1055],
10	in	IN	O	in	_	0	SENT_18	[p2l2017t977r2132b1054],
11	—	CD	NUMBER	—	prep_in	15	SENT_18	[p2l2017t977r2132b1054],
12	novative	JJ	O	novative	amod	11	SENT_18	[p2l11t1105r384b1200],
13	,	,	O	,	_	0	SENT_18	[p2l11t1105r384b1200],
14	Well	UH	O	well	dep	15	SENT_18	[p2l425t1104r1046b1205],
15	—	CD	NUMBER	—	dep	9	SENT_18	[p2l425t1104r1046b1205],
16	designed	VBN	O	design	partmod	7	SENT_18	[p2l425t1104r1046b1205],
17	,	,	O	,	_	0	SENT_18	[p2l425t1104r1046b1205],
18	phase	NN	O	phase	nsubj	31	SENT_18	[p2l1090t1104r1339b1205],
19	3	CD	NUMBER	3	num	21	SENT_18	[p2l1381t1110r1425b1183],
20	clinical	JJ	O	clinical	amod	21	SENT_18	[p2l1469t1104r1782b1183],
21	trial	NN	O	trial	dep	18	SENT_18	[p2l1823t1104r2000b1183],
22	by	IN	O	by	_	0	SENT_18	[p2l2041t1104r2138b1205],
23	Mok	NNP	PERSON	Mok	prep_by	21	SENT_18	[p2l8t1232r204b1311],
24	et	FW	O	et	nn	25	SENT_18	[p2l236t1249r314b1311],
25	al.	FW	O	al.	dep	18	SENT_18	[p2l344t1232r441b1311],
26	is	VBZ	O	be	cop	27	SENT_18	[p2l482t1233r548b1311],
27	inappropriate	JJ	O	inappropriate	_	0	SENT_18	[p2l585t1233r1169b1333],
28	and	CC	O	and	_	0	SENT_18	[p2l1205t1232r1363b1311],
29	does	VBZ	O	do	aux	31	SENT_18	[p2l1399t1232r1592b1311],
30	not	RB	O	not	neg	31	SENT_18	[p2l1631t1249r1773b1311],
31	support	VB	O	support	conj_and	27	SENT_18	[p2l1806t1249r2139b1333],
32	the	DT	O	the	det	33	SENT_18	[p2l12t1360r146b1439],
33	superiority	NN	O	superiority	dobj	31	SENT_18	[p2l211t1361r687b1461],
34	of	IN	O	of	_	0	SENT_18	[p2l745t1360r846b1439],
35	gefitinib	NN	O	gefitinib	prep_of	33	SENT_18	[p2l889t1360r1270b1461],
36	over	IN	O	over	_	0	SENT_18	[p2l1334t1386r1515b1439],
37	carboplatin	NN	O	carboplatin	nn	39	SENT_18	[p2l1575t1360r2137b1461],
38	—	CD	NUMBER	—	num	39	SENT_18	[p2l1575t1360r2137b1461],
39	paclitaxel	NN	O	paclitaxel	prep_over	31	SENT_18	[p2l10t1488r423b1589],
40	in	IN	O	in	_	0	SENT_18	[p2l467t1489r550b1566],
41	patients	NNS	O	patient	prep_in	31	SENT_18	[p2l595t1489r936b1589],
42	with	IN	O	with	_	0	SENT_18	[p2l979t1488r1175b1567],
43	advanced	JJ	O	advanced	amod	45	SENT_18	[p2l1219t1488r1616b1567],
44	pulmonary	JJ	O	pulmonary	amod	45	SENT_18	[p2l1659t1488r2138b1589],
45	adenocarcinoma	NN	O	adenocarcinoma	prep_with	41	SENT_18	[p2l11t1616r748b1695],
46	.	.	O	.	_	0	SENT_18	[p2l11t1616r748b1695],

1	The	DT	O	the	det	6	SENT_19	[p2l796t1616r957b1695],
2	Cox	NN	ORGANIZATION	cox	nn	6	SENT_19	[p2l1003t1622r1167b1695],
3	proportional	JJ	O	proportional	amod	6	SENT_19	[p2l1209t1616r2131b1717],
4	—	NN	O	—	nn	6	SENT_19	[p2l1209t1616r2131b1717],
5	hazards	NNS	O	hazard	nn	6	SENT_19	[p2l1209t1616r2131b1717],
6	model	NN	O	model	nsubjpass	8	SENT_19	[p2l11t1744r278b1823],
7	is	VBZ	O	be	auxpass	8	SENT_19	[p2l316t1745r382b1823],
8	based	VBN	O	base	_	0	SENT_19	[p2l425t1744r669b1823],
9	on	IN	O	on	_	0	SENT_19	[p2l709t1770r815b1823],
10	the	DT	O	the	det	11	SENT_19	[p2l854t1744r986b1823],
11	assumption	NN	O	assumption	prep_on	8	SENT_19	[p2l1026t1745r1529b1845],
12	that	IN	O	that	complm	20	SENT_19	[p2l1569t1744r1741b1823],
13	the	DT	O	the	det	15	SENT_19	[p2l1775t1744r1908b1823],
14	hazard	NN	O	hazard	nn	15	SENT_19	[p2l1948t1744r2132b1823, p2l11t1873r149b1952],
15	ratio	NN	O	ratio	nsubj	20	SENT_19	[p2l180t1874r376b1952],
16	of	IN	O	of	_	0	SENT_19	[p2l409t1873r509b1952],
17	two	CD	NUMBER	two	num	18	SENT_19	[p2l522t1890r679b1952],
18	treatments	NNS	O	treatment	prep_of	15	SENT_19	[p2l711t1890r1174b1952],
19	is	VBZ	O	be	cop	20	SENT_19	[p2l1207t1874r1273b1952],
20	constant	JJ	O	constant	ccomp	8	SENT_19	[p2l1306t1890r1680b1952],
21	over	IN	O	over	_	0	SENT_19	[p2l1706t1899r1884b1952],
22	time	NN	O	time	prep_over	20	SENT_19	[p2l1912t1874r2128b1952],
23	.	.	O	.	_	0	SENT_19	[p2l1912t1874r2128b1952],

1	If	IN	O	if	mark	4	SENT_20	[p2l8t1991r76b2055],
2	the	DT	O	the	det	3	SENT_20	[p2l87t1991r197b2056],
3	curves	NNS	O	curve	nsubj	4	SENT_20	[p2l223t2013r446b2056],
4	cross	VBP	O	cross	advcl	17	SENT_20	[p2l474t2012r674b2070],
5	,	,	O	,	_	0	SENT_20	[p2l474t2012r674b2070],
6	as	IN	O	as	mark	8	SENT_20	[p2l704t2013r774b2056],
7	they	PRP	O	they	nsubj	8	SENT_20	[p2l802t1991r952b2074],
8	do	VBP	O	do	advcl	17	SENT_20	[p2l975t1991r1060b2056],
9	in	IN	O	in	_	0	SENT_20	[p2l1086t1992r1155b2055],
10	Figure	NNP	O	Figure	nn	11	SENT_20	[p2l1180t1992r1404b2074],
11	2A	NN	O	2a	prep_in	8	SENT_20	[p2l1430t1996r1527b2055],
12	in	IN	O	in	_	0	SENT_20	[p2l1549t1992r1618b2055],
13	the	DT	O	the	det	14	SENT_20	[p2l1645t1991r1753b2056],
14	article	NN	O	article	prep_in	8	SENT_20	[p2l9t2096r248b2174],
15	,	,	O	,	_	0	SENT_20	[p2l9t2096r248b2174],
16	there	EX	O	there	expl	17	SENT_20	[p2l283t2096r461b2160],
17	is	VBZ	O	be	_	0	SENT_20	[p2l491t2097r546b2160],
18	clear	JJ	O	clear	amod	19	SENT_20	[p2l579t2096r747b2160],
19	violation	NN	O	violation	nsubj	17	SENT_20	[p2l772t2096r1082b2161],
20	of	IN	O	of	_	0	SENT_20	[p2l1114t2096r1196b2160],
21	the	DT	O	the	det	22	SENT_20	[p2l1211t2096r1321b2160],
22	model	NN	O	model	prep_of	19	SENT_20	[p2l1351t2096r1590b2174],
23	,	,	O	,	_	0	SENT_20	[p2l1351t2096r1590b2174],
24	and	CC	O	and	_	0	SENT_20	[p2l1625t2096r1754b2160],
25	the	DT	O	the	det	27	SENT_20	[p2l10t2201r119b2266],
26	hazard	NN	O	hazard	nn	27	SENT_20	[p2l145t2201r389b2266],
27	ratio	NN	O	ratio	nsubjpass	31	SENT_20	[p2l414t2202r576b2266],
28	should	MD	O	should	aux	31	SENT_20	[p2l605t2201r841b2266],
29	not	RB	O	not	neg	31	SENT_20	[p2l866t2215r984b2266],
30	be	VB	O	be	auxpass	31	SENT_20	[p2l1006t2201r1085b2266],
31	used	VBN	O	use	conj_and	17	SENT_20	[p2l1111t2201r1273b2266],
32	as	IN	O	as	_	0	SENT_20	[p2l1298t2223r1368b2266],
33	a	DT	O	a	det	34	SENT_20	[p2l1396t2223r1432b2266],
34	measure	NN	O	measure	prep_as	31	SENT_20	[p2l1456t2222r1753b2266],
35	of	IN	O	of	_	0	SENT_20	[p2l10t2306r91b2371],
36	relative	JJ	O	relative	amod	37	SENT_20	[p2l103t2306r349b2371],
37	benefit	NN	O	benefit	prep_of	34	SENT_20	[p2l377t2306r669b2371],
38	}	CD	NUMBER	}	num	37	SENT_20	[p2l377t2306r669b2371],
39	We	PRP	O	we	nsubj	40	SENT_20	[p2l693t2312r801b2371],
40	suggest	VBP	O	suggest	rcmod	37	SENT_20	[p2l830t2320r1093b2389],
41	that	IN	O	that	complm	54	SENT_20	[p2l1116t2306r1255b2371],
42	differences	NNS	O	difference	nsubjpass	54	SENT_20	[p2l1278t2306r1658b2371],
43	in	IN	O	in	_	0	SENT_20	[p2l1686t2307r1754b2370],
44	survival	NN	O	survival	prep_in	42	SENT_20	[p2l11t2411r283b2476],
45	in	IN	O	in	_	0	SENT_20	[p2l325t2412r394b2475],
46	the	DT	O	the	det	47	SENT_20	[p2l437t2411r546b2476],
47	intention	NN	O	intention	prep_in	44	SENT_20	[p2l589t2412r1206b2476],
48	—	CD	NUMBER	—	number	50	SENT_20	[p2l589t2412r1206b2476],
49	to	TO	O	to	dep	50	SENT_20	[p2l589t2412r1206b2476],
50	—	CD	NUMBER	—	num	52	SENT_20	[p2l589t2412r1206b2476],
51	treat	NN	O	treat	nn	52	SENT_20	[p2l589t2412r1206b2476],
52	population	NN	O	population	dep	47	SENT_20	[p2l1244t2411r1631b2494],
53	be	VB	O	be	auxpass	54	SENT_20	[p2l1675t2411r1753b2476],
54	reanalyzed	VBN	O	reanalyze	ccomp	40	SENT_20	[p2l9t2516r383b2599],
55	with	IN	O	with	_	0	SENT_20	[p2l402t2516r560b2581],
56	the	DT	O	the	det	57	SENT_20	[p2l583t2516r689b2581],
57	use	NN	O	use	prep_with	54	SENT_20	[p2l712t2538r826b2581],
58	of	IN	O	of	_	0	SENT_20	[p2l849t2516r930b2581],
59	statistical	JJ	O	statistical	amod	60	SENT_20	[p2l939t2516r1271b2581],
60	methods	NNS	O	method	prep_of	57	SENT_20	[p2l1293t2516r1595b2581],
61	that	WDT	O	that	nsubj	64	SENT_20	[p2l1619t2516r1758b2581],
62	do	VBP	O	do	aux	64	SENT_20	[p2l10t2621r94b2686],
63	not	RB	O	not	neg	64	SENT_20	[p2l137t2635r254b2686],
64	rely	VB	O	rely	rcmod	57	SENT_20	[p2l292t2621r420b2704],
65	on	IN	O	on	_	0	SENT_20	[p2l459t2642r546b2686],
66	the	DT	O	the	det	67	SENT_20	[p2l588t2621r697b2686],
67	assumption	NN	O	assumption	prep_on	64	SENT_20	[p2l739t2622r1153b2704],
68	of	IN	O	of	_	0	SENT_20	[p2l1195t2621r1277b2686],
69	proportional	JJ	O	proportional	amod	70	SENT_20	[p2l1303t2621r1754b2704],
70	hazards	NNS	O	hazard	prep_of	67	SENT_20	[p2l9t2726r314b2805],
71	,	,	O	,	_	0	SENT_20	[p2l9t2726r314b2805],
72	such	JJ	O	such	_	0	SENT_20	[p2l374t2726r535b2791],
73	as	IN	O	as	_	0	SENT_20	[p2l589t2748r660b2791],
74	the	DT	O	the	det	79	SENT_20	[p2l716t2726r827b2791],
75	modified	VBN	O	modify	amod	79	SENT_20	[p2l881t2726r1212b2791],
76	Kolmogorov	NNP	O	Kolmogorov	nn	79	SENT_20	[p2l1265t2726r1757b2809],
77	—	NNP	O	—	nn	79	SENT_20	[p2l1265t2726r1757b2809],
78	Smirnov	NNP	PERSON	Smirnov	nn	79	SENT_20	[p2l11t2832r314b2896],
79	test	NN	O	test	prep_such_as	64	SENT_20	[p2l340t2836r522b2896],
80	?	.	O	?	_	0	SENT_20	[p2l340t2836r522b2896],

1	Designing	NNP	O	Designing	nsubj	17	SENT_21	[p2l551t2832r925b2914],
2	a	DT	O	a	det	3	SENT_21	[p2l951t2853r987b2896],
3	trial	NN	O	trial	npadvmod	1	SENT_21	[p2l1016t2831r1165b2896],
4	with	IN	O	with	_	0	SENT_21	[p2l1191t2831r1354b2896],
5	the	DT	O	the	det	6	SENT_21	[p2l1384t2831r1495b2896],
6	expectation	NN	O	expectation	prep_with	1	SENT_21	[p2l1525t2852r1752b2914, p2l10t2937r221b3001],
7	that	IN	O	that	complm	10	SENT_21	[p2l261t2936r405b3001],
8	it	PRP	O	it	nsubj	10	SENT_21	[p2l440t2937r490b3001],
9	would	MD	O	would	aux	10	SENT_21	[p2l521t2936r743b3001],
10	satisfy	VB	O	satisfy	dep	6	SENT_21	[p2l784t2936r1018b3019],
11	the	DT	O	the	det	12	SENT_21	[p2l1054t2936r1165b3001],
12	requirement	NN	O	requirement	dobj	10	SENT_21	[p2l1205t2937r1650b3019],
13	of	IN	O	of	_	0	SENT_21	[p2l1686t2936r1769b3001],
14	proportional	JJ	O	proportional	amod	15	SENT_21	[p2l8t3041r469b3124],
15	hazards	NNS	O	hazard	prep_of	12	SENT_21	[p2l515t3041r798b3106],
16	was	VBD	O	be	cop	17	SENT_21	[p2l843t3063r978b3106],
17	reasonable	JJ	O	reasonable	_	0	SENT_21	[p2l1026t3041r1433b3120],
18	,	,	O	,	_	0	SENT_21	[p2l1026t3041r1433b3120],
19	but	CC	O	but	_	0	SENT_21	[p2l1484t3041r1601b3106],
20	the	DT	O	the	det	21	SENT_21	[p2l1643t3041r1753b3106],
21	analysis	NN	O	analysis	nsubj	22	SENT_21	[p2l9t3146r288b3229],
22	needs	VBZ	O	need	conj_but	17	SENT_21	[p2l318t3146r518b3211],
23	revision	NN	O	revision	dobj	22	SENT_21	[p2l549t3147r826b3211],
24	in	IN	O	in	_	0	SENT_21	[p2l853t3147r922b3210],
25	light	NN	O	light	prep_in	22	SENT_21	[p2l949t3146r1115b3229],
26	of	IN	O	of	_	0	SENT_21	[p2l1140t3146r1222b3211],
27	the	DT	O	the	det	28	SENT_21	[p2l1236t3146r1345b3211],
28	results	NNS	O	result	prep_of	25	SENT_21	[p2l1373t3146r1626b3211],
29	.	.	O	.	_	0	SENT_21	[p2l1373t3146r1626b3211],

1	Bostjan	NNP	PERSON	Bostjan	nn	2	SENT_22	[p2l16t3261r278b3342],
2	Seruga	NNP	PERSON	Seruga	_	0	SENT_22	[p2l310t3261r574b3342],
3	,	,	O	,	_	0	SENT_22	[p2l310t3261r574b3342],
4	M.D.	NNP	PERSON	M.D.	nn	6	SENT_22	[p2l610t3261r779b3321],
5	Eitan	NNP	PERSON	Eitan	nn	6	SENT_22	[p2l16t3366r186b3426],
6	Amir	NNP	PERSON	Amir	appos	2	SENT_22	[p2l215t3365r409b3437],
7	,	,	O	,	_	0	SENT_22	[p2l215t3365r409b3437],
8	M.B.	NNP	LOCATION	M.B.	nn	10	SENT_22	[p2l445t3366r625b3438],
9	,	,	O	,	_	0	SENT_22	[p2l445t3366r625b3438],
10	Ch	NNP	O	Ch	appos	6	SENT_22	[p2l657t3361r844b3426],
11	.	.	O	.	_	0	SENT_22	[p2l657t3361r844b3426],

1	B.	NNP	PERSON	B.	nn	4	SENT_23	[p2l657t3361r844b3426],
2	Ian	NNP	PERSON	Ian	nn	4	SENT_23	[p2l16t3470r116b3530],
3	Tannoc	NNP	PERSON	Tannoc	nn	4	SENT_23	[p2l145t3465r472b3542],
4	|	NN	O	|	_	0	SENT_23	[p2l145t3465r472b3542],
5	<	JJR	O	<	dep	4	SENT_23	[p2l145t3465r472b3542],
6	,	,	O	,	_	0	SENT_23	[p2l145t3465r472b3542],
7	M.D.	NNP	O	M.D.	nn	9	SENT_23	[p2l508t3470r699b3542],
8	,	,	O	,	_	0	SENT_23	[p2l508t3470r699b3542],
9	Ph.D.	NNP	O	Ph.D.	appos	5	SENT_23	[p2l736t3465r924b3530],
10	.	.	O	.	_	0	SENT_23	[p2l736t3465r924b3530],

1	Princess	NNP	O	Princess	nn	4	SENT_24	[p2l13t3586r238b3631],
2	Margaret	NNP	PERSON	Margaret	nn	4	SENT_24	[p2l264t3586r512b3647],
3	Hospital	NNP	PERSON	Hospital	nn	4	SENT_24	[p2l536t3581r764b3646],
4	Toronto	NNP	PERSON	Toronto	_	0	SENT_24	[p2l7t3653r238b3706],
5	,	,	O	,	_	0	SENT_24	[p2l7t3653r238b3706],
6	ON	NNP	O	ON	nn	9	SENT_24	[p2l262t3652r373b3706],
7	,	,	O	,	_	0	SENT_24	[p2l262t3652r373b3706],
8	Canada	NNP	LOCATION	Canada	appos	9	SENT_24	[p2l396t3648r600b3698],
9	ian.tannock@uhn.on.ca	NNP	O	ian.tannock@uhn.on.ca	appos	4	SENT_24	[p2l11t3713r673b3773],

1	1	LS	NUMBER	1	_	0	SENT_25	[p3l11t25r50b67],
2	.	.	O	.	_	0	SENT_25	[p3l11t25r50b67],

1	Concato	NNP	O	Concato	nn	2	SENT_26	[p3l115t22r332b67],
2	J	NNP	O	J	_	0	SENT_26	[p3l346t23r380b78],
3	,	,	O	,	_	0	SENT_26	[p3l346t23r380b78],
4	Feinstein	NNP	PERSON	Feinstein	nn	5	SENT_26	[p3l402t19r645b67],
5	AR	NNS	O	ar	appos	2	SENT_26	[p3l662t23r758b78],
6	,	,	O	,	_	0	SENT_26	[p3l662t23r758b78],
7	Holford	NNP	PERSON	Holford	nn	8	SENT_26	[p3l780t18r988b67],
8	TR	NN	O	tr	appos	5	SENT_26	[p3l1005t22r1097b71],
9	.	.	O	.	_	0	SENT_26	[p3l1005t22r1097b71],

1	The	DT	O	the	det	2	SENT_27	[p3l1118t19r1217b67],
2	risk	NN	O	risk	_	0	SENT_27	[p3l1236t19r1338b68],
3	of	IN	O	of	_	0	SENT_27	[p3l1354t18r1416b67],
4	determining	VBG	O	determine	prepc_of	2	SENT_27	[p3l1424t19r1756b81],
5	risk	NN	O	risk	dobj	4	SENT_27	[p3l9t89r110b137],
6	With	IN	O	with	_	0	SENT_27	[p3l124t89r245b137],
7	multivariable	JJ	O	multivariable	amod	8	SENT_27	[p3l264t89r614b137],
8	models	NNS	O	model	prep_with	4	SENT_27	[p3l634t89r840b137],
9	.	.	O	.	_	0	SENT_27	[p3l634t89r840b137],

1	Ann	NNP	PERSON	Ann	nn	3	SENT_28	[p3l861t93r974b136],
2	Intern	NNP	O	Intern	nn	3	SENT_28	[p3l993t93r1157b137],
3	Med	NNP	O	Med	_	0	SENT_28	[p3l1174t89r1290b137],
4	1993	CD	DATE	1993	num	3	SENT_28	[p3l1312t92r1748b147],
5	;	:	O	;	_	0	SENT_28	[p3l1312t92r1748b147],
6	118:201	CD	NUMBER	118:201	number	7	SENT_28	[p3l1312t92r1748b147],
7	—	CD	NUMBER	—	dep	3	SENT_28	[p3l1312t92r1748b147],
8	10	CD	NUMBER	10	dep	7	SENT_28	[p3l1312t92r1748b147],
9	.	.	O	.	_	0	SENT_28	[p3l1312t92r1748b147],

1	2	LS	NUMBER	2	_	0	SENT_29	[p3l8t163r52b205],
2	.	.	O	.	_	0	SENT_29	[p3l8t163r52b205],

1	Le	NNP	O	Le	nn	2	SENT_30	[p3l114t161r175b205],
2	CT	NNP	O	CT	_	0	SENT_30	[p3l203t160r289b205],
3	.	.	O	.	_	0	SENT_30	[p3l203t160r289b205],

1	Statistical	JJ	O	statistical	amod	2	SENT_31	[p3l323t157r590b205],
2	methods	NNS	O	method	_	0	SENT_31	[p3l618t157r852b205],
3	for	IN	O	for	_	0	SENT_31	[p3l882t156r959b205],
4	the	DT	O	the	det	5	SENT_31	[p3l986t157r1070b205],
5	comparison	NN	O	comparison	prep_for	2	SENT_31	[p3l1098t157r1419b219],
6	of	IN	O	of	_	0	SENT_31	[p3l1448t156r1510b205],
7	crossing	VBG	O	cross	prepc_of	5	SENT_31	[p3l1527t157r1756b219],
8	survival	NN	O	survival	nn	9	SENT_31	[p3l10t227r218b275],
9	curves	NNS	O	curve	dobj	7	SENT_31	[p3l241t243r428b275],
10	.	.	O	.	_	0	SENT_31	[p3l241t243r428b275],

1	In	IN	O	in	dep	4	SENT_32	[p3l453t231r524b275],
2	:	:	O	:	_	0	SENT_32	[p3l453t231r524b275],
3	Balakrishnan	NN	PERSON	balakrishnan	nn	4	SENT_32	[p3l548t227r914b275],
4	N	NN	O	n	_	0	SENT_32	[p3l935t231r994b285],
5	,	,	O	,	_	0	SENT_32	[p3l935t231r994b285],
6	Rao	NNP	PERSON	Rao	nn	7	SENT_32	[p3l1019t231r1123b278],
7	CR	NN	O	cr	appos	4	SENT_32	[p3l1146t230r1239b285],
8	,	,	O	,	_	0	SENT_32	[p3l1146t230r1239b285],
9	eds	NNS	O	ed	appos	4	SENT_32	[p3l1266t227r1369b275],
10	.	.	O	.	_	0	SENT_32	[p3l1266t227r1369b275],

1	Handbook	NN	O	handbook	_	0	SENT_33	[p3l1395t227r1683b276],
2	of	IN	O	of	_	0	SENT_33	[p3l1703t226r1765b275],
3	statistics	NNS	O	statistics	prep_of	1	SENT_33	[p3l10t295r258b343],
4	:	:	O	:	_	0	SENT_33	[p3l10t295r258b343],
5	advances	NNS	O	advance	dep	1	SENT_33	[p3l277t295r513b343],
6	in	IN	O	in	_	0	SENT_33	[p3l532t295r583b342],
7	survival	NN	O	survival	nn	8	SENT_33	[p3l601t295r806b343],
8	analysis	NN	O	analysis	prep_in	5	SENT_33	[p3l822t295r1047b356],
9	.	.	O	.	_	0	SENT_33	[p3l822t295r1047b356],

1	Vol	NNP	O	Vol	_	0	SENT_34	[p3l1066t295r1164b343],
2	.	.	O	.	_	0	SENT_34	[p3l1066t295r1164b343],

1	23	CD	NUMBER	23	_	0	SENT_35	[p3l1185t298r1260b343],
2	.	.	O	.	_	0	SENT_35	[p3l1185t298r1260b343],

1	Amsterdam	NNP	LOCATION	Amsterdam	_	0	SENT_36	[p3l1279t295r1607b343],
2	:	:	O	:	_	0	SENT_36	[p3l1279t295r1607b343],
3	Elsevier	NNP	PERSON	Elsevier	dep	1	SENT_36	[p3l1626t295r1753b343, p3l6t374r118b432],
4	,	,	O	,	_	0	SENT_36	[p3l1626t295r1753b343, p3l6t374r118b432],
5	2004:277	CD	NUMBER	2004:277	num	6	SENT_36	[p3l143t377r488b422],
6	-90	CD	NUMBER	-90	appos	3	SENT_36	[p3l143t377r488b422],
7	.	.	O	.	_	0	SENT_36	[p3l143t377r488b422],

1	To	TO	O	to	_	0	SENT_37	[p3l8t610r99b655],
2	TH	NN	O	th	nn	4	SENT_37	[p3l122t611r211b655],
3	E	NN	O	e	nn	4	SENT_37	[p3l227t611r257b655],
4	EDITOR	NN	O	editor	pobj	1	SENT_37	[p3l287t610r562b656],
5	:	:	O	:	_	0	SENT_37	[p3l287t610r562b656],
6	In	IN	O	in	dep	4	SENT_37	[p3l588t597r660b655],
7	his	PRP$	O	he	poss	8	SENT_37	[p3l683t591r784b656],
8	editorial	NN	O	editorial	pobj	6	SENT_37	[p3l809t591r1099b656],
9	accompanying	VBG	O	accompany	dep	8	SENT_37	[p3l1120t592r1626b674],
10	the	DT	O	the	det	11	SENT_37	[p3l1647t591r1753b656],
11	article	NN	O	article	dobj	9	SENT_37	[p3l9t696r229b761],
12	by	IN	O	by	_	0	SENT_37	[p3l259t696r339b779],
13	Mok	NNP	PERSON	Mok	prep_by	9	SENT_37	[p3l362t696r524b762],
14	et	FW	O	et	nn	15	SENT_37	[p3l550t710r613b761],
15	al.	FW	O	al.	dep	4	SENT_37	[p3l639t696r739b775],
16	,	,	O	,	_	0	SENT_37	[p3l639t696r739b775],
17	Gazdar1	NN	O	gazdar1	nn	18	SENT_37	[p3l773t696r1062b761],
18	states	NNS	O	state	appos	15	SENT_37	[p3l1093t710r1291b761],
19	that	IN	O	that	complm	21	SENT_37	[p3l1323t696r1465b761],
20	there	EX	O	there	expl	21	SENT_37	[p3l1491t696r1669b761],
21	is	VBZ	O	be	dep	18	SENT_37	[p3l1698t697r1752b761],

1	THIS	NNP	DATE	THIS	nn	2	SENT_38	[p3l707t963r868b1009],
2	WEEK	NNP	DATE	WEEK	poss	4	SENT_38	[p3l898t948r1148b1009],
3	'S	POS	O	's	_	0	SENT_38	[p3l898t948r1148b1009],
4	LETTERS	NNS	O	letter	_	0	SENT_38	[p3l1184t963r1466b1009],

1	Treatment	NN	O	treatment	_	0	SENT_39	[p3l324t1113r702b1173],
2	of	IN	O	of	_	0	SENT_39	[p3l722t1107r808b1173],
3	Lung	NN	O	lung	nn	6	SENT_39	[p3l813t1114r1003b1191],
4	Cancer	NN	O	cancer	nn	6	SENT_39	[p3l1025t1113r1275b1173],
5	Asymptomatic	JJ	O	asymptomatic	amod	6	SENT_39	[p3l324t1272r840b1355],
6	Reactivation	NN	O	reactivation	prep_of	1	SENT_39	[p3l860t1272r1301b1341],
7	of	IN	O	of	_	0	SENT_39	[p3l1323t1271r1407b1337],
8	JC	NNP	O	JC	nn	9	SENT_39	[p3l1405t1277r1488b1347],
9	Virus	NN	O	virus	prep_of	1	SENT_39	[p3l1508t1272r1697b1337],
10	in	IN	O	in	dep	1	SENT_39	[p3l1720t1272r1790b1335],
11	Patients	NNS	O	patient	pobj	10	SENT_39	[p3l1809t1272r2092b1337],
12	Treated	VBN	O	treat	partmod	11	SENT_39	[p3l325t1386r596b1452],
13	with	IN	O	with	_	0	SENT_39	[p3l618t1386r784b1452],
14	Natalizumab	NN	PERSON	natalizumab	prep_with	12	SENT_39	[p3l806t1386r1274b1452],

1	Coronary	JJ	O	coronary	amod	4	SENT_40	[p3l327t1555r668b1633],
2	Calcium	NN	O	calcium	nn	4	SENT_40	[p3l690t1549r988b1615],
3	Screening	NN	O	screening	nn	4	SENT_40	[p3l1013t1550r1373b1633],
4	Proposals	NNS	O	proposal	dep	21	SENT_40	[p3l324t1713r681b1796],
5	for	IN	O	for	_	0	SENT_40	[p3l706t1713r809b1779],
6	Payment	NN	O	payment	nn	7	SENT_40	[p3l829t1719r1143b1797],
7	Reform	NN	O	reform	prep_for	4	SENT_40	[p3l1161t1713r1436b1782],
8	in	IN	O	in	_	0	SENT_40	[p3l1459t1714r1530b1777],
9	Massachusetts	NNP	LOCATION	Massachusetts	nn	11	SENT_40	[p3l1551t1713r2079b1779],
10	Rapid-Test	NNP	O	Rapid-Test	nn	11	SENT_40	[p3l324t1876r712b1960],
11	Sensitivity	NN	O	sensitivity	prep_in	7	SENT_40	[p3l735t1877r1109b1960],
12	for	IN	O	for	_	0	SENT_40	[p3l1131t1876r1234b1942],
13	Novel	JJ	MISC	novel	amod	16	SENT_40	[p3l1254t1877r1459b1942],
14	Swine-Origin	NN	MISC	swine-origin	nn	16	SENT_40	[p3l1484t1877r1976b1960],
15	Influenza	NN	MISC	influenza	nn	16	SENT_40	[p3l326t1991r679b2057],
16	A	NN	MISC	a	prep_for	11	SENT_40	[p3l699t1998r755b2056],
17	(	CD	NUMBER	(	num	18	SENT_40	[p3l781t1997r979b2067],
18	H1N	NN	O	h1n	dep	21	SENT_40	[p3l781t1997r979b2067],
19	1	CD	NUMBER	1	number	20	SENT_40	[p3l982t1997r1042b2067],
20	)	CD	NUMBER	)	num	21	SENT_40	[p3l982t1997r1042b2067],
21	Virus	NN	O	virus	_	0	SENT_40	[p3l1067t1992r1259b2057],
22	in	IN	O	in	_	0	SENT_40	[p3l1285t1992r1355b2056],
23	Humans	NNS	MISC	human	prep_in	21	SENT_40	[p3l1377t1998r1688b2057],

1	N	NN	O	n	nn	3	SENT_41	[p3l537t2222r551b2237],
2	ENGLJ	NN	O	englj	nn	3	SENT_41	[p3l565t2222r643b2244],
3	MED	NN	O	med	_	0	SENT_41	[p3l658t2222r710b2237],
4	361	CD	NUMBER	361	dep	3	SENT_41	[p3l720t2216r796b2244],
5	;	:	O	;	_	0	SENT_41	[p3l720t2216r796b2244],
6	25	CD	NUMBER	25	num	9	SENT_41	[p3l720t2216r796b2244],
7	NE	NN	O	ne	nn	9	SENT_41	[p3l831t2222r861b2237],
8	M.ORG	NN	O	m.org	nn	9	SENT_41	[p3l875t2222r955b2238],
9	DECEMBER17	NN	O	december17	dep	4	SENT_41	[p3l992t2222r1162b2243],
10	,	,	O	,	_	0	SENT_41	[p3l992t2222r1162b2243],
11	2009	CD	DATE	2009	num	12	SENT_41	[p3l1173t2222r1237b2243],
12	2435	CD	DATE	2435	appos	9	SENT_41	[p3l1940t2212r2015b2235],

1	The	DT	O	the	det	2	SENT_42	[p3l702t2255r753b2279],
2	New	NNP	O	New	_	0	SENT_42	[p3l762t2256r824b2279],
3	and	CC	O	and	_	0	SENT_42	[p3l897t2255r944b2279],
4	Joumal	NNP	O	Joumal	conj_and	2	SENT_42	[p3l953t2255r1050b2279],
5	of	IN	O	of	_	0	SENT_42	[p3l1060t2255r1089b2279],
6	Medicine	NNP	O	Medicine	prep_of	2	SENT_42	[p3l1095t2255r1220b2279],

1	The	DT	O	the	det	4	SENT_43	[p3l673t2443r719b2464],
2	NEW	NNP	O	NEW	nn	4	SENT_43	[p3l737t2445r822b2464],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_43	[p3l841t2445r1030b2464],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_43	[p3l1049t2445r1228b2471],
5	of	IN	O	of	_	0	SENT_43	[p3l1248t2443r1276b2470],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_43	[p3l1288t2445r1487b2464],

1	incomplete	JJ	O	incomplete	amod	2	SENT_44	[p3l11t2666r491b2767],
2	evidence	NN	O	evidence	nsubj	17	SENT_44	[p3l536t2666r904b2746],
3	that	IN	O	that	_	0	SENT_44	[p3l948t2666r1121b2745],
4	mutations	NNS	O	mutation	prep_that	2	SENT_44	[p3l1160t2667r1597b2745],
5	in	IN	O	in	_	0	SENT_44	[p3l1643t2667r1726b2744],
6	the	DT	O	the	det	7	SENT_44	[p3l1771t2666r1904b2745],
7	gene	NN	O	gene	prep_in	4	SENT_44	[p3l1948t2692r2148b2767],
8	encoding	VBG	O	encode	partmod	7	SENT_44	[p3l12t2794r408b2895],
9	epidermal	JJ	O	epidermal	amod	11	SENT_44	[p3l434t2794r860b2895],
10	growth	NN	O	growth	nn	11	SENT_44	[p3l889t2794r1200b2895],
11	factor	NN	O	factor	dobj	8	SENT_44	[p3l1230t2794r1476b2873],
12	receptor	NN	O	receptor	nn	15	SENT_44	[p3l1502t2811r1853b2895],
13	(	CD	NUMBER	(	num	15	SENT_44	[p3l1884t2801r2143b2886],
14	EGFR	NN	ORGANIZATION	egfr	nn	15	SENT_44	[p3l1884t2801r2143b2886],
15	)	NN	O	)	dep	11	SENT_44	[p3l1884t2801r2143b2886],
16	can	MD	O	can	aux	17	SENT_44	[p3l12t2948r163b3001],
17	predict	VB	O	predict	_	0	SENT_44	[p3l212t2922r517b3023],
18	a	DT	O	a	det	20	SENT_44	[p3l562t2949r607b3001],
19	differential	JJ	O	differential	amod	20	SENT_44	[p3l657t2922r1143b3001],
20	effect	NN	O	effect	dobj	17	SENT_44	[p3l1195t2922r1438b3001],
21	on	IN	O	on	_	0	SENT_44	[p3l1484t2948r1591b3001],
22	survival	NN	O	survival	prep_on	17	SENT_44	[p3l1643t2922r1977b3001],
23	for	IN	O	for	_	0	SENT_44	[p3l2027t2922r2151b3001],
24	tyrosine	NN	O	tyrosine	nn	26	SENT_44	[p3l12t3051r360b3151],
25	kinase	NN	O	kinase	nn	26	SENT_44	[p3l407t3050r688b3130],
26	inhibitors	NNS	O	inhibitor	prep_for	22	SENT_44	[p3l734t3050r1183b3129],
27	.	.	O	.	_	0	SENT_44	[p3l734t3050r1183b3129],

1	Mok	NNP	PERSON	Mok	nsubj	4	SENT_45	[p3l1232t3050r1429b3130],
2	et	FW	O	et	nn	3	SENT_45	[p3l1472t3067r1550b3129],
3	al.	FW	O	al.	dep	1	SENT_45	[p3l1591t3050r1688b3129],
4	found	VBN	O	find	_	0	SENT_45	[p3l1740t3050r1994b3129],
5	no	DT	O	no	det	7	SENT_45	[p3l2040t3076r2146b3129],
6	significant	JJ	O	significant	amod	7	SENT_45	[p3l13t3178r485b3279],
7	difference	NN	O	difference	dobj	4	SENT_45	[p3l512t3178r946b3257],
8	in	IN	O	in	_	0	SENT_45	[p3l977t3179r1061b3256],
9	survival	NN	O	survival	prep_in	7	SENT_45	[p3l1094t3178r1428b3257],
10	between	IN	O	between	_	0	SENT_45	[p3l1459t3178r1819b3257],
11	the	DT	O	the	det	15	SENT_45	[p3l1851t3178r1984b3257],
12	ge	NN	O	ge	nn	15	SENT_45	[p3l2016t3205r2147b3279],
13	—	NN	O	—	nn	15	SENT_45	[p3l2016t3205r2147b3279],
14	fitinib	NN	O	fitinib	nn	15	SENT_45	[p3l12t3306r277b3385],
15	group	NN	O	group	prep_between	9	SENT_45	[p3l300t3332r550b3407],
16	and	CC	O	and	_	0	SENT_45	[p3l573t3306r729b3385],
17	the	DT	O	the	det	21	SENT_45	[p3l752t3306r883b3385],
18	carboplatin	NN	O	carboplatin	nn	21	SENT_45	[p3l906t3306r1850b3407],
19	—	CD	NUMBER	—	num	21	SENT_45	[p3l906t3306r1850b3407],
20	paclitaXel	NN	O	paclitaxel	nn	21	SENT_45	[p3l906t3306r1850b3407],
21	group	NN	O	group	prep_between	9	SENT_45	[p3l1871t3332r2143b3407],
22	,	,	O	,	_	0	SENT_45	[p3l1871t3332r2143b3407],
23	either	CC	O	either	preconj	4	SENT_45	[p3l12t3434r261b3513],
24	among	IN	O	among	_	0	SENT_45	[p3l312t3460r613b3535],
25	patients	NNS	O	patient	prep_among	4	SENT_45	[p3l663t3435r1006b3535],
26	with	IN	O	with	_	0	SENT_45	[p3l1058t3434r1255b3514],
27	EGFR	NN	ORGANIZATION	egfr	nn	28	SENT_45	[p3l1306t3441r1520b3514],
28	mutations	NNS	O	mutation	prep_with	25	SENT_45	[p3l1568t3435r2005b3513],
29	or	CC	O	or	_	0	SENT_45	[p3l2062t3460r2151b3513],
30	among	IN	O	among	_	0	SENT_45	[p3l11t3588r313b3663],
31	those	DT	O	those	prep_among	4	SENT_45	[p3l350t3562r582b3641],
32	without	IN	O	without	_	0	SENT_45	[p3l618t3562r960b3642],
33	EGFR	NN	ORGANIZATION	egfr	nn	34	SENT_45	[p3l992t3569r1206b3642],
34	mutations	NNS	O	mutation	prep_without	31	SENT_45	[p3l1239t3563r1701b3641],
35	.	.	O	.	_	0	SENT_45	[p3l1239t3563r1701b3641],

1	However	RB	O	however	advmod	7	SENT_46	[p3l1745t3570r2142b3658],
2	,	,	O	,	_	0	SENT_46	[p3l1745t3570r2142b3658],
3	the	DT	O	the	det	5	SENT_46	[p3l12t3690r146b3769],
4	survival	NN	O	survival	nn	5	SENT_46	[p3l193t3690r526b3770],
5	data	NNS	O	datum	nsubj	7	SENT_46	[p3l572t3690r755b3769],
6	were	VBD	O	be	cop	7	SENT_46	[p3l794t3716r997b3770],
7	immature	JJ	O	immature	_	0	SENT_46	[p3l1042t3691r1494b3786],
8	,	,	O	,	_	0	SENT_46	[p3l1042t3691r1494b3786],
9	and	CC	O	and	_	0	SENT_46	[p3l1544t3690r1703b3769],
10	even	RB	O	even	advmod	11	SENT_46	[p3l1748t3716r1938b3770],
11	mature	JJ	O	mature	conj_and	7	SENT_46	[p3l1983t3716r2147b3769, p4l12t40r184b102],

1	data	NNS	O	datum	nsubj	3	SENT_47	[p4l220t23r403b102],
2	will	MD	O	will	aux	3	SENT_47	[p4l433t23r598b102],
3	tell	VB	O	tell	_	0	SENT_47	[p4l633t23r767b102],
4	us	PRP	O	we	iobj	3	SENT_47	[p4l801t50r894b102],
5	only	RB	O	only	advmod	7	SENT_47	[p4l932t23r1117b124],
6	the	DT	O	the	det	7	SENT_47	[p4l1148t23r1281b102],
7	difference	NN	O	difference	dobj	3	SENT_47	[p4l1317t23r1752b102],
8	between	IN	O	between	_	0	SENT_47	[p4l1788t23r2148b102],
9	gefitinib	NN	O	gefitinib	prep_between	7	SENT_47	[p4l12t151r386b252],
10	followed	VBN	O	follow	partmod	9	SENT_47	[p4l428t151r800b230],
11	by	IN	O	by	_	0	SENT_47	[p4l842t151r939b252],
12	chemotherapy	NN	O	chemotherapy	agent	10	SENT_47	[p4l976t151r1591b252],
13	and	CC	O	and	_	0	SENT_47	[p4l1626t151r1785b230],
14	chemotherapy	NN	O	chemotherapy	agent	10	SENT_47	[p4l1826t151r2147b230, p4l12t279r336b380],
15	followed	VBN	O	follow	partmod	12	SENT_47	[p4l373t279r746b359],
16	by	IN	O	by	_	0	SENT_47	[p4l787t279r885b380],
17	gefitinib	NN	O	gefitinib	agent	15	SENT_47	[p4l921t279r1318b380],
18	.	.	O	.	_	0	SENT_47	[p4l921t279r1318b380],

1	Because	IN	O	because	mark	12	SENT_48	[p4l1364t286r1709b358],
2	all	DT	O	all	det	3	SENT_48	[p4l1750t279r1856b358],
3	ongoing	JJ	O	ongoing	nsubj	12	SENT_48	[p4l1897t305r2147b380, p4l11t408r151b508],
4	randomized	VBN	O	randomize	partmod	3	SENT_48	[p4l188t407r735b503],
5	,	,	O	,	_	0	SENT_48	[p4l188t407r735b503],
6	controlled	VBN	O	control	dep	4	SENT_48	[p4l781t407r1221b486],
7	trials	NNS	O	trial	dobj	4	SENT_48	[p4l1261t407r1482b486],
8	using	VBG	O	use	partmod	3	SENT_48	[p4l1523t408r1762b508],
9	tyrosine	NN	O	tyrosine	nn	11	SENT_48	[p4l1799t408r2147b508],
10	kinase	NN	O	kinase	nn	11	SENT_48	[p4l12t535r292b615],
11	inhibitors	NNS	O	inhibitor	dobj	8	SENT_48	[p4l333t535r757b614],
12	allow	VBP	O	allow	advcl	20	SENT_48	[p4l799t535r1037b614],
13	crossover	NN	O	crossover	dobj	12	SENT_48	[p4l1074t561r1481b614],
14	between	IN	O	between	_	0	SENT_48	[p4l1519t535r1879b614],
15	study	NN	O	study	nn	16	SENT_48	[p4l1922t535r2152b636],
16	groups	NNS	O	group	prep_between	13	SENT_48	[p4l12t689r334b764],
17	,	,	O	,	_	0	SENT_48	[p4l12t689r334b764],
18	it	PRP	O	it	nsubj	20	SENT_48	[p4l379t664r439b742],
19	is	VBZ	O	be	cop	20	SENT_48	[p4l474t664r541b742],
20	difficult	JJ	O	difficult	_	0	SENT_48	[p4l585t663r942b742],
21	to	TO	O	to	aux	22	SENT_48	[p4l978t680r1060b742],
22	compare	VB	O	compare	xcomp	20	SENT_48	[p4l1103t689r1475b764],
23	survival	NN	O	survival	dobj	22	SENT_48	[p4l1518t663r1852b742],
24	in	IN	O	in	_	0	SENT_48	[p4l1892t664r1975b741],
25	patients	NNS	O	patient	prep_in	22	SENT_48	[p4l2015t689r2147b764, p4l12t792r250b870],
26	receiving	VBG	O	receive	partmod	25	SENT_48	[p4l311t792r703b892],
27	tyrosine	NN	O	tyrosine	nn	29	SENT_48	[p4l759t792r1107b892],
28	kinase	NN	O	kinase	nn	29	SENT_48	[p4l1166t791r1447b871],
29	inhibitors	NNS	O	inhibitor	dobj	26	SENT_48	[p4l1505t791r1929b870],
30	and	CC	O	and	_	0	SENT_48	[p4l1989t791r2148b870],
31	those	DT	O	those	conj_and	25	SENT_48	[p4l12t919r245b998],
32	who	WP	O	who	nsubj	35	SENT_48	[p4l274t919r459b999],
33	do	VBP	O	do	aux	35	SENT_48	[p4l494t919r597b998],
34	not	RB	O	not	neg	35	SENT_48	[p4l631t936r775b998],
35	receive	VB	O	receive	rcmod	31	SENT_48	[p4l803t920r1094b998],
36	such	JJ	O	such	amod	37	SENT_48	[p4l1129t919r1324b998],
37	therapy	NN	O	therapy	dobj	35	SENT_48	[p4l1357t919r1695b1020],
38	.	.	O	.	_	0	SENT_48	[p4l1357t919r1695b1020],

1	Our	PRP$	O	we	poss	2	SENT_49	[p4l1733t925r1901b998],
2	comparison	NN	O	comparison	nsubj	25	SENT_49	[p4l1932t945r2147b998, p4l11t1048r338b1148],
3	of	IN	O	of	_	0	SENT_49	[p4l382t1047r482b1126],
4	patients	NNS	O	patient	prep_of	2	SENT_49	[p4l504t1048r848b1148],
5	who	WP	O	who	nsubjpass	7	SENT_49	[p4l888t1047r1072b1127],
6	were	VBD	O	be	auxpass	7	SENT_49	[p4l1112t1073r1315b1127],
7	treated	VBN	O	treat	rcmod	4	SENT_49	[p4l1357t1047r1657b1126],
8	before	IN	O	before	_	0	SENT_49	[p4l1701t1047r1971b1126],
9	the	DT	O	the	det	10	SENT_49	[p4l2014t1047r2148b1126],
10	approval	NN	O	approval	prep_before	7	SENT_49	[p4l11t1175r381b1276],
11	of	IN	O	of	_	0	SENT_49	[p4l423t1175r524b1254],
12	gefitinib	NN	O	gefitinib	prep_of	10	SENT_49	[p4l547t1175r921b1276],
13	for	IN	O	for	_	0	SENT_49	[p4l964t1175r1088b1254],
14	use	NN	O	use	prep_for	7	SENT_49	[p4l1127t1202r1269b1254],
15	in	IN	O	in	_	0	SENT_49	[p4l1310t1176r1394b1253],
16	Japan	NNP	LOCATION	Japan	prep_in	14	SENT_49	[p4l1426t1183r1672b1276],
17	and	CC	O	and	_	0	SENT_49	[p4l1714t1175r1873b1254],
18	those	DT	O	those	conj_and	14	SENT_49	[p4l1915t1175r2148b1254],
19	who	WP	O	who	nsubjpass	21	SENT_49	[p4l7t1303r192b1382],
20	were	VBD	O	be	auxpass	21	SENT_49	[p4l234t1329r438b1382],
21	treated	VBN	O	treat	rcmod	18	SENT_49	[p4l485t1303r785b1382],
22	after	IN	O	after	_	0	SENT_49	[p4l830t1303r1034b1382],
23	such	JJ	O	such	amod	24	SENT_49	[p4l1078t1303r1273b1382],
24	approval	NN	O	approval	prep_after	21	SENT_49	[p4l1318t1303r1687b1404],
25	showed	VBD	O	show	_	0	SENT_49	[p4l1735t1303r2060b1383],
26	a	DT	O	a	det	28	SENT_49	[p4l2105t1330r2149b1382],
27	significant	JJ	O	significant	amod	28	SENT_49	[p4l13t1431r485b1532],
28	improvement	NN	O	improvement	dobj	25	SENT_49	[p4l525t1432r1103b1532],
29	in	IN	O	in	_	0	SENT_49	[p4l1144t1432r1228b1509],
30	survival	NN	O	survival	prep_in	25	SENT_49	[p4l1276t1431r1609b1510],
31	only	RB	O	only	advmod	30	SENT_49	[p4l1657t1431r1842b1532],
32	in	IN	O	in	_	0	SENT_49	[p4l1883t1432r1967b1509],
33	the	DT	O	the	det	34	SENT_49	[p4l2014t1431r2148b1510],
34	subgroup	NN	O	subgroup	prep_in	30	SENT_49	[p4l13t1559r419b1660],
35	with	IN	O	with	_	0	SENT_49	[p4l456t1559r652b1638],
36	EGFR	NN	ORGANIZATION	egfr	nn	37	SENT_49	[p4l690t1566r904b1639],
37	mutations	NNS	O	mutation	prep_with	25	SENT_49	[p4l937t1560r1399b1638],
38	.	.	O	.	_	0	SENT_49	[p4l937t1560r1399b1638],

1	Our	PRP$	O	we	poss	2	SENT_50	[p4l1444t1565r1612b1638],
2	results	NNS	O	result	nsubj	4	SENT_50	[p4l1648t1559r1933b1638],
3	also	RB	O	also	advmod	4	SENT_50	[p4l1974t1559r2147b1638],
4	showed	VBD	O	show	_	0	SENT_50	[p4l13t1687r333b1766],
5	a	DT	O	a	det	7	SENT_50	[p4l359t1714r404b1766],
6	significant	JJ	O	significant	amod	7	SENT_50	[p4l431t1687r891b1788],
7	interaction	NN	O	interaction	dobj	4	SENT_50	[p4l912t1688r1372b1766],
8	between	IN	O	between	_	0	SENT_50	[p4l1400t1687r1753b1767],
9	the	DT	O	the	det	10	SENT_50	[p4l1780t1687r1912b1766],
10	presence	NN	O	presence	prep_between	4	SENT_50	[p4l1937t1713r2147b1788, p4l13t1841r202b1894],
11	of	IN	O	of	_	0	SENT_50	[p4l246t1815r347b1894],
12	EGFR	NN	ORGANIZATION	egfr	nn	13	SENT_50	[p4l370t1822r584b1895],
13	mutations	NNS	O	mutation	prep_of	10	SENT_50	[p4l620t1816r1057b1894],
14	and	CC	O	and	_	0	SENT_50	[p4l1102t1815r1261b1894],
15	an	DT	O	a	det	16	SENT_50	[p4l1304t1841r1407b1894],
16	improvement	NN	O	improvement	prep_of	10	SENT_50	[p4l1449t1816r2027b1916],
17	in	IN	O	in	_	0	SENT_50	[p4l2064t1816r2148b1893],
18	survival	NN	O	survival	prep_in	4	SENT_50	[p4l13t1943r411b2022],
19	?	.	O	?	_	0	SENT_50	[p4l13t1943r411b2022],

1	We	PRP	O	we	nsubj	2	SENT_51	[p4l442t1951r576b2022],
2	believe	VBP	O	believe	_	0	SENT_51	[p4l610t1943r903b2022],
3	that	IN	O	that	complm	6	SENT_51	[p4l936t1943r1110b2022],
4	EGFR	NN	ORGANIZATION	egfr	nn	5	SENT_51	[p4l1136t1950r1350b2023],
5	mutations	NNS	O	mutation	nsubj	6	SENT_51	[p4l1377t1944r1813b2022],
6	predict	VBP	O	predict	ccomp	2	SENT_51	[p4l1848t1943r2153b2044],
7	a	DT	O	a	det	9	SENT_51	[p4l12t2098r56b2150],
8	survival	NN	O	survival	nn	9	SENT_51	[p4l91t2071r425b2150],
9	benefit	NN	O	benefit	dobj	6	SENT_51	[p4l460t2071r767b2150],
10	from	IN	O	from	_	0	SENT_51	[p4l796t2071r1008b2150],
11	gefitinib	JJ	O	gefitinib	prep_from	6	SENT_51	[p4l1043t2071r1439b2172],
12	.	.	O	.	_	0	SENT_51	[p4l1043t2071r1439b2172],

1	Toshimi	NNP	PERSON	Toshimi	nn	3	SENT_52	[p4l9t2207r368b2287],
2	Ta	NNP	O	Ta	nn	3	SENT_52	[p4l402t2207r747b2302],
3	|	NN	O	|	_	0	SENT_52	[p4l402t2207r747b2302],
4	<	JJR	O	<	dep	3	SENT_52	[p4l402t2207r747b2302],
5	ano	CD	NUMBER	ano	dep	3	SENT_52	[p4l402t2207r747b2302],
6	,	,	O	,	_	0	SENT_52	[p4l402t2207r747b2302],
7	M.D.	NNP	O	M.D.	appos	5	SENT_52	[p4l792t2214r999b2287],

1	Teikyo	NNP	ORGANIZATION	Teikyo	nn	3	SENT_53	[p4l9t2350r223b2430],
2	University	NNP	ORGANIZATION	University	nn	3	SENT_53	[p4l251t2356r590b2430],
3	School	NNP	ORGANIZATION	School	_	0	SENT_53	[p4l613t2350r838b2411],
4	of	IN	ORGANIZATION	of	_	0	SENT_53	[p4l866t2350r939b2411],
5	Medicine	NNP	ORGANIZATION	Medicine	nn	6	SENT_53	[p4l957t2350r1264b2411],
6	Tokyo	NNP	ORGANIZATION	Tokyo	prep_of	3	SENT_53	[p4l9t2432r434b2512],
7	,	,	O	,	_	0	SENT_53	[p4l9t2432r434b2512],
8	Japan	NNP	LOCATION	Japan	nn	9	SENT_53	[p4l9t2432r434b2512],
9	takano@med.teikyo-u.ac.jp	NN	O	takano@med.teikyo-u.ac.jp	appos	6	SENT_53	[p4l9t2514r954b2594],

1	Dr.	NNP	O	Dr.	nn	2	SENT_54	[p4l97t2617r194b2672],
2	Takano	NNP	PERSON	Takano	nsubj	3	SENT_54	[p4l231t2612r477b2672],
3	reports	VBZ	O	report	_	0	SENT_54	[p4l513t2625r749b2688],
4	receiving	VBG	O	receive	xcomp	3	SENT_54	[p4l786t2613r1087b2689],
5	lecture	NN	O	lecture	nn	6	SENT_54	[p4l1118t2612r1344b2672],
6	fees	NNS	O	fee	dobj	4	SENT_54	[p4l1379t2612r1506b2671],
7	from	IN	O	from	_	0	SENT_54	[p4l1543t2612r1704b2672],
8	AstraZeneca	NNP	ORGANIZATION	AstraZeneca	prep_from	4	SENT_54	[p4l1736t2617r2149b2671],
9	and	CC	O	and	_	0	SENT_54	[p4l11t2700r132b2760],
10	Chugai	NNP	ORGANIZATION	Chugai	conj_and	8	SENT_54	[p4l165t2700r416b2777],
11	.	.	O	.	_	0	SENT_54	[p4l165t2700r416b2777],

1	No	DT	O	no	det	4	SENT_55	[p4l453t2705r548b2760],
2	other	JJ	O	other	amod	4	SENT_55	[p4l583t2700r759b2760],
3	potential	JJ	O	potential	amod	4	SENT_55	[p4l790t2700r1089b2776],
4	conflict	NN	O	conflict	nsubjpass	12	SENT_55	[p4l1123t2700r1382b2760],
5	of	IN	O	of	_	0	SENT_55	[p4l1413t2700r1490b2760],
6	interest	NN	O	interest	prep_of	4	SENT_55	[p4l1509t2701r1761b2759],
7	relevant	JJ	O	relevant	amod	6	SENT_55	[p4l1792t2700r2055b2760],
8	to	TO	O	to	_	0	SENT_55	[p4l2085t2713r2148b2760],
9	this	DT	O	this	det	10	SENT_55	[p4l11t2786r134b2845],
10	letter	NN	O	letter	prep_to	7	SENT_55	[p4l161t2786r334b2845],
11	was	VBD	O	be	auxpass	12	SENT_55	[p4l355t2805r479b2846],
12	reported	VBN	O	report	_	0	SENT_55	[p4l506t2786r807b2861],
13	.	.	O	.	_	0	SENT_55	[p4l506t2786r807b2861],

1	1	LS	NUMBER	1	_	0	SENT_56	[p4l13t2897r63b2948],
2	.	.	O	.	_	0	SENT_56	[p4l13t2897r63b2948],

1	Gazdar	NNP	PERSON	Gazdar	nn	2	SENT_57	[p4l141t2889r385b2949],
2	AF	NNP	O	AF	_	0	SENT_57	[p4l417t2894r522b2949],
3	.	.	O	.	_	0	SENT_57	[p4l417t2894r522b2949],

1	Personalized	VBN	O	personalize	_	0	SENT_58	[p4l562t2889r990b2949],
2	medicine	NN	O	medicine	dobj	1	SENT_58	[p4l1027t2889r1329b2949],
3	and	CC	O	and	_	0	SENT_58	[p4l1366t2889r1487b2949],
4	inhibition	NN	O	inhibition	dobj	1	SENT_58	[p4l1524t2889r1855b2949],
5	of	IN	O	of	_	0	SENT_58	[p4l1893t2889r1969b2949],
6	EGFR	NN	ORGANIZATION	egfr	nn	7	SENT_58	[p4l1991t2894r2153b2949],
7	signaling	NN	O	signaling	prep_of	2	SENT_58	[p4l12t2975r324b3052],
8	in	IN	O	in	_	0	SENT_58	[p4l347t2976r410b3034],
9	lung	NN	O	lung	nn	10	SENT_58	[p4l435t2975r584b3052],
10	cancer	NN	O	cancer	prep_in	7	SENT_58	[p4l608t2994r839b3035],
11	.	.	O	.	_	0	SENT_58	[p4l608t2994r839b3035],

1	N	NN	O	n	nn	2	SENT_59	[p4l868t2980r924b3035],
2	EnglJ	NN	O	englj	nsubj	3	SENT_59	[p4l948t2975r1143b3052],
3	Med	VBD	O	med	_	0	SENT_59	[p4l1165t2975r1308b3035],
4	2009	CD	DATE	2009	dobj	3	SENT_59	[p4l1334t2979r1929b3047],
5	;	:	O	;	_	0	SENT_59	[p4l1334t2979r1929b3047],
6	361:1018	CD	NUMBER	361:1018	number	7	SENT_59	[p4l1334t2979r1929b3047],
7	—	CD	NUMBER	—	dep	4	SENT_59	[p4l1334t2979r1929b3047],
8	20	CD	NUMBER	20	dep	7	SENT_59	[p4l1334t2979r1929b3047],
9	.	.	O	.	_	0	SENT_59	[p4l1334t2979r1929b3047],

1	2	LS	NUMBER	2	_	0	SENT_60	[p4l10t3069r64b3120],
2	.	.	O	.	_	0	SENT_60	[p4l10t3069r64b3120],

1	Takano	NNP	PERSON	Takano	nn	2	SENT_61	[p4l138t3061r384b3121],
2	T	NN	O	t	_	0	SENT_61	[p4l420t3066r478b3133],
3	,	,	O	,	_	0	SENT_61	[p4l420t3066r478b3133],
4	Fukui	NNP	ORGANIZATION	Fukui	nn	5	SENT_61	[p4l520t3061r711b3121],
5	T	NN	ORGANIZATION	t	appos	2	SENT_61	[p4l746t3066r804b3133],
6	,	,	O	,	_	0	SENT_61	[p4l746t3066r804b3133],
7	Ohe	NN	O	ohe	nn	8	SENT_61	[p4l847t3061r977b3120],
8	Y	NN	O	y	appos	2	SENT_61	[p4l1013t3066r1068b3133],
9	,	,	O	,	_	0	SENT_61	[p4l1013t3066r1068b3133],
10	et	FW	O	et	nn	11	SENT_61	[p4l1110t3074r1170b3120],
11	al.	FW	O	al.	appos	2	SENT_61	[p4l1204t3061r1278b3120],
12	.	.	O	.	_	0	SENT_61	[p4l1204t3061r1278b3120],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_62	[p4l1319t3065r1515b3123],
2	mutations	NNS	O	mutation	nsubj	3	SENT_62	[p4l1545t3062r1879b3121],
3	predict	VBP	O	predict	_	0	SENT_62	[p4l1918t3061r2153b3136],
4	survival	NN	O	survival	nn	5	SENT_62	[p4l12t3149r268b3209],
5	benefit	NN	O	benefit	dobj	3	SENT_62	[p4l303t3149r538b3209],
6	from	IN	O	from	_	0	SENT_62	[p4l569t3149r730b3209],
7	gefitinib	NN	O	gefitinib	prep_from	3	SENT_62	[p4l764t3149r1051b3226],
8	in	IN	O	in	_	0	SENT_62	[p4l1087t3150r1150b3208],
9	patients	NNS	O	patient	prep_in	7	SENT_62	[p4l1184t3150r1447b3225],
10	with	IN	O	with	_	0	SENT_62	[p4l1480t3149r1630b3209],
11	advanced	JJ	O	advanced	amod	13	SENT_62	[p4l1664t3149r1969b3209],
12	lung	NN	O	lung	nn	13	SENT_62	[p4l2002t3149r2151b3226],
13	adenocarcinoma	NN	O	adenocarcinoma	prep_with	9	SENT_62	[p4l11t3235r580b3294],
14	:	:	O	:	_	0	SENT_62	[p4l11t3235r580b3294],
15	a	DT	O	a	det	17	SENT_62	[p4l606t3254r640b3294],
16	historical	JJ	O	historical	amod	17	SENT_62	[p4l662t3235r977b3294],
17	comparison	NN	O	comparison	nsubj	20	SENT_62	[p4l1001t3236r1394b3310],
18	of	IN	O	of	_	0	SENT_62	[p4l1418t3235r1495b3294],
19	patients	NNS	O	patient	prep_of	17	SENT_62	[p4l1504t3236r1768b3310],
20	treated	VBN	O	treat	parataxis	3	SENT_62	[p4l1793t3235r2023b3294],
21	before	IN	O	before	_	0	SENT_62	[p4l2048t3235r2148b3294, p4l11t3321r140b3381],
22	and	CC	O	and	_	0	SENT_62	[p4l165t3321r286b3381],
23	after	IN	O	after	_	0	SENT_62	[p4l312t3321r468b3380],
24	gefitinib	NN	O	gefitinib	nn	25	SENT_62	[p4l493t3321r780b3398],
25	approval	NN	O	approval	prep_before	20	SENT_62	[p4l807t3321r1090b3397],
26	in	IN	O	in	_	0	SENT_62	[p4l1116t3322r1180b3380],
27	Japan	NNP	LOCATION	Japan	prep_in	20	SENT_62	[p4l1199t3327r1405b3397],
28	.	.	O	.	_	0	SENT_62	[p4l1199t3327r1405b3397],

1	J	NNP	O	J	nn	3	SENT_63	[p4l1428t3327r1457b3390],
2	Clin	NNP	O	Clin	nn	3	SENT_63	[p4l1482t3321r1617b3381],
3	Oncol	NNP	O	Oncol	_	0	SENT_63	[p4l1644t3321r1839b3381],
4	2008	CD	DATE	2008	num	3	SENT_63	[p4l1866t3326r2145b3393],
5	;	:	O	;	_	0	SENT_63	[p4l1866t3326r2145b3393],
6	26	CD	NUMBER	26	num	8	SENT_63	[p4l1866t3326r2145b3393],
7	:	:	O	:	_	0	SENT_63	[p4l1866t3326r2145b3393],
8	5589-95	CD	NUMBER	5589-95	dep	3	SENT_63	[p4l12t3421r289b3477],
9	.	.	O	.	_	0	SENT_63	[p4l12t3421r289b3477],

1	TO	TO	O	to	aux	3	SENT_64	[p4l10t3680r123b3736],
2	TH	NN	O	th	nn	3	SENT_64	[p4l151t3681r259b3735],
3	E	NN	O	e	_	0	SENT_64	[p4l278t3681r316b3735],
4	EDITO	NN	O	edito	nn	5	SENT_64	[p4l352t3680r607b3736],
5	R	NN	O	r	dobj	3	SENT_64	[p4l621t3681r690b3736],
6	:	:	O	:	_	0	SENT_64	[p4l621t3681r690b3736],
7	Rosell	NNP	PERSON	Rosell	dep	5	SENT_64	[p4l722t3657r991b3741],
8	et	FW	O	et	nn	9	SENT_64	[p4l1022t3674r1099b3736],
9	al.	FW	O	al.	dep	7	SENT_64	[p4l1124t3657r1262b3736],
10	1	CD	NUMBER	1	num	11	SENT_64	[p4l1124t3657r1262b3736],
11	report	NN	O	report	dep	7	SENT_64	[p4l1293t3674r1561b3758],
12	a	DT	O	a	det	14	SENT_64	[p4l1587t3684r1631b3736],
13	remarkable	JJ	O	remarkable	amod	14	SENT_64	[p4l1659t3657r2148b3737],
14	response	NN	O	response	dep	11	SENT_64	[p5l12t46r395b121],
15	to	TO	O	to	aux	16	SENT_64	[p5l425t37r507b99],
16	erlotinib	VB	O	erlotinib	xcomp	3	SENT_64	[p5l539t20r908b99],
17	in	IN	O	in	_	0	SENT_64	[p5l939t21r1022b98],
18	patients	NNS	O	patient	prep_in	16	SENT_64	[p5l1051t21r1394b121],
19	with	IN	O	with	_	0	SENT_64	[p5l1422t20r1618b99],
20	lung	NN	O	lung	nn	21	SENT_64	[p5l1647t20r1842b121],
21	cancer	NN	O	cancer	prep_with	16	SENT_64	[p5l1869t46r2151b99],
22	who	WP	O	who	nsubj	23	SENT_64	[p5l7t148r189b227],
23	have	VBP	O	have	rcmod	21	SENT_64	[p5l216t148r402b227],
24	an	DT	O	a	det	26	SENT_64	[p5l429t174r530b227],
25	EGFR	NN	ORGANIZATION	egfr	nn	26	SENT_64	[p5l556t155r764b228],
26	mutation	NN	O	mutation	dobj	23	SENT_64	[p5l784t149r1191b227],
27	.	.	O	.	_	0	SENT_64	[p5l784t149r1191b227],

1	However	RB	O	however	advmod	11	SENT_65	[p5l1222t156r1608b244],
2	,	,	O	,	_	0	SENT_65	[p5l1222t156r1608b244],
3	217	CD	NUMBER	217	num	4	SENT_65	[p5l1640t154r1787b227],
4	patients	NNS	O	patient	nsubjpass	11	SENT_65	[p5l1813t149r2146b249],
5	who	WP	O	who	nsubjpass	7	SENT_65	[p5l8t276r192b356],
6	were	VBD	O	be	auxpass	7	SENT_65	[p5l237t302r440b356],
7	treated	VBN	O	treat	rcmod	4	SENT_65	[p5l488t276r789b355],
8	with	IN	O	with	_	0	SENT_65	[p5l832t276r1029b356],
9	erlotinib	NN	O	erlotinib	prep_with	7	SENT_65	[p5l1078t276r1447b355],
10	were	VBD	O	be	auxpass	11	SENT_65	[p5l1492t302r1695b355],
11	evaluated	VBN	O	evaluate	_	0	SENT_65	[p5l1744t276r2148b355],
12	for	IN	O	for	_	0	SENT_65	[p5l12t404r136b483],
13	survival	NN	O	survival	prep_for	11	SENT_65	[p5l186t404r543b500],
14	,	,	O	,	_	0	SENT_65	[p5l186t404r543b500],
15	but	CC	O	but	_	0	SENT_65	[p5l601t404r742b483],
16	only	RB	O	only	advmod	17	SENT_65	[p5l790t404r974b505],
17	197	CD	NUMBER	197	nsubjpass	19	SENT_65	[p5l1025t410r1173b483],
18	were	VBD	O	be	auxpass	19	SENT_65	[p5l1221t430r1424b483],
19	evaluated	VBN	O	evaluate	conj_but	11	SENT_65	[p5l1476t404r1882b483],
20	for	IN	O	for	_	0	SENT_65	[p5l1933t404r2057b483],
21	a	DT	O	a	det	22	SENT_65	[p5l2105t431r2149b483],
22	response	NN	O	response	prep_for	19	SENT_65	[p5l12t558r395b633],
23	to	TO	O	to	_	0	SENT_65	[p5l429t549r511b611],
24	therapy	NN	O	therapy	prep_to	19	SENT_65	[p5l546t532r883b633],
25	.	.	O	.	_	0	SENT_65	[p5l546t532r883b633],

1	Second	RB	ORDINAL	second	advmod	5	SENT_66	[p5l924t532r1253b628],
2	,	,	O	,	_	0	SENT_66	[p5l924t532r1253b628],
3	55	CD	NUMBER	55	num	4	SENT_66	[p5l1294t540r1386b611],
4	patients	NNS	O	patient	nsubj	5	SENT_66	[p5l1422t533r1765b633],
5	received	VBD	O	receive	_	0	SENT_66	[p5l1801t532r2148b611],
6	additional	JJ	O	additional	amod	7	SENT_66	[p5l12t660r451b739],
7	treatment	NN	O	treatment	dobj	5	SENT_66	[p5l486t677r912b739],
8	after	IN	O	after	_	0	SENT_66	[p5l942t660r1145b739],
9	erlotinib	NN	O	erlotinib	prep_after	5	SENT_66	[p5l1178t660r1569b739],
10	.	.	O	.	_	0	SENT_66	[p5l1178t660r1569b739],

1	Did	VBD	O	do	_	0	SENT_67	[p5l1609t660r1761b739],
2	they	PRP	O	they	nsubj	4	SENT_67	[p5l1796t660r1979b761],
3	not	RB	O	not	neg	4	SENT_67	[p5l2010t677r2153b739],
4	have	VBP	O	have	ccomp	1	SENT_67	[p5l12t788r203b868],
5	a	DT	O	a	det	6	SENT_67	[p5l232t815r276b868],
6	response	NN	O	response	dobj	4	SENT_67	[p5l304t814r687b890],
7	to	TO	O	to	aux	8	SENT_67	[p5l717t805r799b868],
8	erlotinib	VB	O	erlotinib	infmod	6	SENT_67	[p5l830t787r1238b868],
9	?	.	O	?	_	0	SENT_67	[p5l830t787r1238b868],

1	Finally	RB	O	finally	advmod	13	SENT_68	[p5l1266t788r1574b890],
2	,	,	O	,	_	0	SENT_68	[p5l1266t788r1574b890],
3	the	DT	O	the	det	4	SENT_68	[p5l1609t788r1742b868],
4	presence	NN	O	presence	nsubj	13	SENT_68	[p5l1770t814r2148b890],
5	or	CC	O	or	_	0	SENT_68	[p5l13t943r102b996],
6	absence	NN	O	absence	nsubj	13	SENT_68	[p5l139t917r479b996],
7	of	IN	O	of	_	0	SENT_68	[p5l521t917r622b996],
8	mutant	JJ	O	mutant	amod	9	SENT_68	[p5l644t934r960b996],
9	alleles	NNS	O	allele	prep_of	4	SENT_68	[p5l996t917r1263b996],
10	of	IN	O	of	_	0	SENT_68	[p5l1308t917r1408b996],
11	T79OM	NN	O	t79om	prep_of	9	SENT_68	[p5l1427t923r1731b996],
12	is	VBZ	O	be	cop	13	SENT_68	[p5l1773t918r1839b996],
13	useful	JJ	O	useful	_	0	SENT_68	[p5l1883t917r2149b996],
14	for	IN	O	for	_	0	SENT_68	[p5l12t1045r136b1124],
15	predicting	VBG	O	predict	prepc_for	13	SENT_68	[p5l170t1045r620b1146],
16	gefitinib	NN	O	gefitinib	nn	17	SENT_68	[p5l655t1045r1029b1146],
17	resistance	NN	O	resistance	dobj	15	SENT_68	[p5l1069t1046r1524b1124],
18	.	.	O	.	_	0	SENT_68	[p5l1069t1046r1524b1124],

1	In	IN	O	in	_	0	SENT_69	[p5l1566t1053r1656b1123],
2	this	DT	O	this	det	3	SENT_69	[p5l1695t1045r1856b1124],
3	study	NN	O	study	prep_in	9	SENT_69	[p5l1898t1045r2142b1146],
4	,	,	O	,	_	0	SENT_69	[p5l1898t1045r2142b1146],
5	T	NN	O	t	nsubjpass	9	SENT_69	[p5l8t1179r70b1251],
6	790M	CD	NUMBER	790m	num	7	SENT_69	[p5l75t1179r313b1252],
7	data	NNS	O	datum	dep	5	SENT_69	[p5l355t1173r538b1252],
8	were	VBD	O	be	auxpass	9	SENT_69	[p5l573t1199r776b1252],
9	reported	VBN	O	report	_	0	SENT_69	[p5l815t1173r1184b1274],
10	for	IN	O	for	_	0	SENT_69	[p5l1223t1173r1347b1252],
11	35	CD	NUMBER	35	num	12	SENT_69	[p5l1384t1179r1478b1252],
12	patients	NNS	O	patient	prep_for	9	SENT_69	[p5l1519t1174r1888b1274],
13	.	.	O	.	_	0	SENT_69	[p5l1519t1174r1888b1274],

1	Were	VBD	O	be	cop	3	SENT_70	[p5l1930t1181r2148b1252],
2	these	DT	O	these	det	3	SENT_70	[p5l12t1301r233b1381],
3	patients	NNS	O	patient	_	0	SENT_70	[p5l264t1303r599b1403],
4	resistant	JJ	O	resistant	amod	3	SENT_70	[p5l634t1303r1000b1381],
5	to	TO	O	to	aux	6	SENT_70	[p5l1027t1318r1108b1381],
6	erlotinib	VB	O	erlotinib	xcomp	4	SENT_70	[p5l1143t1300r1540b1381],
7	?	.	O	?	_	0	SENT_70	[p5l1143t1300r1540b1381],

1	What	WDT	O	what	det	2	SENT_71	[p5l1569t1301r1803b1381],
2	proportion	NN	O	proportion	nsubj	7	SENT_71	[p5l1828t1327r2147b1403, p5l12t1432r181b1510],
3	of	IN	O	of	_	0	SENT_71	[p5l216t1430r317b1510],
4	all	DT	O	all	det	6	SENT_71	[p5l333t1431r438b1510],
5	2105	CD	DATE	2105	num	6	SENT_71	[p5l472t1437r669b1510],
6	patients	NNS	O	patient	prep_of	2	SENT_71	[p5l707t1432r1050b1532],
7	had	VBD	O	have	_	0	SENT_71	[p5l1087t1431r1245b1510],
8	a	DT	O	a	det	10	SENT_71	[p5l1279t1458r1324b1510],
9	T79OM	NN	O	t79om	nn	10	SENT_71	[p5l1353t1437r1657b1510],
10	mutation	NN	O	mutation	dobj	7	SENT_71	[p5l1694t1428r2127b1510],
11	?	.	O	?	_	0	SENT_71	[p5l1694t1428r2127b1510],

1	jian	NN	PERSON	jian	_	0	SENT_72	[p5l7t1554r177b1649],
2	Wang	NNP	PERSON	Wang	nn	4	SENT_72	[p5l211t1554r485b1652],
3	,	,	O	,	_	0	SENT_72	[p5l211t1554r485b1652],
4	Ph.D.	NNP	O	Ph.D.	dep	1	SENT_72	[p5l530t1547r758b1626],
5	.	.	O	.	_	0	SENT_72	[p5l530t1547r758b1626],

1	Jian-hua	JJ	O	jian-hua	amod	2	SENT_73	[p5l7t1664r376b1767],
2	Qiu	NNP	O	Qiu	_	0	SENT_73	[p5l412t1670r591b1766],
3	,	,	O	,	_	0	SENT_73	[p5l412t1670r591b1766],
4	M.D.	NNP	ORGANIZATION	M.D.	appos	2	SENT_73	[p5l635t1671r841b1744],
5	Fourth	JJ	ORGANIZATION	fourth	amod	9	SENT_73	[p5l26t1800r241b1859],
6	Military	NNP	ORGANIZATION	Military	nn	9	SENT_73	[p5l274t1800r525b1878],
7	Medical	NNP	ORGANIZATION	Medical	nn	9	SENT_73	[p5l553t1800r809b1859],
8	University	NNP	ORGANIZATION	University	nn	9	SENT_73	[p5l841t1805r1177b1878],
9	Xi'an	NNP	ORGANIZATION	Xi'an	dep	2	SENT_73	[p5l18t1900r201b1967],
10	,	,	O	,	_	0	SENT_73	[p5l18t1900r201b1967],
11	China	NNP	LOCATION	China	appos	9	SENT_73	[p5l229t1896r418b1956],

1	1	LS	NUMBER	1	_	0	SENT_74	[p5l22t2065r71b2116],
2	.	.	O	.	_	0	SENT_74	[p5l22t2065r71b2116],

1	Rosell	NNP	PERSON	Rosell	nn	2	SENT_75	[p5l147t2057r351b2119],
2	R	NNP	PERSON	R	_	0	SENT_75	[p5l375t2062r440b2128],
3	,	,	O	,	_	0	SENT_75	[p5l375t2062r440b2128],
4	Moran	NNP	PERSON	Moran	nn	5	SENT_75	[p5l468t2062r684b2116],
5	T	NN	O	t	appos	2	SENT_75	[p5l707t2061r765b2128],
6	,	,	O	,	_	0	SENT_75	[p5l707t2061r765b2128],
7	Queralt	NN	O	queralt	nn	8	SENT_75	[p5l795t2057r1042b2131],
8	C	NN	O	c	appos	2	SENT_75	[p5l1063t2061r1126b2128],
9	,	,	O	,	_	0	SENT_75	[p5l1063t2061r1126b2128],
10	et	FW	O	et	nn	11	SENT_75	[p5l1156t2070r1215b2116],
11	al.	FW	O	al.	appos	2	SENT_75	[p5l1236t2057r1310b2116],
12	.	.	O	.	_	0	SENT_75	[p5l1236t2057r1310b2116],

1	Screening	VBG	O	screen	_	0	SENT_76	[p5l1342t2058r1666b2132],
2	for	IN	O	for	_	0	SENT_76	[p5l1689t2056r1783b2116],
3	epidermal	JJ	O	epidermal	amod	7	SENT_76	[p5l1807t2057r2136b2132],
4	growth	NN	O	growth	nn	7	SENT_76	[p5l20t2153r259b2228],
5	factor	NN	O	factor	nn	7	SENT_76	[p5l287t2152r479b2212],
6	receptor	NN	O	receptor	nn	7	SENT_76	[p5l505t2166r778b2228],
7	mutations	NNS	O	mutation	prep_for	1	SENT_76	[p5l804t2154r1135b2213],
8	in	IN	O	in	_	0	SENT_76	[p5l1166t2154r1229b2211],
9	lung	NN	O	lung	nn	10	SENT_76	[p5l1257t2153r1404b2228],
10	cancer	NN	O	cancer	prep_in	7	SENT_76	[p5l1431t2172r1659b2212],
11	.	.	O	.	_	0	SENT_76	[p5l1431t2172r1659b2212],

1	N	NN	O	n	nn	3	SENT_77	[p5l1690t2158r1747b2213],
2	Engl	NNP	O	Engl	nn	3	SENT_77	[p5l1774t2153r1921b2228],
3	J	NNP	O	J	nsubj	4	SENT_77	[p5l1942t2158r1970b2221],
4	Med	VBD	O	med	_	0	SENT_77	[p5l1995t2153r2136b2212],
5	2009	CD	DATE	2009	dobj	4	SENT_77	[p5l20t2253r571b2320],
6	;	:	O	;	_	0	SENT_77	[p5l20t2253r571b2320],
7	361:958	CD	NUMBER	361:958	number	8	SENT_77	[p5l20t2253r571b2320],
8	—	CD	NUMBER	—	dep	5	SENT_77	[p5l20t2253r571b2320],
9	67	CD	NUMBER	67	dep	8	SENT_77	[p5l20t2253r571b2320],
10	.	.	O	.	_	0	SENT_77	[p5l20t2253r571b2320],

1	DR.	NNP	O	DR.	nn	2	SENT_78	[p5l27t2537r161b2591],
2	MOK	NNP	O	MOK	_	0	SENT_78	[p5l203t2536r392b2591],
3	AND	CC	O	and	_	0	SENT_78	[p5l424t2537r606b2590],
4	COLLEAGUES	NNS	O	colleague	nn	5	SENT_78	[p5l640t2536r1186b2591],
5	REPLY	NN	O	reply	conj_and	2	SENT_78	[p5l1224t2537r1489b2591],
6	:	:	O	:	_	0	SENT_78	[p5l1224t2537r1489b2591],
7	Ballatori	NNP	O	Ballatori	dep	2	SENT_78	[p5l1524t2513r1894b2591],
8	et	FW	O	et	nn	9	SENT_78	[p5l1928t2530r2005b2591],
9	al.	FW	O	al.	dep	7	SENT_78	[p5l2033t2513r2130b2591],
10	and	CC	O	and	_	0	SENT_78	[p5l20t2639r177b2717],
11	Seruga	FW	PERSON	seruga	nn	12	SENT_78	[p5l221t2645r510b2739],
12	et	FW	O	et	dep	2	SENT_78	[p5l551t2656r628b2717],
13	al.	FW	O	al.	nsubj	14	SENT_78	[p5l664t2639r760b2717],
14	ask	VB	O	ask	rcmod	12	SENT_78	[p5l807t2639r951b2718],
15	whether	IN	O	whether	complm	25	SENT_78	[p5l984t2639r1337b2718],
16	the	DT	O	the	det	17	SENT_78	[p5l1377t2639r1509b2717],
17	superiority	NN	O	superiority	nsubj	25	SENT_78	[p5l1553t2640r2016b2739],
18	of	IN	O	of	_	0	SENT_78	[p5l2054t2639r2153b2717],
19	gefitinib	NN	O	gefitinib	prep_of	17	SENT_78	[p5l21t2766r391b2866],
20	over	IN	O	over	_	0	SENT_78	[p5l437t2792r614b2845],
21	carboplatin	NN	O	carboplatin	nn	23	SENT_78	[p5l656t2766r1612b2866],
22	—	CD	NUMBER	—	num	23	SENT_78	[p5l656t2766r1612b2866],
23	paclitaXel	NN	O	paclitaxel	prep_over	19	SENT_78	[p5l656t2766r1612b2866],
24	was	VBD	O	be	cop	25	SENT_78	[p5l1652t2793r1814b2845],
25	due	JJ	O	due	ccomp	14	SENT_78	[p5l1860t2766r2008b2845],
26	to	TO	O	to	_	0	SENT_78	[p5l2053t2783r2134b2844],
27	crossing	VBG	O	cross	prepc_to	25	SENT_78	[p5l21t2894r377b2993],
28	progression	NN	O	progression	npadvmod	30	SENT_78	[p5l399t2893r1089b2993],
29	—	CD	NUMBER	—	num	28	SENT_78	[p5l399t2893r1089b2993],
30	free	JJ	O	free	amod	32	SENT_78	[p5l399t2893r1089b2993],
31	survival	NN	O	survival	nn	32	SENT_78	[p5l1117t2893r1440b2972],
32	curves	NNS	O	curve	dobj	27	SENT_78	[p5l1468t2919r1755b2972],
33	.	.	O	.	_	0	SENT_78	[p5l1468t2919r1755b2972],

1	The	DT	O	the	det	4	SENT_79	[p5l1784t2893r1942b2971],
2	prespecified	JJ	O	prespecified	amod	4	SENT_79	[p5l1968t2919r2134b2993, p5l22t3020r398b3120],
3	primary	JJ	O	primary	amod	4	SENT_79	[p5l429t3021r772b3120],
4	analysis	NN	O	analysis	nsubj	14	SENT_79	[p5l798t3020r1129b3120],
5	of	IN	O	of	_	0	SENT_79	[p5l1164t3020r1263b3098],
6	our	PRP$	O	we	poss	8	SENT_79	[p5l1277t3046r1420b3099],
7	regulatory	JJ	O	regulatory	amod	8	SENT_79	[p5l1449t3020r1886b3120],
8	study	NN	O	study	prep_of	4	SENT_79	[p5l1915t3020r2139b3120],
9	was	VBD	O	be	cop	14	SENT_79	[p5l16t3174r178b3226],
10	noninferiority	JJ	O	noninferiority	amod	14	SENT_79	[p5l209t3147r814b3247],
11	(	NN	O	(	nn	14	SENT_79	[p5l843t3148r1184b3247],
12	margin	NN	O	margin	nn	14	SENT_79	[p5l843t3148r1184b3247],
13	hazard	NN	O	hazard	nn	14	SENT_79	[p5l1212t3147r1508b3225],
14	ratio	NN	O	ratio	_	0	SENT_79	[p5l1537t3148r1755b3242],
15	,	,	O	,	_	0	SENT_79	[p5l1537t3148r1755b3242],
16	1.20	CD	NUMBER	1.20	num	17	SENT_79	[p5l1793t3153r1995b3238],
17	)	NN	O	)	appos	14	SENT_79	[p5l1793t3153r1995b3238],
18	on	IN	O	on	_	0	SENT_79	[p5l2030t3173r2135b3225],
19	the	DT	O	the	det	20	SENT_79	[p5l21t3274r154b3352],
20	basis	NN	O	basis	prep_on	17	SENT_79	[p5l185t3274r396b3352],
21	of	IN	O	of	_	0	SENT_79	[p5l430t3274r529b3352],
22	a	DT	O	a	det	24	SENT_79	[p5l541t3301r585b3352],
23	standard	JJ	O	standard	amod	24	SENT_79	[p5l616t3274r994b3352],
24	Cox	NN	ORGANIZATION	cox	prep_of	20	SENT_79	[p5l1025t3280r1188b3352],
25	proportional	JJ	O	proportional	amod	28	SENT_79	[p5l1215t3274r2133b3374],
26	—	NN	O	—	nn	28	SENT_79	[p5l1215t3274r2133b3374],
27	hazards	NNS	O	hazard	nn	28	SENT_79	[p5l1215t3274r2133b3374],
28	model	NN	O	model	tmod	24	SENT_79	[p5l21t3401r309b3496],
29	,	,	O	,	_	0	SENT_79	[p5l21t3401r309b3496],
30	from	IN	O	from	_	0	SENT_79	[p5l364t3401r574b3479],
31	which	WDT	O	which	rel	44	SENT_79	[p5l617t3401r879b3480],
32	the	DT	O	the	dep	35	SENT_79	[p5l928t3401r1060b3479],
33	reported	VBN	O	report	amod	35	SENT_79	[p5l1109t3401r1473b3501],
34	hazard	NN	O	hazard	nn	35	SENT_79	[p5l1522t3401r1818b3479],
35	ratios	NNS	O	ratio	nsubjpass	44	SENT_79	[p5l1866t3402r2130b3496],
36	,	,	O	,	_	0	SENT_79	[p5l1866t3402r2130b3496],
37	confidence	NN	O	confidence	nn	38	SENT_79	[p5l21t3528r491b3606],
38	intervals	NNS	O	interval	appos	35	SENT_79	[p5l526t3528r917b3623],
39	,	,	O	,	_	0	SENT_79	[p5l526t3528r917b3623],
40	and	CC	O	and	_	0	SENT_79	[p5l956t3528r1114b3606],
41	P	NN	O	p	nn	42	SENT_79	[p5l1147t3535r1199b3605],
42	values	NNS	O	value	conj_and	35	SENT_79	[p5l1228t3528r1489b3607],
43	were	VBD	O	be	auxpass	44	SENT_79	[p5l1522t3555r1723b3607],
44	obtained	VBN	O	obtain	rcmod	28	SENT_79	[p5l1758t3528r2135b3606],
45	(	JJ	O	(	acomp	44	SENT_79	[p5l26t3662r194b3746],
46	not	RB	O	not	neg	44	SENT_79	[p5l26t3662r194b3746],
47	from	IN	O	from	_	0	SENT_79	[p5l221t3655r430b3733],
48	medians	NNS	O	median	prep_from	44	SENT_79	[p5l463t3655r827b3733],
49	or	CC	O	or	_	0	SENT_79	[p5l862t3681r950b3733],
50	12-month	JJ	DURATION	12-month	amod	51	SENT_79	[p5l983t3655r1398b3733],
51	progression	NN	O	progression	prep_from	44	SENT_79	[p5l1429t3655r2135b3755],
52	—	CD	NUMBER	—	num	54	SENT_79	[p5l1429t3655r2135b3755],
53	free	JJ	O	free	amod	54	SENT_79	[p5l1429t3655r2135b3755],
54	survival	NN	O	survival	dep	51	SENT_79	[p6l22t20r367b115],
55	,	,	O	,	_	0	SENT_79	[p6l22t20r367b115],
56	which	WDT	O	which	nsubj	59	SENT_79	[p6l395t20r652b99],
57	are	VBP	O	be	cop	59	SENT_79	[p6l678t46r804b98],
58	summary	NN	O	summary	nn	59	SENT_79	[p6l832t46r1236b120],
59	statistics	NNS	O	statistics	rcmod	17	SENT_79	[p6l1260t21r1674b110],
60	)	CD	NUMBER	)	attr	59	SENT_79	[p6l1260t21r1674b110],
61	.	.	O	.	_	0	SENT_79	[p6l1260t21r1674b110],

1	The	DT	O	the	det	3	SENT_80	[p6l1703t20r1860b98],
2	crossing	VBG	O	cross	amod	3	SENT_80	[p6l1888t46r2134b98, p6l20t148r159b247],
3	curves	NNS	O	curve	nsubjpass	8	SENT_80	[p6l196t173r466b226],
4	could	MD	O	could	aux	8	SENT_80	[p6l508t147r741b226],
5	not	RB	O	not	neg	8	SENT_80	[p6l781t164r923b225],
6	have	VB	O	have	aux	8	SENT_80	[p6l958t147r1147b226],
7	been	VBN	O	be	auxpass	8	SENT_80	[p6l1187t147r1387b225],
8	predicted	VBN	O	predict	_	0	SENT_80	[p6l1426t147r1827b247],
9	before	IN	O	before	_	0	SENT_80	[p6l1867t147r2135b225],
10	analysis	NN	O	analysis	prep_before	8	SENT_80	[p6l20t274r383b374],
11	,	,	O	,	_	0	SENT_80	[p6l20t274r383b374],
12	and	CC	O	and	_	0	SENT_80	[p6l417t274r574b352],
13	the	DT	O	the	det	17	SENT_80	[p6l603t274r735b352],
14	prespecified	JJ	O	prespecified	amod	17	SENT_80	[p6l762t274r1290b374],
15	primary	JJ	O	primary	amod	17	SENT_80	[p6l1316t275r1665b374],
16	Cox	NN	ORGANIZATION	cox	nn	17	SENT_80	[p6l1689t280r1852b352],
17	analysis	NN	O	analysis	nsubjpass	20	SENT_80	[p6l1878t274r2134b374, p6l22t402r128b479],
18	must	MD	O	must	aux	20	SENT_80	[p6l177t417r391b480],
19	be	VB	O	be	auxpass	20	SENT_80	[p6l433t401r529b479],
20	reported	VBN	O	report	conj_and	8	SENT_80	[p6l575t401r963b501],
21	.	.	O	.	_	0	SENT_80	[p6l575t401r963b501],

1	This	DT	O	this	det	2	SENT_81	[p6l1012t401r1198b479],
2	analysis	NN	O	analysis	nsubj	3	SENT_81	[p6l1246t401r1585b501],
3	showed	VBD	O	show	_	0	SENT_81	[p6l1635t401r1956b480],
4	the	DT	O	the	det	5	SENT_81	[p6l2002t401r2135b479],
5	superiority	NN	O	superiority	dobj	3	SENT_81	[p6l22t529r497b628],
6	of	IN	O	of	_	0	SENT_81	[p6l543t528r643b606],
7	gefitinib	NN	O	gefitinib	nn	9	SENT_81	[p6l675t528r1053b628],
8	(	CD	NUMBER	(	num	9	SENT_81	[p6l1110t534r1536b619],
9	P	NN	O	p	prep_of	5	SENT_81	[p6l1110t534r1536b619],
10	<	JJR	O	<	tmod	3	SENT_81	[p6l1110t534r1536b619],
11	0.001	CD	NUMBER	0.001	num	12	SENT_81	[p6l1110t534r1536b619],
12	)	NN	O	)	dep	10	SENT_81	[p6l1110t534r1536b619],
13	.	.	O	.	_	0	SENT_81	[p6l1110t534r1536b619],

1	However	RB	O	however	advmod	10	SENT_82	[p6l1591t535r1992b623],
2	,	,	O	,	_	0	SENT_82	[p6l1591t535r1992b623],
3	as	IN	O	as	mark	6	SENT_82	[p6l2047t555r2133b606],
4	crossing	VBG	O	cross	csubj	6	SENT_82	[p6l21t656r390b755],
5	became	VBD	O	become	cop	6	SENT_82	[p6l449t655r780b733],
6	apparent	JJ	O	apparent	advcl	10	SENT_82	[p6l840t672r1248b755],
7	,	,	O	,	_	0	SENT_82	[p6l840t672r1248b755],
8	further	JJ	O	further	amod	9	SENT_82	[p6l1314t655r1628b734],
9	evaluation	NN	O	evaluation	nsubj	10	SENT_82	[p6l1686t655r2135b734],
10	showed	VBD	O	show	_	0	SENT_82	[p6l22t783r349b863],
11	that	IN	O	that	complm	15	SENT_82	[p6l388t783r561b862],
12	this	DT	O	this	det	13	SENT_82	[p6l593t783r751b862],
13	difference	NN	O	difference	nsubj	15	SENT_82	[p6l791t783r1220b862],
14	was	VBD	O	be	cop	15	SENT_82	[p6l1253t810r1415b862],
15	due	JJ	O	due	ccomp	10	SENT_82	[p6l1454t783r1602b862],
16	to	TO	O	to	_	0	SENT_82	[p6l1639t800r1720b862],
17	two	CD	NUMBER	two	num	18	SENT_82	[p6l1758t800r1915b862],
18	subgroups	NNS	O	subgroup	prep_to	15	SENT_82	[p6l1955t783r2134b862, p6l21t936r340b1010],
19	:	:	O	:	_	0	SENT_82	[p6l1955t783r2134b862, p6l21t936r340b1010],

1	patients	NNS	O	patient	nsubj	5	SENT_83	[p6l382t911r723b1010],
2	with	IN	O	with	_	0	SENT_83	[p6l761t910r955b989],
3	EGFR	NN	ORGANIZATION	egfr	nn	4	SENT_83	[p6l994t917r1205b990],
4	mutations	NNS	O	mutation	prep_with	1	SENT_83	[p6l1239t911r1672b989],
5	(	VBP	O	(	_	0	SENT_83	[p6l1719t911r1829b1001],
6	in	IN	O	in	dep	11	SENT_83	[p6l1719t911r1829b1001],
7	whom	WP	O	whom	pobj	6	SENT_83	[p6l1865t910r2135b989],
8	gefitinib	NN	O	gefitinib	nsubj	11	SENT_83	[p6l21t1037r391b1137],
9	was	VBD	O	be	cop	11	SENT_83	[p6l435t1064r597b1116],
10	superior	JJ	O	superior	amod	11	SENT_83	[p6l647t1038r1023b1137],
11	)	NN	O	)	dep	5	SENT_83	[p6l647t1038r1023b1137],
12	and	CC	O	and	_	0	SENT_83	[p6l1075t1037r1232b1115],
13	those	DT	O	those	nsubj	17	SENT_83	[p6l1279t1037r1509b1115],
14	without	IN	O	without	_	0	SENT_83	[p6l1552t1037r1890b1116],
15	EGFR	NN	ORGANIZATION	egfr	nn	16	SENT_83	[p6l1930t1044r2142b1117],
16	mutations	NNS	O	mutation	prep_without	13	SENT_83	[p6l21t1165r453b1243],
17	(	VBP	O	(	dep	5	SENT_83	[p6l498t1165r608b1255],
18	in	IN	O	in	_	0	SENT_83	[p6l498t1165r608b1255],
19	whom	WP	O	whom	dobj	24	SENT_83	[p6l641t1164r911b1243],
20	gefitinib	NN	O	gefitinib	nsubj	24	SENT_83	[p6l948t1164r1318b1264],
21	was	VBD	O	be	cop	24	SENT_83	[p6l1352t1191r1514b1243],
22	not	RB	O	not	neg	24	SENT_83	[p6l1554t1181r1696b1242],
23	superior	JJ	O	superior	amod	24	SENT_83	[p6l1729t1165r2130b1264],
24	)	NN	O	)	prepc_in	17	SENT_83	[p6l1729t1165r2130b1264],
25	.	.	O	.	_	0	SENT_83	[p6l1729t1165r2130b1264],

1	The	DT	O	the	det	6	SENT_84	[p6l17t1291r178b1369],
2	progression	NN	O	progression	nn	6	SENT_84	[p6l202t1291r908b1391],
3	—	CD	NUMBER	—	num	6	SENT_84	[p6l202t1291r908b1391],
4	free	JJ	O	free	amod	6	SENT_84	[p6l202t1291r908b1391],
5	survival	NN	O	survival	nn	6	SENT_84	[p6l936t1291r1266b1370],
6	curves	NNS	O	curve	nsubj	9	SENT_84	[p6l1293t1317r1562b1370],
7	did	VBD	O	do	aux	9	SENT_84	[p6l1592t1291r1725b1369],
8	not	RB	O	not	neg	9	SENT_84	[p6l1752t1308r1894b1369],
9	cross	VB	O	cross	_	0	SENT_84	[p6l1916t1317r2133b1369],
10	within	IN	O	within	_	0	SENT_84	[p6l17t1418r305b1497],
11	either	DT	O	either	prep_within	9	SENT_84	[p6l363t1418r614b1496],
12	of	IN	O	of	_	0	SENT_84	[p6l667t1418r768b1496],
13	these	DT	O	these	det	14	SENT_84	[p6l806t1418r1033b1496],
14	subgroups	NNS	O	subgroup	prep_of	11	SENT_84	[p6l1091t1418r1570b1518],
15	,	,	O	,	_	0	SENT_84	[p6l1091t1418r1570b1518],
16	so	IN	O	so	dep	9	SENT_84	[p6l1634t1444r1724b1496],
17	the	DT	O	the	det	19	SENT_84	[p6l1783t1418r1917b1496],
18	Cox	NN	ORGANIZATION	cox	nn	19	SENT_84	[p6l1973t1424r2138b1496],
19	model	NN	O	model	nsubj	21	SENT_84	[p6l21t1545r287b1623],
20	was	VBD	O	be	cop	21	SENT_84	[p6l317t1572r479b1624],
21	appropriate	JJ	O	appropriate	ccomp	9	SENT_84	[p6l515t1546r1008b1645],
22	in	IN	O	in	_	0	SENT_84	[p6l1042t1546r1125b1622],
23	these	DT	O	these	det	24	SENT_84	[p6l1160t1545r1382b1623],
24	subgroups	NNS	O	subgroup	prep_in	21	SENT_84	[p6l1419t1545r1887b1645],
25	.	.	O	.	_	0	SENT_84	[p6l1419t1545r1887b1645],

1	After	IN	O	after	_	0	SENT_85	[p6l146t1672r361b1750],
2	these	DT	O	these	det	3	SENT_85	[p6l389t1672r605b1750],
3	observations	NNS	O	observation	prep_after	9	SENT_85	[p6l636t1672r1182b1767],
4	,	,	O	,	_	0	SENT_85	[p6l636t1672r1182b1767],
5	the	DT	O	the	det	8	SENT_85	[p6l1218t1672r1347b1750],
6	overall	JJ	O	overall	amod	8	SENT_85	[p6l1378t1672r1652b1751],
7	population	NN	O	population	nn	8	SENT_85	[p6l1681t1672r2135b1772],
8	result	NN	O	result	nsubj	9	SENT_85	[p6l21t1799r255b1878],
9	is	VBZ	O	be	_	0	SENT_85	[p6l283t1800r346b1877],
10	clearly	RB	O	clearly	advmod	9	SENT_85	[p6l382t1799r650b1899],
11	of	IN	O	of	_	0	SENT_85	[p6l679t1799r777b1877],
12	less	JJR	O	less	amod	13	SENT_85	[p6l791t1799r940b1877],
13	relevance	NN	O	relevance	prep_of	9	SENT_85	[p6l976t1799r1358b1878],
14	than	IN	O	than	_	0	SENT_85	[p6l1391t1799r1582b1877],
15	the	DT	O	the	det	16	SENT_85	[p6l1616t1799r1744b1877],
16	outcome	NN	O	outcome	prep_than	13	SENT_85	[p6l1778t1816r2135b1878],
17	in	IN	O	in	_	0	SENT_85	[p6l21t1927r102b2003],
18	these	DT	O	these	det	19	SENT_85	[p6l155t1926r371b2004],
19	subgroups	NNS	O	subgroup	prep_in	16	SENT_85	[p6l426t1926r881b2026],
20	.	.	O	.	_	0	SENT_85	[p6l426t1926r881b2026],

1	However	RB	O	however	advmod	17	SENT_86	[p6l938t1934r1320b2021],
2	,	,	O	,	_	0	SENT_86	[p6l938t1934r1320b2021],
3	since	IN	O	since	mark	10	SENT_86	[p6l1380t1927r1588b2004],
4	the	DT	O	the	det	8	SENT_86	[p6l1642t1926r1770b2004],
5	proportional	JJ	O	proportional	amod	8	SENT_86	[p6l1823t1952r2134b2026, p6l21t2053r620b2131],
6	—	NN	O	—	nn	8	SENT_86	[p6l1823t1952r2134b2026, p6l21t2053r620b2131],
7	hazards	NNS	O	hazard	nn	8	SENT_86	[p6l1823t1952r2134b2026, p6l21t2053r620b2131],
8	assumption	NN	O	assumption	nsubjpass	10	SENT_86	[p6l660t2054r1148b2153],
9	is	VBZ	O	be	auxpass	10	SENT_86	[p6l1185t2054r1249b2131],
10	violated	VBN	O	violate	advcl	17	SENT_86	[p6l1284t2053r1610b2132],
11	in	IN	O	in	_	0	SENT_86	[p6l1647t2054r1728b2130],
12	the	DT	O	the	det	14	SENT_86	[p6l1767t2053r1896b2131],
13	overall	JJ	O	overall	amod	14	SENT_86	[p6l1934t2079r2134b2132, p6l21t2180r121b2258],
14	population	NN	O	population	prep_in	10	SENT_86	[p6l178t2180r653b2280],
15	,	,	O	,	_	0	SENT_86	[p6l178t2180r653b2280],
16	we	PRP	O	we	nsubj	17	SENT_86	[p6l712t2207r828b2259],
17	performed	VBD	O	perform	_	0	SENT_86	[p6l885t2180r1327b2280],
18	several	JJ	O	several	amod	20	SENT_86	[p6l1386t2180r1666b2259],
19	sensitivity	NN	O	sensitivity	nn	20	SENT_86	[p6l1725t2181r2140b2280],
20	analyses	NNS	O	analysis	dobj	17	SENT_86	[p6l21t2307r390b2407],
21	,	,	O	,	_	0	SENT_86	[p6l21t2307r390b2407],
22	including	VBG	O	include	_	0	SENT_86	[p6l427t2307r824b2407],
23	a	DT	O	a	det	25	SENT_86	[p6l853t2334r897b2385],
24	nonparametric	JJ	O	nonparametric	amod	25	SENT_86	[p6l928t2308r1545b2407],
25	log	NN	O	log	prep_including	17	SENT_86	[p6l1576t2307r1933b2407],
26	—	CD	NUMBER	—	num	27	SENT_86	[p6l1576t2307r1933b2407],
27	ranl	NN	O	ranl	dep	25	SENT_86	[p6l1576t2307r1933b2407],
28	<	JJR	O	<	amod	29	SENT_86	[p6l1576t2307r1933b2407],
29	test	NN	O	test	dep	27	SENT_86	[p6l1962t2324r2130b2385],
30	.	.	O	.	_	0	SENT_86	[p6l1962t2324r2130b2385],

1	All	PDT	O	all	predet	3	SENT_87	[p6l17t2434r138b2511],
2	these	DT	O	these	det	3	SENT_87	[p6l184t2434r400b2512],
3	analyses	NNS	O	analysis	nsubj	4	SENT_87	[p6l445t2434r791b2534],
4	showed	VBD	O	show	_	0	SENT_87	[p6l841t2434r1154b2513],
5	significant	JJ	O	significant	amod	6	SENT_87	[p6l1201t2434r1651b2534],
6	superiority	NN	O	superiority	dobj	4	SENT_87	[p6l1693t2435r2139b2534],
7	for	IN	O	for	_	0	SENT_87	[p6l21t2561r141b2639],
8	gefitinib	NN	O	gefitinib	prep_for	6	SENT_87	[p6l185t2561r543b2661],
9	in	IN	O	in	_	0	SENT_87	[p6l592t2562r673b2638],
10	the	DT	O	the	det	12	SENT_87	[p6l721t2561r850b2639],
11	overall	JJ	O	overall	amod	12	SENT_87	[p6l900t2561r1174b2640],
12	population	NN	O	population	prep_in	4	SENT_87	[p6l1220t2561r1675b2661],
13	(	CD	NUMBER	(	num	14	SENT_87	[p6l1729t2567r2130b2656],
14	P	NN	O	p	npadvmod	15	SENT_87	[p6l1729t2567r2130b2656],
15	<	JJR	O	<	amod	12	SENT_87	[p6l1729t2567r2130b2656],
16	0.001	CD	NUMBER	0.001	num	17	SENT_87	[p6l1729t2567r2130b2656],
17	)	NN	O	)	tmod	4	SENT_87	[p6l1729t2567r2130b2656],
18	,	,	O	,	_	0	SENT_87	[p6l1729t2567r2130b2656],
19	which	WDT	O	which	nsubj	21	SENT_87	[p6l17t2689r272b2769],
20	was	VBD	O	be	cop	21	SENT_87	[p6l304t2716r462b2769],
21	consistent	JJ	O	consistent	rcmod	17	SENT_87	[p6l501t2690r924b2768],
22	with	IN	O	with	_	0	SENT_87	[p6l951t2689r1141b2768],
23	the	DT	O	the	det	25	SENT_87	[p6l1177t2689r1306b2768],
24	Cox	NN	ORGANIZATION	cox	nn	25	SENT_87	[p6l1342t2695r1502b2768],
25	model	NN	O	model	prep_with	21	SENT_87	[p6l1535t2689r1816b2768],
26	.	.	O	.	_	0	SENT_87	[p6l1535t2689r1816b2768],

1	Seruga	NNP	O	Seruga	nsubj	4	SENT_88	[p6l152t2822r446b2916],
2	et	FW	O	et	nn	3	SENT_88	[p6l508t2833r587b2894],
3	al.	FW	O	al.	dep	1	SENT_88	[p6l644t2816r742b2894],
4	recommend	VB	O	recommend	_	0	SENT_88	[p6l811t2816r1332b2894],
5	that	IN	O	that	_	0	SENT_88	[p6l1396t2816r1571b2894],
6	a	DT	O	a	det	8	SENT_88	[p6l1628t2843r1672b2894],
7	modified	VBN	O	modify	amod	8	SENT_88	[p6l1734t2816r2135b2894],
8	Kolmogorov	NNP	PERSON	Kolmogorov	prep_that	4	SENT_88	[p6l21t2943r988b3043],
9	.	.	O	.	_	0	SENT_88	[p6l21t2943r988b3043],

1	—	NN	O	—	_	0	SENT_89	[p6l21t2943r988b3043],
2	.	.	O	.	_	0	SENT_89	[p6l21t2943r988b3043],

1	Smirnov	NNP	PERSON	Smirnov	nn	2	SENT_90	[p6l21t2943r988b3043],
2	test	NN	O	test	nsubj	6	SENT_90	[p6l1028t2960r1185b3021],
3	may	MD	O	may	aux	6	SENT_90	[p6l1224t2969r1404b3043],
4	be	VB	O	be	cop	6	SENT_90	[p6l1445t2943r1541b3021],
5	more	RBR	O	more	advmod	6	SENT_90	[p6l1585t2969r1807b3021],
6	appropriate	JJ	O	appropriate	_	0	SENT_90	[p6l1851t2969r2134b3043, p6l20t3071r271b3170],
7	for	IN	O	for	_	0	SENT_90	[p6l311t3070r436b3148],
8	crossing	VBG	O	cross	prepc_for	6	SENT_90	[p6l473t3071r842b3170],
9	curves	NNS	O	curve	dobj	8	SENT_90	[p6l879t3096r1180b3149],
10	.	.	O	.	_	0	SENT_90	[p6l879t3096r1180b3149],

1	However	RB	O	however	advmod	7	SENT_91	[p6l1225t3078r1625b3165],
2	,	,	O	,	_	0	SENT_91	[p6l1225t3078r1625b3165],
3	this	DT	O	this	det	4	SENT_91	[p6l1671t3070r1833b3148],
4	test	NN	O	test	nsubj	7	SENT_91	[p6l1875t3086r2032b3148],
5	is	VBZ	O	be	cop	7	SENT_91	[p6l2066t3071r2133b3148],
6	not	RB	O	not	neg	7	SENT_91	[p6l21t3214r161b3275],
7	appropriate	JJ	O	appropriate	_	0	SENT_91	[p6l187t3198r669b3297],
8	for	IN	O	for	_	0	SENT_91	[p6l700t3197r821b3275],
9	assessing	VBG	O	assess	prepc_for	7	SENT_91	[p6l849t3198r1247b3297],
10	noninferiority	NN	O	noninferiority	dobj	9	SENT_91	[p6l1275t3197r1878b3297],
11	,	,	O	,	_	0	SENT_91	[p6l1275t3197r1878b3297],
12	since	IN	O	since	mark	14	SENT_91	[p6l1916t3198r2135b3275],
13	it	PRP	O	it	nsubj	14	SENT_91	[p6l21t3325r78b3402],
14	produces	VBZ	O	produce	advcl	7	SENT_91	[p6l106t3324r485b3424],
15	only	RB	O	only	advmod	18	SENT_91	[p6l522t3324r702b3424],
16	a	DT	O	a	det	18	SENT_91	[p6l732t3351r776b3402],
17	P	NN	O	p	nn	18	SENT_91	[p6l808t3331r859b3401],
18	value	NN	O	value	dobj	14	SENT_91	[p6l888t3324r1124b3419],
19	,	,	O	,	_	0	SENT_91	[p6l888t3324r1124b3419],
20	essentially	RB	O	essentially	advmod	14	SENT_91	[p6l1165t3324r1606b3424],
21	for	IN	O	for	_	0	SENT_91	[p6l1636t3324r1756b3402],
22	Kaplan	NNP	PERSON	Kaplan	nn	25	SENT_91	[p6l1787t3324r2139b3424],
23	—	NNP	O	—	nn	25	SENT_91	[p6l1787t3324r2139b3424],
24	Meier	NNP	O	Meier	nn	25	SENT_91	[p6l18t3453r267b3530],
25	curves	NNS	O	curve	prep_for	14	SENT_91	[p6l310t3478r585b3530],
26	for	IN	O	for	_	0	SENT_91	[p6l634t3452r759b3530],
27	each	DT	O	each	det	28	SENT_91	[p6l803t3452r998b3530],
28	treatment	NN	O	treatment	prep_for	25	SENT_91	[p6l1044t3468r1475b3530],
29	with	IN	O	with	_	0	SENT_91	[p6l1512t3452r1710b3530],
30	different	JJ	O	different	amod	31	SENT_91	[p6l1757t3452r2140b3530],
31	shapes	NNS	O	shape	prep_with	28	SENT_91	[p6l22t3578r313b3678],
32	of	IN	O	of	_	0	SENT_91	[p6l383t3578r484b3656],
33	distribution	NN	O	distribution	prep_of	31	SENT_91	[p6l532t3578r1076b3657],
34	.	.	O	.	_	0	SENT_91	[p6l532t3578r1076b3657],

1	A	DT	O	a	det	3	SENT_92	[p6l1144t3586r1210b3655],
2	P	NN	O	p	nn	3	SENT_92	[p6l1271t3585r1323b3655],
3	value	NN	O	value	nsubjpass	7	SENT_92	[p6l1383t3578r1607b3657],
4	can	MD	O	can	aux	7	SENT_92	[p6l1674t3595r1976b3656],
5	not	RB	O	not	neg	7	SENT_92	[p6l1674t3595r1976b3656],
6	be	VB	O	be	auxpass	7	SENT_92	[p6l2038t3578r2135b3656],
7	compared	VBN	O	compare	_	0	SENT_92	[p6l22t3705r454b3805],
8	with	IN	O	with	_	0	SENT_92	[p6l508t3705r706b3784],
9	a	DT	O	a	det	11	SENT_92	[p6l764t3732r808b3783],
10	noninferiority	JJ	O	noninferiority	amod	11	SENT_92	[p6l865t3705r1484b3805],
11	margin	NN	O	margin	prep_with	7	SENT_92	[p6l1538t3706r1882b3805],
12	.	.	O	.	_	0	SENT_92	[p6l1538t3706r1882b3805],

1	This	DT	O	this	det	2	SENT_93	[p6l1943t3705r2133b3783],
2	test	NN	O	test	nsubj	4	SENT_93	[p7l21t36r178b98],
3	also	RB	O	also	advmod	4	SENT_93	[p7l208t20r382b98],
4	gives	VBZ	O	give	_	0	SENT_93	[p7l419t21r633b120],
5	no	DT	O	no	det	6	SENT_93	[p7l671t46r777b98],
6	indication	NN	O	indication	iobj	4	SENT_93	[p7l814t20r1258b98],
7	of	IN	O	of	_	0	SENT_93	[p7l1294t20r1395b98],
8	which	WDT	O	which	rel	11	SENT_93	[p7l1408t20r1674b99],
9	treatment	NN	O	treatment	nsubj	11	SENT_93	[p7l1710t36r2140b98],
10	is	VBZ	O	be	cop	11	SENT_93	[p7l21t148r87b225],
11	better	RBR	O	better	dobj	4	SENT_93	[p7l151t147r407b225],
12	or	CC	O	or	_	0	SENT_93	[p7l467t173r556b225],
13	the	DT	O	the	det	14	SENT_93	[p7l615t147r749b225],
14	magnitude	NN	O	magnitude	dobj	4	SENT_93	[p7l811t147r1283b247],
15	of	IN	O	of	_	0	SENT_93	[p7l1346t147r1446b225],
16	benefit	NN	O	benefit	prep_of	14	SENT_93	[p7l1490t147r1822b225],
17	.	.	O	.	_	0	SENT_93	[p7l1490t147r1822b225],

1	Given	VBN	O	give	prep	19	SENT_94	[p7l1888t148r2135b226],
2	the	DT	O	the	det	4	SENT_94	[p7l21t274r156b352],
3	clear	JJ	O	clear	amod	4	SENT_94	[p7l197t274r401b352],
4	difference	NN	O	difference	dep	1	SENT_94	[p7l436t274r867b352],
5	in	IN	O	in	_	0	SENT_94	[p7l904t275r987b351],
6	the	DT	O	the	det	7	SENT_94	[p7l1025t274r1157b352],
7	shape	NN	O	shape	prep_in	4	SENT_94	[p7l1197t274r1440b374],
8	of	IN	O	of	_	0	SENT_94	[p7l1478t274r1578b352],
9	the	DT	O	the	det	10	SENT_94	[p7l1598t274r1730b352],
10	distributions	NNS	O	distribution	prep_of	7	SENT_94	[p7l1769t274r2134b353, p7l21t402r256b496],
11	,	,	O	,	_	0	SENT_94	[p7l1769t274r2134b353, p7l21t402r256b496],
12	the	DT	O	the	det	14	SENT_94	[p7l305t401r439b479],
13	P	NN	O	p	nn	14	SENT_94	[p7l478t408r530b478],
14	value	NN	O	value	nsubj	19	SENT_94	[p7l566t401r783b480],
15	would	MD	O	would	aux	19	SENT_94	[p7l820t401r1085b480],
16	probably	RB	O	probably	advmod	19	SENT_94	[p7l1125t401r1500b501],
17	be	VB	O	be	cop	19	SENT_94	[p7l1537t401r1634b479],
18	highly	RB	O	highly	advmod	19	SENT_94	[p7l1675t401r1946b501],
19	sig2486	JJ	O	sig2486	_	0	SENT_94	[p7l1985t402r2134b501, p7l149t576r226b599],

1	N	NN	O	n	nn	3	SENT_95	[p7l930t587r943b602],
2	ENGLJ	NN	O	englj	nn	3	SENT_95	[p7l958t587r1036b609],
3	MED	NN	O	med	_	0	SENT_95	[p7l1051t587r1103b602],
4	361	CD	NUMBER	361	dep	3	SENT_95	[p7l1113t581r1188b609],
5	;	:	O	;	_	0	SENT_95	[p7l1113t581r1188b609],
6	25	CD	NUMBER	25	num	8	SENT_95	[p7l1113t581r1188b609],
7	NEjM.ORG	NN	O	nejm.org	nn	8	SENT_95	[p7l1224t587r1348b609],
8	DECEMBER17	NN	O	december17	dep	4	SENT_95	[p7l1385t587r1554b608],
9	,	,	O	,	_	0	SENT_95	[p7l1385t587r1554b608],
10	2009	CD	DATE	2009	appos	8	SENT_95	[p7l1566t587r1630b608],

1	The	DT	O	the	det	4	SENT_96	[p7l936t620r987b644],
2	New	NNP	O	New	nn	4	SENT_96	[p7l996t621r1058b644],
3	England	NNP	O	England	nn	4	SENT_96	[p7l1067t620r1178b651],
4	Journal	NNP	O	Journal	_	0	SENT_96	[p7l1187t620r1284b644],
5	of	IN	O	of	_	0	SENT_96	[p7l1294t620r1323b644],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_96	[p7l1330t620r1455b644],

1	CORRESPONDENCE	NN	O	correspondence	_	0	SENT_97	[p7l926t808r1233b827],

1	nificant	JJ	O	nificant	_	0	SENT_98	[p7l10t1022r381b1118],
2	,	,	O	,	_	0	SENT_98	[p7l10t1022r381b1118],
3	but	CC	O	but	cc	10	SENT_98	[p7l430t1022r573b1101],
4	the	DT	O	the	det	6	SENT_98	[p7l611t1022r746b1101],
5	clinical	JJ	O	clinical	amod	6	SENT_98	[p7l790t1022r1106b1101],
6	meaning	NN	O	meaning	nsubj	10	SENT_98	[p7l1146t1023r1532b1123],
7	would	MD	O	would	aux	10	SENT_98	[p7l1565t1022r1832b1101],
8	not	RB	O	not	neg	10	SENT_98	[p7l1872t1039r2016b1101],
9	be	VB	O	be	cop	10	SENT_98	[p7l2052t1022r2149b1101],
10	obvious	JJ	O	obvious	ccomp	1	SENT_98	[p7l11t1148r366b1227],
11	.	.	O	.	_	0	SENT_98	[p7l11t1148r366b1227],

1	We	PRP	O	we	nsubj	2	SENT_99	[p7l136t1282r269b1353],
2	disagree	VBP	O	disagree	_	0	SENT_99	[p7l301t1274r656b1375],
3	that	IN	O	that	complm	8	SENT_99	[p7l688t1274r859b1353],
4	hazard	NN	O	hazard	nn	5	SENT_99	[p7l885t1274r1178b1353],
5	ratios	NNS	O	ratio	nsubj	8	SENT_99	[p7l1210t1275r1446b1353],
6	can	MD	O	can	aux	8	SENT_99	[p7l1480t1300r1629b1353],
7	be	VB	O	be	cop	8	SENT_99	[p7l1660t1274r1756b1353],
8	misleading	VBG	O	mislead	ccomp	2	SENT_99	[p7l1788t1274r2148b1353, p7l10t1401r150b1501],
9	for	IN	O	for	_	0	SENT_99	[p7l197t1400r321b1479],
10	clinicians	NNS	O	clinician	prep_for	8	SENT_99	[p7l370t1400r784b1479],
11	if	IN	O	if	mark	15	SENT_99	[p7l837t1400r914b1478],
12	such	JJ	O	such	amod	13	SENT_99	[p7l948t1400r1143b1479],
13	ratios	NNS	O	ratio	nsubjpass	15	SENT_99	[p7l1193t1401r1435b1479],
14	are	VBP	O	be	auxpass	15	SENT_99	[p7l1488t1426r1617b1479],
15	interpreted	VBN	O	interpret	advcl	8	SENT_99	[p7l1668t1400r2149b1501],
16	properly	RB	O	properly	advmod	15	SENT_99	[p7l9t1526r371b1627],
17	as	IN	O	as	_	0	SENT_99	[p7l420t1553r506b1605],
18	an	DT	O	a	det	20	SENT_99	[p7l562t1552r665b1605],
19	average	JJ	O	average	amod	20	SENT_99	[p7l719t1552r1040b1627],
20	effect	NN	O	effect	prep_as	15	SENT_99	[p7l1095t1526r1339b1605],
21	across	IN	O	across	_	0	SENT_99	[p7l1387t1552r1655b1605],
22	the	DT	O	the	det	25	SENT_99	[p7l1712t1526r1845b1605],
23	entire	JJ	O	entire	amod	25	SENT_99	[p7l1900t1527r2149b1605],
24	study	NN	O	study	nn	25	SENT_99	[p7l12t1652r243b1753],
25	period	NN	O	period	prep_across	20	SENT_99	[p7l271t1652r551b1753],
26	and	CC	O	and	_	0	SENT_99	[p7l583t1652r742b1731],
27	population	NN	O	population	conj_and	20	SENT_99	[p7l774t1652r1313b1753],
28	}	CD	NUMBER	}	num	29	SENT_99	[p7l774t1652r1313b1753],
29	Medians	NNPS	O	Medians	dep	27	SENT_99	[p7l1345t1652r1715b1731],
30	and	CC	O	and	_	0	SENT_99	[p7l1751t1652r1910b1731],
31	rates	NNS	O	rate	nsubj	35	SENT_99	[p7l1943t1669r2147b1731],
32	can	MD	O	can	aux	35	SENT_99	[p7l11t1804r161b1857],
33	be	VB	O	be	cop	35	SENT_99	[p7l213t1778r310b1857],
34	more	RBR	O	more	advmod	35	SENT_99	[p7l361t1804r582b1857],
35	misleading	JJ	O	misleading	conj_and	2	SENT_99	[p7l634t1778r1136b1879],
36	,	,	O	,	_	0	SENT_99	[p7l634t1778r1136b1879],
37	since	IN	O	since	mark	44	SENT_99	[p7l1194t1779r1411b1857],
38	these	DT	O	these	det	39	SENT_99	[p7l1463t1778r1688b1857],
39	measures	NNS	O	measure	nsubj	44	SENT_99	[p7l1739t1804r2147b1857],
40	are	VBP	O	be	cop	44	SENT_99	[p7l10t1930r139b1983],
41	a	DT	O	a	det	44	SENT_99	[p7l179t1931r223b1983],
42	“	NN	O	“	nn	44	SENT_99	[p7l266t1904r739b2005],
43	snapshot	NN	O	snapshot	nn	44	SENT_99	[p7l266t1904r739b2005],
44	”	NN	O	”	advcl	35	SENT_99	[p7l266t1904r739b2005],
45	at	IN	O	at	_	0	SENT_99	[p7l782t1921r862b1983],
46	one	CD	NUMBER	one	num	47	SENT_99	[p7l898t1930r1050b1983],
47	point	NN	O	point	prep_at	44	SENT_99	[p7l1089t1905r1321b2005],
48	in	IN	O	in	_	0	SENT_99	[p7l1354t1905r1438b1982],
49	a	DT	O	a	det	50	SENT_99	[p7l1478t1931r1522b1983],
50	study	NN	O	study	prep_in	47	SENT_99	[p7l1562t1904r1807b2005],
51	.	.	O	.	_	0	SENT_99	[p7l1562t1904r1807b2005],

1	We	PRP	O	we	nsubj	2	SENT_100	[p7l136t2038r271b2109],
2	agree	VBP	O	agree	_	0	SENT_100	[p7l316t2056r552b2131],
3	with	IN	O	with	mark	13	SENT_100	[p7l593t2030r793b2109],
4	Takano	NNP	PERSON	Takano	nsubjpass	13	SENT_100	[p7l834t2030r1161b2110],
5	that	WDT	O	that	nsubj	6	SENT_100	[p7l1208t2030r1385b2109],
6	crossover	VBP	O	crossover	rcmod	4	SENT_100	[p7l1426t2056r1841b2109],
7	to	TO	O	to	_	0	SENT_100	[p7l1883t2047r1967b2109],
8	the	DT	O	the	det	10	SENT_100	[p7l2013t2030r2149b2109],
9	comparator	NN	O	comparator	nn	10	SENT_100	[p7l11t2173r525b2257],
10	treatment	NN	O	treatment	prep_to	6	SENT_100	[p7l559t2173r995b2235],
11	would	MD	O	would	aux	13	SENT_100	[p7l1022t2156r1295b2235],
12	be	VB	O	be	auxpass	13	SENT_100	[p7l1332t2156r1430b2235],
13	expected	VBN	O	expect	ccomp	2	SENT_100	[p7l1469t2156r1855b2257],
14	in	IN	O	in	_	0	SENT_100	[p7l1891t2157r1976b2234],
15	the	DT	O	the	det	19	SENT_100	[p7l2013t2156r2150b2235],
16	first	JJ	ORDINAL	first	amod	19	SENT_100	[p7l10t2282r392b2361],
17	—	NN	O	—	nn	19	SENT_100	[p7l10t2282r392b2361],
18	line	NN	O	line	nn	19	SENT_100	[p7l10t2282r392b2361],
19	setting	NN	O	setting	prep_in	13	SENT_100	[p7l453t2283r760b2383],
20	and	CC	O	and	_	0	SENT_100	[p7l815t2282r976b2361],
21	that	IN	O	that	complm	25	SENT_100	[p7l1035t2282r1212b2361],
22	such	JJ	O	such	amod	23	SENT_100	[p7l1267t2282r1465b2361],
23	crossover	NN	O	crossover	nsubj	25	SENT_100	[p7l1525t2308r1940b2361],
24	can	MD	O	can	aux	25	SENT_100	[p7l1997t2308r2149b2361],
25	confound	VB	O	confound	conj_and	13	SENT_100	[p7l11t2408r418b2487],
26	analysis	NN	O	analysis	dobj	25	SENT_100	[p7l453t2408r788b2509],
27	of	IN	O	of	_	0	SENT_100	[p7l827t2408r927b2487],
28	overall	JJ	O	overall	amod	29	SENT_100	[p7l945t2408r1226b2488],
29	survival	NN	O	survival	prep_of	26	SENT_100	[p7l1263t2408r1612b2487],
30	.	.	O	.	_	0	SENT_100	[p7l1263t2408r1612b2487],

1	That	DT	O	that	nsubj	2	SENT_101	[p7l1650t2408r1849b2487],
2	is	VBZ	O	be	_	0	SENT_101	[p7l1878t2409r1944b2487],
3	why	WRB	O	why	advmod	11	SENT_101	[p7l1977t2408r2154b2509],
4	progression	NN	O	progression	dep	3	SENT_101	[p7l9t2534r738b2635],
5	—	CD	NUMBER	—	num	4	SENT_101	[p7l9t2534r738b2635],
6	free	JJ	O	free	amod	7	SENT_101	[p7l9t2534r738b2635],
7	survival	NN	O	survival	nsubj	11	SENT_101	[p7l787t2534r1129b2613],
8	was	VBD	O	be	cop	11	SENT_101	[p7l1171t2561r1337b2613],
9	our	PRP$	O	we	poss	11	SENT_101	[p7l1387t2560r1536b2613],
10	primary	JJ	O	primary	amod	11	SENT_101	[p7l1578t2535r1937b2635],
11	outcome	NN	O	outcome	advcl	2	SENT_101	[p7l1981t2551r2148b2613, p7l11t2686r267b2739],
12	.	.	O	.	_	0	SENT_101	[p7l1981t2551r2148b2613, p7l11t2686r267b2739],

1	Similar	JJ	O	similar	amod	2	SENT_102	[p7l353t2660r668b2739],
2	outcomes	NNS	O	outcome	nsubjpass	16	SENT_102	[p7l743t2677r1158b2739],
3	for	IN	O	for	_	0	SENT_102	[p7l1238t2660r1362b2739],
4	progression	NN	O	progression	npadvmod	6	SENT_102	[p7l1435t2660r2149b2761],
5	—	CD	NUMBER	—	num	4	SENT_102	[p7l1435t2660r2149b2761],
6	free	JJ	O	free	amod	7	SENT_102	[p7l1435t2660r2149b2761],
7	survival	NN	O	survival	prep_for	2	SENT_102	[p7l12t2786r346b2865],
8	among	IN	O	among	_	0	SENT_102	[p7l409t2812r712b2887],
9	patients	NNS	O	patient	prep_among	7	SENT_102	[p7l772t2787r1115b2887],
10	with	IN	O	with	_	0	SENT_102	[p7l1178t2786r1374b2865],
11	EGFR	NN	ORGANIZATION	egfr	nn	12	SENT_102	[p7l1437t2793r1652b2866],
12	mutations	NNS	O	mutation	prep_with	9	SENT_102	[p7l1709t2787r2148b2865],
13	have	VBP	O	have	aux	16	SENT_102	[p7l10t2912r201b2991],
14	recently	RB	DATE	recently	advmod	16	SENT_102	[p7l238t2912r581b3013],
15	been	VBN	O	be	auxpass	16	SENT_102	[p7l613t2912r816b2991],
16	reported	VBN	O	report	_	0	SENT_102	[p7l852t2912r1222b3013],
17	in	IN	O	in	_	0	SENT_102	[p7l1258t2913r1341b2990],
18	three	CD	NUMBER	three	num	20	SENT_102	[p7l1378t2912r1600b2991],
19	other	JJ	O	other	amod	20	SENT_102	[p7l1637t2912r1867b2991],
20	phase	NN	O	phase	prep_in	16	SENT_102	[p7l1899t2912r2149b3013],
21	3	CD	NUMBER	3	num	22	SENT_102	[p7l11t3044r55b3117],
22	studies	NNS	O	study	tmod	16	SENT_102	[p7l97t3038r392b3117],
23	comparing	VBG	O	compare	partmod	22	SENT_102	[p7l432t3039r897b3139],
24	first	JJ	ORDINAL	first	amod	27	SENT_102	[p7l930t3038r1293b3117],
25	—	NN	O	—	nn	27	SENT_102	[p7l930t3038r1293b3117],
26	line	NN	O	line	nn	27	SENT_102	[p7l930t3038r1293b3117],
27	gefitinib	NN	O	gefitinib	dobj	23	SENT_102	[p7l1329t3038r1695b3139],
28	with	IN	O	with	_	0	SENT_102	[p7l1729t3038r1923b3117],
29	dou	FW	O	dou	prep_with	27	SENT_102	[p7l1960t3038r2148b3117],
30	—	FW	O	—	nn	32	SENT_102	[p7l1960t3038r2148b3117],
31	blet	FW	O	blet	nn	32	SENT_102	[p7l11t3164r170b3243],
32	chemotherapy	NN	O	chemotherapy	dep	22	SENT_102	[p7l228t3164r963b3265],
33	.	.	O	.	_	0	SENT_102	[p7l228t3164r963b3265],

1	“	NN	O	“	npadvmod	26	SENT_103	[p7l228t3164r963b3265],
2	In	IN	O	in	_	0	SENT_103	[p7l1025t3172r1114b3242],
3	conclusion	NN	O	conclusion	prep_in	26	SENT_103	[p7l1178t3164r1665b3260],
4	,	,	O	,	_	0	SENT_103	[p7l1178t3164r1665b3260],
5	since	IN	O	since	mark	9	SENT_103	[p7l1735t3165r1952b3243],
6	the	DT	O	the	det	7	SENT_103	[p7l2016t3164r2149b3243],
7	effect	NN	O	effect	nsubj	9	SENT_103	[p7l11t3290r255b3369],
8	was	VBD	O	be	cop	9	SENT_103	[p7l280t3317r444b3370],
9	different	JJ	O	different	advcl	26	SENT_103	[p7l482t3290r862b3369],
10	for	IN	O	for	_	0	SENT_103	[p7l891t3290r1015b3369],
11	patients	NNS	O	patient	prep_for	9	SENT_103	[p7l1046t3291r1391b3391],
12	with	IN	O	with	_	0	SENT_103	[p7l1423t3290r1620b3369],
13	EGFR	NN	ORGANIZATION	egfr	nn	14	SENT_103	[p7l1654t3297r1868b3370],
14	mutations	NNS	O	mutation	prep_with	11	SENT_103	[p7l1896t3307r2148b3369, p7l11t3416r217b3494],
15	and	CC	O	and	_	0	SENT_103	[p7l250t3415r407b3494],
16	those	DT	O	those	conj_and	14	SENT_103	[p7l439t3415r665b3494],
17	without	IN	O	without	_	0	SENT_103	[p7l694t3415r1026b3495],
18	EGFR	NN	ORGANIZATION	egfr	nn	19	SENT_103	[p7l1051t3422r1261b3495],
19	mutations	NNS	O	mutation	prep_without	9	SENT_103	[p7l1286t3416r1734b3511],
20	,	,	O	,	_	0	SENT_103	[p7l1286t3416r1734b3511],
21	our	PRP$	O	we	poss	23	SENT_103	[p7l1773t3441r1916b3494],
22	overall	JJ	O	overall	amod	23	SENT_103	[p7l1946t3441r2148b3495, p7l10t3542r115b3621],
23	results	NNS	O	result	nsubjpass	26	SENT_103	[p7l163t3542r448b3621],
24	should	MD	O	should	aux	26	SENT_103	[p7l500t3542r789b3621],
25	be	VB	O	be	auxpass	26	SENT_103	[p7l838t3542r936b3621],
26	interpreted	VBN	O	interpret	_	0	SENT_103	[p7l984t3542r1465b3643],
27	as	IN	O	as	_	0	SENT_103	[p7l1513t3569r1599b3621],
28	a	DT	O	a	det	29	SENT_103	[p7l1649t3569r1694b3621],
29	combination	NN	O	combination	prep_as	26	SENT_103	[p7l1742t3542r2148b3621, p7l11t3669r181b3747],
30	from	IN	O	from	_	0	SENT_103	[p7l221t3668r433b3747],
31	two	CD	NUMBER	two	num	34	SENT_103	[p7l473t3685r632b3748],
32	very	RB	O	very	advmod	33	SENT_103	[p7l669t3694r848b3769],
33	different	JJ	O	different	amod	34	SENT_103	[p7l884t3668r1263b3747],
34	subgroups	NNS	O	subgroup	prep_from	29	SENT_103	[p7l1299t3668r1774b3769],
35	.	.	O	.	_	0	SENT_103	[p7l1299t3668r1774b3769],

1	Tony	NNP	PERSON	Tony	_	0	SENT_104	[p8l7t28r225b127],
2	3	CD	NUMBER	3	dep	1	SENT_104	[p8l257t27r329b101],
3	.	.	O	.	_	0	SENT_104	[p8l257t27r329b101],

1	Mok	NNP	PERSON	Mok	nsubj	12	SENT_105	[p8l373t20r582b116],
2	,	,	O	,	_	0	SENT_105	[p8l373t20r582b116],
3	M.D.	NNP	ORGANIZATION	M.D.	nn	9	SENT_105	[p8l627t28r835b101],
4	Chinese	NNP	ORGANIZATION	Chinese	nn	9	SENT_105	[p8l11t160r278b222],
5	University	NNP	ORGANIZATION	University	nn	9	SENT_105	[p8l307t166r646b241],
6	ofHong	NNP	O	ofHong	nn	9	SENT_105	[p8l669t160r944b241],
7	Kong	NNP	LOCATION	Kong	nn	9	SENT_105	[p8l973t166r1139b241],
8	Hong	NNP	LOCATION	Hong	nn	9	SENT_105	[p8l15t247r200b322],
9	Kong	NNP	LOCATION	Kong	appos	1	SENT_105	[p8l228t247r411b322],
10	,	,	O	,	_	0	SENT_105	[p8l228t247r411b322],
11	China	NNP	LOCATION	China	appos	9	SENT_105	[p8l440t241r630b303],
12	tony@c	VBD	O	tony@c	_	0	SENT_105	[p8l7t322r773b403],
13	|	CD	NUMBER	|	num	14	SENT_105	[p8l7t322r773b403],
14	o.cuhk.edu	NN	O	o.cuhk.edu	dobj	12	SENT_105	[p8l7t322r773b403],
15	.	.	O	.	_	0	SENT_105	[p8l7t322r773b403],

1	hk	NN	O	hk	_	0	SENT_106	[p8l7t322r773b403],

1	Claire	NNP	PERSON	Claire	nn	3	SENT_107	[p8l12t455r260b536],
2	L.	NNP	PERSON	L.	nn	3	SENT_107	[p8l301t462r362b535],
3	Watkins	NNP	PERSON	Watkins	_	0	SENT_107	[p8l396t455r777b550],
4	,	,	O	,	_	0	SENT_107	[p8l396t455r777b550],
5	M.	NNP	PERSON	M.	nn	6	SENT_107	[p8l821t461r1058b536],
6	Sc	NNP	PERSON	Sc	appos	3	SENT_107	[p8l821t461r1058b536],
7	.	.	O	.	_	0	SENT_107	[p8l821t461r1058b536],

1	AstraZeneca	NNP	ORGANIZATION	AstraZeneca	nn	2	SENT_108	[p8l7t598r437b654],
2	Macclesfield	NNP	ORGANIZATION	Macclesfield	_	0	SENT_108	[p8l15t672r458b744],
3	,	,	O	,	_	0	SENT_108	[p8l15t672r458b744],
4	United	NNP	LOCATION	United	nn	5	SENT_108	[p8l490t672r709b734],
5	Kingdom	NNP	LOCATION	Kingdom	appos	2	SENT_108	[p8l743t672r1041b753],

1	Masahiro	NNP	PERSON	Masahiro	nn	2	SENT_109	[p8l19t805r428b886],
2	Fukuoka	NNP	PERSON	Fukuoka	_	0	SENT_109	[p8l469t805r858b900],
3	,	,	O	,	_	0	SENT_109	[p8l469t805r858b900],
4	M.D.	NNP	O	M.D.	nn	6	SENT_109	[p8l903t813r1137b900],
5	,	,	O	,	_	0	SENT_109	[p8l903t813r1137b900],
6	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_109	[p8l1182t805r1413b886],
7	.	.	O	.	_	0	SENT_109	[p8l1182t805r1413b886],

1	Kinki	NNP	ORGANIZATION	Kinki	nn	3	SENT_110	[p8l15t944r172b1005],
2	University	NNP	ORGANIZATION	University	nn	3	SENT_110	[p8l204t949r543b1024],
3	School	NNP	ORGANIZATION	School	_	0	SENT_110	[p8l566t944r792b1006],
4	of	IN	ORGANIZATION	of	_	0	SENT_110	[p8l820t943r893b1005],
5	Medicine	NNP	ORGANIZATION	Medicine	nn	6	SENT_110	[p8l911t944r1218b1006],
6	Osaka	NNP	ORGANIZATION	Osaka	prep_of	3	SENT_110	[p8l11t1024r449b1103],
7	,	,	O	,	_	0	SENT_110	[p8l11t1024r449b1103],
8	Japan	NNP	LOCATION	Japan	appos	6	SENT_110	[p8l11t1024r449b1103],
9	1	CD	NUMBER	1	num	8	SENT_110	[p8l12t1137r61b1188],
10	.	.	O	.	_	0	SENT_110	[p8l12t1137r61b1188],

1	Carroll	NNP	PERSON	Carroll	nn	2	SENT_111	[p8l139t1129r371b1188],
2	K	NNP	O	K	_	0	SENT_111	[p8l392t1134r483b1198],
3	]	NN	O	]	dep	2	SENT_111	[p8l392t1134r483b1198],
4	.	.	O	.	_	0	SENT_111	[p8l392t1134r483b1198],

1	On	IN	O	on	_	0	SENT_112	[p8l510t1134r607b1188],
2	the	DT	O	the	det	3	SENT_112	[p8l629t1129r732b1188],
3	use	NN	O	use	pobj	1	SENT_112	[p8l754t1148r862b1189],
4	and	CC	O	and	_	0	SENT_112	[p8l885t1129r1006b1188],
5	utility	NN	O	utility	conj_and	3	SENT_112	[p8l1028t1129r1228b1204],
6	of	IN	O	of	_	0	SENT_112	[p8l1248t1129r1324b1188],
7	the	DT	O	the	det	9	SENT_112	[p8l1333t1129r1435b1188],
8	Weibull	NNP	PERSON	Weibull	nn	9	SENT_112	[p8l1455t1129r1712b1189],
9	model	NN	O	model	prep_of	3	SENT_112	[p8l1734t1129r1940b1188],
10	in	IN	O	in	_	0	SENT_112	[p8l1961t1130r2025b1187],
11	the	DT	O	the	det	12	SENT_112	[p8l2048t1129r2150b1188],
12	analysis	NN	O	analysis	prep_in	9	SENT_112	[p8l9t1207r271b1283],
13	of	IN	O	of	_	0	SENT_112	[p8l300t1207r376b1267],
14	survival	NN	O	survival	nn	15	SENT_112	[p8l389t1207r646b1268],
15	data	NNS	O	datum	prep_of	12	SENT_112	[p8l673t1207r831b1267],
16	.	.	O	.	_	0	SENT_112	[p8l673t1207r831b1267],

1	Control	NNP	O	Control	nn	3	SENT_113	[p8l861t1207r1113b1267],
2	Clin	NNP	O	Clin	nn	3	SENT_113	[p8l1138t1207r1274b1267],
3	Trials	NNPS	O	Trials	_	0	SENT_113	[p8l1297t1207r1487b1266],
4	2003	CD	DATE	2003	dep	3	SENT_113	[p8l1515t1211r2069b1279],
5	;	:	O	;	_	0	SENT_113	[p8l1515t1211r2069b1279],
6	24:682	CD	NUMBER	24:682	num	7	SENT_113	[p8l1515t1211r2069b1279],
7	-701	CD	NUMBER	-701	dep	3	SENT_113	[p8l1515t1211r2069b1279],
8	.	.	O	.	_	0	SENT_113	[p8l1515t1211r2069b1279],

1	2	LS	NUMBER	2	_	0	SENT_114	[p8l8t1294r62b1345],
2	.	.	O	.	_	0	SENT_114	[p8l8t1294r62b1345],

1	Lee	NNP	PERSON	Lee	nn	2	SENT_115	[p8l138t1291r249b1345],
2	JS	NNP	O	JS	_	0	SENT_115	[p8l266t1290r350b1358],
3	,	,	O	,	_	0	SENT_115	[p8l266t1290r350b1358],
4	Park	NNP	O	Park	nn	5	SENT_115	[p8l378t1286r529b1346],
5	K	NNP	O	K	appos	2	SENT_115	[p8l549t1291r616b1358],
6	,	,	O	,	_	0	SENT_115	[p8l549t1291r616b1358],
7	Kim	NNP	PERSON	Kim	nn	8	SENT_115	[p8l644t1287r785b1347],
8	S	NNP	O	S	appos	5	SENT_115	[p8l811t1290r952b1358],
9	.	.	O	.	_	0	SENT_115	[p8l811t1290r952b1358],

1	—	NN	O	—	_	0	SENT_116	[p8l811t1290r952b1358],
2	.	.	O	.	_	0	SENT_116	[p8l811t1290r952b1358],

1	W	NN	O	w	_	0	SENT_117	[p8l811t1290r952b1358],
2	,	,	O	,	_	0	SENT_117	[p8l811t1290r952b1358],
3	et	FW	O	et	nn	4	SENT_117	[p8l981t1299r1041b1345],
4	al.	FW	O	al.	appos	1	SENT_117	[p8l1060t1286r1136b1345],
5	.	.	O	.	_	0	SENT_117	[p8l1060t1286r1136b1345],

1	A	DT	O	a	det	3	SENT_118	[p8l1162t1291r1212b1344],
2	randomized	JJ	O	randomized	amod	3	SENT_118	[p8l1234t1286r1635b1345],
3	phase	NN	O	phase	_	0	SENT_118	[p8l1659t1286r1850b1361],
4	III	CD	NUMBER	iii	num	5	SENT_118	[p8l1874t1291r1951b1344],
5	study	NN	O	study	dep	3	SENT_118	[p8l1977t1286r2154b1361],
6	of	IN	O	of	_	0	SENT_118	[p8l10t1363r87b1423],
7	gefitinib	NN	O	gefitinib	prep_of	5	SENT_118	[p8l107t1363r395b1440],
8	(	CD	NUMBER	(	num	7	SENT_118	[p8l434t1368r727b1432],
9	IRESSA	NNP	O	IRESSA	dep	3	SENT_118	[p8l434t1368r727b1432],
10	)	CD	NUMBER	)	num	9	SENT_118	[p8l434t1368r727b1432],
11	versus	CC	O	versus	prep	9	SENT_118	[p8l762t1383r968b1423],
12	standard	JJ	O	standard	amod	15	SENT_118	[p8l1006t1363r1297b1423],
13	chemotherapy	NN	O	chemotherapy	nn	15	SENT_118	[p8l1333t1363r1804b1439],
14	(	NN	O	(	nn	15	SENT_118	[p8l1839t1364r2149b1440, p8l10t1442r149b1501],
15	gemcitabine	NN	O	gemcitabine	dep	11	SENT_118	[p8l1839t1364r2149b1440, p8l10t1442r149b1501],
16	plus	CC	O	plus	_	0	SENT_118	[p8l183t1442r318b1517],
17	cisplatin	NN	O	cisplatin	conj_plus	9	SENT_118	[p8l354t1442r658b1517],
18	)	RB	O	)	advmod	17	SENT_118	[p8l354t1442r658b1517],
19	as	IN	O	as	_	0	SENT_118	[p8l695t1461r761b1501],
20	a	DT	O	a	det	24	SENT_118	[p8l796t1461r830b1501],
21	first	JJ	ORDINAL	first	amod	24	SENT_118	[p8l863t1442r1150b1501],
22	—	NN	O	—	nn	24	SENT_118	[p8l863t1442r1150b1501],
23	line	NN	O	line	nn	24	SENT_118	[p8l863t1442r1150b1501],
24	treatment	NN	O	treatment	prep_as	17	SENT_118	[p8l1185t1455r1512b1501],
25	for	IN	O	for	prep	24	SENT_118	[p8l1542t1442r1637b1501],
26	never	RB	O	never	pcomp	25	SENT_118	[p8l1669t1442r2149b1502],
27	—	CD	NUMBER	—	num	28	SENT_118	[p8l1669t1442r2149b1502],
28	smokers	NNS	O	smoker	dep	3	SENT_118	[p8l1669t1442r2149b1502],
29	with	IN	O	with	_	0	SENT_118	[p8l6t1519r156b1579],
30	advanced	JJ	O	advanced	amod	33	SENT_118	[p8l180t1519r486b1579],
31	or	CC	O	or	_	0	SENT_118	[p8l510t1539r578b1579],
32	metastatic	JJ	O	metastatic	amod	33	SENT_118	[p8l600t1520r946b1578],
33	adenocarcinoma	NN	O	adenocarcinoma	prep_with	28	SENT_118	[p8l969t1519r1521b1579],
34	of	IN	O	of	_	0	SENT_118	[p8l1545t1519r1622b1579],
35	the	DT	O	the	det	36	SENT_118	[p8l1633t1519r1734b1578],
36	lung	NN	O	lung	prep_of	33	SENT_118	[p8l1759t1519r1923b1596],
37	.	.	O	.	_	0	SENT_118	[p8l1759t1519r1923b1596],

1	J	NNP	O	J	nn	3	SENT_119	[p8l1943t1525r1972b1588],
2	Thorac	NNP	O	Thorac	nn	3	SENT_119	[p8l1993t1519r2149b1579, p8l9t1615r106b1655],
3	Oncol	NNP	O	Oncol	_	0	SENT_119	[p8l132t1596r327b1655],
4	2009	CD	DATE	2009	num	3	SENT_119	[p8l353t1596r784b1671],
5	;	:	O	;	_	0	SENT_119	[p8l353t1596r784b1671],
6	4	CD	NUMBER	4	dep	3	SENT_119	[p8l353t1596r784b1671],
7	:	:	O	:	_	0	SENT_119	[p8l353t1596r784b1671],
8	Suppl	NN	O	suppl	dep	3	SENT_119	[p8l353t1596r784b1671],
9	1	CD	NUMBER	1	num	8	SENT_119	[p8l812t1600r1044b1656],
10	:	:	O	:	_	0	SENT_119	[p8l812t1600r1044b1656],
11	S283	NN	O	s283	dep	8	SENT_119	[p8l812t1600r1044b1656],
12	.	.	O	.	_	0	SENT_119	[p8l812t1600r1044b1656],

1	abstract	JJ	O	abstract	_	0	SENT_120	[p8l1073t1596r1356b1655],
2	.	.	O	.	_	0	SENT_120	[p8l1073t1596r1356b1655],

1	3	LS	NUMBER	3	_	0	SENT_121	[p8l9t1681r61b1733],
2	.	.	O	.	_	0	SENT_121	[p8l9t1681r61b1733],

1	Inoue	NNP	O	Inoue	nn	2	SENT_122	[p8l138t1679r328b1734],
2	A	NNP	O	A	_	0	SENT_122	[p8l357t1679r425b1746],
3	,	,	O	,	_	0	SENT_122	[p8l357t1679r425b1746],
4	Kobayashi	NNP	PERSON	Kobayashi	nn	5	SENT_122	[p8l460t1674r807b1749],
5	K	NNP	PERSON	K	appos	2	SENT_122	[p8l838t1679r905b1746],
6	,	,	O	,	_	0	SENT_122	[p8l838t1679r905b1746],
7	Maemondo	NNP	O	Maemondo	nn	8	SENT_122	[p8l938t1674r1317b1733],
8	M	NNP	O	M	appos	2	SENT_122	[p8l1346t1679r1430b1746],
9	,	,	O	,	_	0	SENT_122	[p8l1346t1679r1430b1746],
10	et	FW	O	et	nn	11	SENT_122	[p8l1466t1687r1526b1733],
11	al.	FW	O	al.	appos	2	SENT_122	[p8l1553t1674r1630b1733],
12	.	.	O	.	_	0	SENT_122	[p8l1553t1674r1630b1733],

1	A	DT	O	a	det	3	SENT_123	[p8l1662t1679r1712b1732],
2	randomized	JJ	O	randomized	amod	3	SENT_123	[p8l1742t1674r2150b1733],
3	phase	NN	O	phase	_	0	SENT_123	[p8l8t1753r203b1829],
4	III	CD	NUMBER	iii	num	5	SENT_123	[p8l225t1758r304b1812],
5	study	NN	O	study	dep	3	SENT_123	[p8l327t1753r508b1829],
6	comparing	VBG	O	compare	partmod	3	SENT_123	[p8l528t1754r897b1830],
7	gefitinib	NN	O	gefitinib	dobj	6	SENT_123	[p8l916t1753r1210b1830],
8	with	IN	O	with	_	0	SENT_123	[p8l1231t1753r1383b1813],
9	carboplatinlpaclitaxel	NN	O	carboplatinlpaclitaxel	prep_with	6	SENT_123	[p8l1407t1753r2150b1829],
10	for	IN	O	for	_	0	SENT_123	[p8l9t1831r106b1891],
11	the	DT	O	the	det	13	SENT_123	[p8l135t1831r239b1890],
12	first-line	JJ	O	first-line	amod	13	SENT_123	[p8l270t1831r564b1890],
13	treatment	NN	O	treatment	prep_for	9	SENT_123	[p8l596t1844r929b1890],
14	of	IN	O	of	_	0	SENT_123	[p8l958t1831r1035b1891],
15	non-small	JJ	O	non-small	amod	18	SENT_123	[p8l1051t1831r1395b1891],
16	cell	NN	O	cell	nn	18	SENT_123	[p8l1426t1831r1542b1890],
17	lung	NN	O	lung	nn	18	SENT_123	[p8l1571t1831r1722b1908],
18	cancer	NN	O	cancer	prep_of	13	SENT_123	[p8l1752t1851r1972b1890],
19	With	IN	O	with	_	0	SENT_123	[p8l1998t1831r2150b1891],
20	sensitive	JJ	O	sensitive	amod	22	SENT_123	[p8l10t1909r299b1968],
21	EGFR	NN	ORGANIZATION	egfr	nn	22	SENT_123	[p8l323t1912r521b1970],
22	mutations	NNS	O	mutation	prep_with	18	SENT_123	[p8l539t1909r901b1968],
23	:	:	O	:	_	0	SENT_123	[p8l539t1909r901b1968],
24	N	NN	O	n	nn	26	SENT_123	[p8l928t1913r984b1968],
25	EJO02	NN	O	ejo02	nn	26	SENT_123	[p8l988t1912r1175b1977],
26	study	NN	O	study	dep	18	SENT_123	[p8l1202t1908r1395b1983],
27	.	.	O	.	_	0	SENT_123	[p8l1202t1908r1395b1983],

1	Eur	NNP	MISC	Eur	nn	3	SENT_124	[p8l1423t1913r1583b1977],
2	]	NNP	O	]	nn	3	SENT_124	[p8l1423t1913r1583b1977],
3	Cancer	NNP	O	Cancer	_	0	SENT_124	[p8l1606t1912r1841b1967],
4	2009	CD	DATE	2009	num	6	SENT_124	[p8l1864t1912r2147b1979],
5	;	:	O	;	_	0	SENT_124	[p8l1864t1912r2147b1979],
6	45	CD	NUMBER	45	dep	3	SENT_124	[p8l1864t1912r2147b1979],
7	:	:	O	:	_	0	SENT_124	[p8l1864t1912r2147b1979],
8	Suppl	NNP	O	Suppl	dep	3	SENT_124	[p8l11t1985r197b2060],
9	1:9	CD	NUMBER	1:9	num	8	SENT_124	[p8l227t1989r483b2044],
10	LBA	NNP	ORGANIZATION	LBA	dep	8	SENT_124	[p8l227t1989r483b2044],
11	.	.	O	.	_	0	SENT_124	[p8l227t1989r483b2044],

1	abstract	JJ	O	abstract	_	0	SENT_125	[p8l514t1985r803b2044],
2	.	.	O	.	_	0	SENT_125	[p8l514t1985r803b2044],

1	4	LS	NUMBER	4	_	0	SENT_126	[p8l8t2089r62b2140],
2	.	.	O	.	_	0	SENT_126	[p8l8t2089r62b2140],

1	Tsurutani	JJ	PERSON	tsurutani	amod	2	SENT_127	[p8l137t2082r461b2141],
2	J	NN	PERSON	j	_	0	SENT_127	[p8l476t2087r519b2153],
3	,	,	O	,	_	0	SENT_127	[p8l476t2087r519b2153],
4	Mitsudomi	NNP	ORGANIZATION	Mitsudomi	nn	5	SENT_127	[p8l545t2082r907b2141],
5	T	NN	ORGANIZATION	t	appos	2	SENT_127	[p8l927t2086r985b2153],
6	,	,	O	,	_	0	SENT_127	[p8l927t2086r985b2153],
7	Mori	NNP	LOCATION	Mori	nn	8	SENT_127	[p8l1011t2082r1169b2140],
8	S	NNP	LOCATION	S	appos	2	SENT_127	[p8l1193t2086r1244b2153],
9	,	,	O	,	_	0	SENT_127	[p8l1193t2086r1244b2153],
10	et	FW	O	et	nn	11	SENT_127	[p8l1272t2094r1331b2140],
11	al.	FW	O	al.	appos	2	SENT_127	[p8l1350t2082r1425b2140],
12	.	.	O	.	_	0	SENT_127	[p8l1350t2082r1425b2140],

1	A	DT	O	a	det	2	SENT_128	[p8l1449t2087r1500b2139],
2	phase	NN	O	phase	_	0	SENT_128	[p8l1519t2082r1709b2157],
3	III	CD	NUMBER	iii	num	2	SENT_128	[p8l1731t2087r1826b2153],
4	,	,	O	,	_	0	SENT_128	[p8l1731t2087r1826b2153],
5	first	RB	ORDINAL	first	advmod	2	SENT_128	[p8l1854t2081r2140b2140],
6	—	CD	NUMBER	—	num	8	SENT_128	[p8l1854t2081r2140b2140],
7	line	NN	O	line	nn	8	SENT_128	[p8l1854t2081r2140b2140],
8	trial	NN	O	trial	dep	2	SENT_128	[p8l11t2178r148b2236],
9	of	IN	O	of	_	0	SENT_128	[p8l171t2177r247b2236],
10	gefitinib	NN	O	gefitinib	prep_of	8	SENT_128	[p8l256t2177r543b2253],
11	versus	CC	O	versus	prep	10	SENT_128	[p8l563t2197r768b2237],
12	cisplatin	NN	O	cisplatin	dep	11	SENT_128	[p8l793t2178r1076b2253],
13	plus	CC	O	plus	_	0	SENT_128	[p8l1097t2178r1232b2253],
14	docetaxel	NN	O	docetaxel	npadvmod	8	SENT_128	[p8l1258t2178r1570b2236],
15	for	IN	O	for	_	0	SENT_128	[p8l1592t2177r1686b2236],
16	patients	NNS	O	patient	prep_for	14	SENT_128	[p8l1707t2178r1969b2253],
17	with	IN	O	with	_	0	SENT_128	[p8l1991t2178r2140b2237],
18	advanced	JJ	O	advanced	amod	23	SENT_128	[p8l10t2274r314b2333],
19	or	CC	O	or	_	0	SENT_128	[p8l343t2293r411b2332],
20	recurrent	JJ	O	recurrent	conj_or	18	SENT_128	[p8l438t2286r745b2333],
21	non-small	JJ	O	non-small	amod	23	SENT_128	[p8l770t2274r1105b2332],
22	cell	NN	O	cell	nn	23	SENT_128	[p8l1135t2274r1247b2332],
23	lung	NN	O	lung	prep_with	8	SENT_128	[p8l1274t2274r1422b2349],
24	cancer	NN	O	cancer	nn	26	SENT_128	[p8l1450t2293r1665b2332],
25	(	CD	NUMBER	(	num	26	SENT_128	[p8l1696t2278r1973b2342],
26	NSCLC	NN	O	nsclc	dep	8	SENT_128	[p8l1696t2278r1973b2342],
27	)	CD	NUMBER	)	num	26	SENT_128	[p8l1696t2278r1973b2342],
28	harboring	VBG	O	harbor	partmod	8	SENT_128	[p8l2006t2274r2139b2332, p8l11t2370r231b2445],
29	activating	VBG	O	activate	xcomp	28	SENT_128	[p8l263t2370r587b2445],
30	mutation	NN	O	mutation	dobj	29	SENT_128	[p8l619t2370r920b2429],
31	of	IN	O	of	_	0	SENT_128	[p8l955t2369r1031b2428],
32	the	DT	O	the	det	35	SENT_128	[p8l1052t2370r1153b2428],
33	epidermal	JJ	O	epidermal	amod	35	SENT_128	[p8l1188t2370r1520b2445],
34	growth	NN	O	growth	nn	35	SENT_128	[p8l1554t2370r1794b2445],
35	factor	NN	O	factor	prep_of	30	SENT_128	[p8l1828t2369r2021b2428],
36	re	NN	O	re	nn	42	SENT_128	[p8l2053t2389r2139b2428],
37	—	NN	O	—	nn	42	SENT_128	[p8l2053t2389r2139b2428],
38	ceptor	NN	O	ceptor	nn	42	SENT_128	[p8l11t2478r218b2541],
39	(	CD	NUMBER	(	num	42	SENT_128	[p8l250t2470r484b2534],
40	EGFR	NN	ORGANIZATION	egfr	nn	42	SENT_128	[p8l250t2470r484b2534],
41	)	NN	O	)	nn	42	SENT_128	[p8l250t2470r484b2534],
42	gene	NN	O	gene	dep	35	SENT_128	[p8l518t2485r690b2541],
43	:	:	O	:	_	0	SENT_128	[p8l518t2485r690b2541],
44	preliminary	JJ	O	preliminary	amod	45	SENT_128	[p8l721t2466r1117b2541],
45	results	NNS	O	result	dep	2	SENT_128	[p8l1143t2466r1361b2525],
46	of	IN	O	of	_	0	SENT_128	[p8l1393t2465r1469b2524],
47	WJTOG	NNP	O	WJTOG	prep_of	45	SENT_128	[p8l1483t2470r1741b2534],
48	3405	CD	NUMBER	3405	num	47	SENT_128	[p8l1772t2470r1946b2525],
49	.	.	O	.	_	0	SENT_128	[p8l1772t2470r1946b2525],

1	Eur	NNP	MISC	Eur	nn	3	SENT_129	[p8l1979t2471r2142b2534],
2	]	NNP	O	]	nn	3	SENT_129	[p8l1979t2471r2142b2534],
3	Cancer	NNP	O	Cancer	_	0	SENT_129	[p8l10t2566r239b2620],
4	2009	CD	DATE	2009	num	3	SENT_129	[p8l263t2562r729b2637],
5	;	:	O	;	_	0	SENT_129	[p8l263t2562r729b2637],
6	45	CD	NUMBER	45	dep	3	SENT_129	[p8l263t2562r729b2637],
7	:	:	O	:	_	0	SENT_129	[p8l263t2562r729b2637],
8	Suppl	NNP	O	Suppl	dep	6	SENT_129	[p8l263t2562r729b2637],
9	1:9.002	CD	NUMBER	1:9.002	num	8	SENT_129	[p8l757t2566r1008b2620],
10	.	.	O	.	_	0	SENT_129	[p8l757t2566r1008b2620],

1	abstract	JJ	O	abstract	_	0	SENT_130	[p8l1038t2562r1320b2620],
2	.	.	O	.	_	0	SENT_130	[p8l1038t2562r1320b2620],

1	DR.	NNP	O	DR.	nn	2	SENT_131	[p8l17t2855r153b2910],
2	ROSELL	NNP	PERSON	ROSELL	nsubj	28	SENT_131	[p8l185t2854r493b2910],
3	AND	CC	O	and	_	0	SENT_131	[p8l517t2855r699b2909],
4	COLLEAGUES	NNS	O	colleague	nn	5	SENT_131	[p8l727t2854r1276b2910],
5	REPLY	NN	O	reply	conj_and	2	SENT_131	[p8l1309t2855r1575b2910],
6	:	:	O	:	_	0	SENT_131	[p8l1309t2855r1575b2910],
7	In	IN	O	in	_	0	SENT_131	[p8l1603t2839r1692b2909],
8	our	PRP$	O	we	poss	9	SENT_131	[p8l1719t2857r1865b2910],
9	study	NN	O	study	prep_in	14	SENT_131	[p8l1890t2831r2133b2932],
10	,	,	O	,	_	0	SENT_131	[p8l1890t2831r2133b2932],
11	we	PRP	O	we	nsubj	14	SENT_131	[p8l7t2986r125b3038],
12	could	MD	O	could	aux	14	SENT_131	[p8l161t2959r395b3038],
13	not	RB	O	not	neg	14	SENT_131	[p8l430t2976r573b3038],
14	evaluate	VB	O	evaluate	dep	2	SENT_131	[p8l603t2959r950b3038],
15	the	DT	O	the	det	16	SENT_131	[p8l985t2959r1118b3038],
16	response	NN	O	response	dobj	14	SENT_131	[p8l1153t2985r1535b3060],
17	to	TO	O	to	_	0	SENT_131	[p8l1571t2976r1652b3038],
18	treatment	NN	O	treatment	prep_to	14	SENT_131	[p8l1689t2976r2134b3055],
19	,	,	O	,	_	0	SENT_131	[p8l1689t2976r2134b3055],
20	according	VBG	O	accord	_	0	SENT_131	[p8l11t3087r430b3188],
21	to	TO	O	to	prepc_according_to	14	SENT_131	[p8l457t3104r538b3166],
22	Response	NN	O	response	nn	24	SENT_131	[p8l567t3094r971b3188],
23	Evaluation	NN	O	evaluation	nn	24	SENT_131	[p8l1000t3087r1443b3166],
24	Criteria	NNS	O	criterion	pobj	14	SENT_131	[p8l1473t3088r1789b3166],
25	in	IN	O	in	_	0	SENT_131	[p8l1817t3088r1899b3165],
26	Solid	JJ	MISC	solid	amod	27	SENT_131	[p8l1932t3087r2139b3166],
27	Tumors	NNS	MISC	tumor	prep_in	2	SENT_131	[p8l8t3221r337b3294],
28	(	VBP	O	(	_	0	SENT_131	[p8l396t3221r813b3311],
29	RECIST	NN	O	recist	dobj	28	SENT_131	[p8l396t3221r813b3311],
30	)	CD	NUMBER	)	num	29	SENT_131	[p8l396t3221r813b3311],
31	,	,	O	,	_	0	SENT_131	[p8l396t3221r813b3311],
32	in	IN	O	in	_	0	SENT_131	[p8l870t3216r953b3293],
33	20	CD	NUMBER	20	num	34	SENT_131	[p8l1005t3221r1105b3294],
34	patients	NNS	O	patient	prep_in	29	SENT_131	[p8l1157t3216r1524b3316],
35	,	,	O	,	_	0	SENT_131	[p8l1157t3216r1524b3316],
36	all	DT	O	all	dep	37	SENT_131	[p8l1581t3215r1686b3294],
37	of	IN	O	of	nsubj	42	SENT_131	[p8l1739t3215r1839b3294],
38	whom	WP	O	whom	pobj	37	SENT_131	[p8l1868t3215r2139b3294],
39	were	VBD	O	be	cop	42	SENT_131	[p8l7t3370r209b3422],
40	disease	NN	O	disease	npadvmod	42	SENT_131	[p8l247t3343r759b3422],
41	—	CD	NUMBER	—	num	40	SENT_131	[p8l247t3343r759b3422],
42	free	JJ	O	free	rcmod	34	SENT_131	[p8l247t3343r759b3422],
43	at	IN	O	at	_	0	SENT_131	[p8l796t3360r874b3422],
44	the	DT	O	the	det	45	SENT_131	[p8l907t3343r1040b3422],
45	time	NN	O	time	prep_at	42	SENT_131	[p8l1078t3344r1271b3422],
46	of	IN	O	of	_	0	SENT_131	[p8l1309t3343r1409b3422],
47	publication	NN	O	publication	prep_of	45	SENT_131	[p8l1427t3343r1939b3444],
48	.	.	O	.	_	0	SENT_131	[p8l1427t3343r1939b3444],

1	The	DT	O	the	det	2	SENT_132	[p8l1978t3343r2139b3422],
2	response	NN	O	response	nsubj	14	SENT_132	[p8l11t3497r393b3572],
3	in	IN	O	in	_	0	SENT_132	[p8l442t3472r526b3549],
4	the	DT	O	the	det	6	SENT_132	[p8l576t3471r708b3550],
5	55	CD	NUMBER	55	num	6	SENT_132	[p8l761t3479r853b3550],
6	patients	NNS	O	patient	prep_in	2	SENT_132	[p8l905t3472r1246b3572],
7	who	WP	O	who	nsubj	8	SENT_132	[p8l1294t3471r1478b3550],
8	received	VBD	O	receive	rcmod	6	SENT_132	[p8l1528t3471r1875b3550],
9	additional	JJ	O	additional	amod	10	SENT_132	[p8l1924t3471r2138b3550, p8l12t3600r257b3679],
10	treatment	NN	O	treatment	dobj	8	SENT_132	[p8l286t3617r702b3679],
11	after	IN	O	after	_	0	SENT_132	[p8l726t3600r924b3679],
12	erlotinib	NN	O	erlotinib	prep_after	8	SENT_132	[p8l952t3600r1311b3679],
13	was	VBD	O	be	cop	14	SENT_132	[p8l1338t3627r1499b3679],
14	similar	JJ	O	similar	_	0	SENT_132	[p8l1533t3600r1832b3679],
15	to	TO	O	to	_	0	SENT_132	[p8l1860t3617r1941b3679],
16	that	DT	O	that	prep_to	14	SENT_132	[p8l1972t3600r2145b3679],
17	in	IN	O	in	_	0	SENT_132	[p9l11t32r94b109],
18	the	DT	O	the	det	21	SENT_132	[p9l129t31r262b110],
19	entire	JJ	O	entire	amod	21	SENT_132	[p9l297t32r544b110],
20	cohort	NN	O	cohort	nn	21	SENT_132	[p9l579t31r862b110],
21	(	NN	O	(	prep_in	16	SENT_132	[p9l896t37r968b123],
22	4	CD	NUMBER	4	tmod	14	SENT_132	[p9l896t37r968b123],
23	with	IN	O	with	_	0	SENT_132	[p9l998t31r1193b111],
24	a	DT	O	a	det	26	SENT_132	[p9l1227t58r1272b110],
25	complete	JJ	O	complete	amod	26	SENT_132	[p9l1306t31r1695b132],
26	response	NN	O	response	prep_with	14	SENT_132	[p9l1729t57r2134b132],
27	,	,	O	,	_	0	SENT_132	[p9l1729t57r2134b132],
28	36	CD	NUMBER	36	prep_with	14	SENT_132	[p9l12t165r111b238],
29	with	IN	O	with	_	0	SENT_132	[p9l140t159r336b238],
30	a	DT	O	a	det	32	SENT_132	[p9l369t186r413b238],
31	partial	JJ	O	partial	amod	32	SENT_132	[p9l444t159r732b260],
32	response	NN	O	response	prep_with	28	SENT_132	[p9l765t185r1170b260],
33	,	,	O	,	_	0	SENT_132	[p9l765t185r1170b260],
34	8	CD	NUMBER	8	prep_with	14	SENT_132	[p9l1210t165r1254b238],
35	with	IN	O	with	_	0	SENT_132	[p9l1286t159r1482b238],
36	stable	JJ	O	stable	amod	37	SENT_132	[p9l1517t159r1765b238],
37	disease	NN	O	disease	prep_with	34	SENT_132	[p9l1800t159r2134b255],
38	,	,	O	,	_	0	SENT_132	[p9l1800t159r2134b255],
39	5	CD	NUMBER	5	prep_with	14	SENT_132	[p9l13t295r56b366],
40	with	IN	O	with	_	0	SENT_132	[p9l81t287r274b366],
41	progressive	JJ	O	progressive	amod	42	SENT_132	[p9l298t288r778b388],
42	disease	NN	O	disease	prep_with	39	SENT_132	[p9l805t287r1131b383],
43	,	,	O	,	_	0	SENT_132	[p9l805t287r1131b383],
44	and	CC	O	and	_	0	SENT_132	[p9l1162t287r1319b366],
45	2	CD	NUMBER	2	prep_with	14	SENT_132	[p9l1344t293r1392b365],
46	with	IN	O	with	_	0	SENT_132	[p9l1414t287r1607b366],
47	no	DT	O	no	det	48	SENT_132	[p9l1633t313r1738b366],
48	response	NN	O	response	prep_with	45	SENT_132	[p9l1765t313r2139b388],
49	that	WDT	O	that	nsubjpass	52	SENT_132	[p9l12t415r187b494],
50	could	MD	O	could	aux	52	SENT_132	[p9l225t415r464b494],
51	be	VB	O	be	auxpass	52	SENT_132	[p9l506t415r604b494],
52	evaluated	VBN	O	evaluate	rcmod	48	SENT_132	[p9l647t415r1114b507],
53	)	RB	O	)	advmod	52	SENT_132	[p9l647t415r1114b507],
54	.	.	O	.	_	0	SENT_132	[p9l647t415r1114b507],

1	For	IN	O	for	_	0	SENT_133	[p9l1161t423r1306b494],
2	the	DT	O	the	det	4	SENT_133	[p9l1345t415r1480b494],
3	34	CD	NUMBER	34	num	4	SENT_133	[p9l1523t421r1625b494],
4	patients	NNS	O	patient	prep_for	41	SENT_133	[p9l1665t416r2015b516],
5	(	IN	O	(	mark	9	SENT_133	[p9l2065t421r2139b507],
6	1	CD	NUMBER	1	num	7	SENT_133	[p9l2065t421r2139b507],
7	patient	NN	O	patient	nsubjpass	9	SENT_133	[p9l10t544r312b644],
8	was	VBD	O	be	auxpass	9	SENT_133	[p9l333t570r495b623],
9	counted	VBN	O	count	advcl	41	SENT_133	[p9l528t543r872b622],
10	twice	RB	O	twice	advmod	9	SENT_133	[p9l902t544r1130b622],
11	in	IN	O	in	_	0	SENT_133	[p9l1159t544r1243b621],
12	the	DT	O	the	det	14	SENT_133	[p9l1272t543r1405b622],
13	report	NN	O	report	nn	14	SENT_133	[p9l1435t550r1725b644],
14	)	NN	O	)	prep_in	9	SENT_133	[p9l1435t550r1725b644],
15	in	IN	O	in	_	0	SENT_133	[p9l1760t544r1843b621],
16	whom	WP	O	whom	rel	21	SENT_133	[p9l1868t543r2140b623],
17	the	DT	O	the	det	19	SENT_133	[p9l12t671r144b750],
18	T79OM	NN	O	t79om	nn	19	SENT_133	[p9l181t677r484b750],
19	mutation	NN	O	mutation	nsubjpass	21	SENT_133	[p9l525t672r919b750],
20	was	VBD	O	be	auxpass	21	SENT_133	[p9l954t698r1117b751],
21	assessed	VBN	O	assess	rcmod	14	SENT_133	[p9l1158t671r1527b750],
22	in	IN	O	in	_	0	SENT_133	[p9l1567t672r1650b749],
23	a	DT	O	a	det	26	SENT_133	[p9l1689t698r1734b750],
24	repeated	VBN	O	repeat	amod	26	SENT_133	[p9l1772t671r2140b772],
25	tumor	NN	O	tumor	nn	26	SENT_133	[p9l12t816r280b878],
26	biopsy	NN	O	biopsy	prep_in	21	SENT_133	[p9l324t799r603b900],
27	and	CC	O	and	_	0	SENT_133	[p9l643t799r802b878],
28	in	IN	O	in	_	0	SENT_133	[p9l847t800r931b877],
29	serum	NN	O	serum	conj_and	14	SENT_133	[p9l978t825r1247b878],
30	at	IN	O	at	_	0	SENT_133	[p9l1293t816r1372b878],
31	the	DT	O	the	det	32	SENT_133	[p9l1413t799r1545b878],
32	time	NN	O	time	prep_at	29	SENT_133	[p9l1593t800r1786b878],
33	of	IN	O	of	_	0	SENT_133	[p9l1833t799r1933b878],
34	progression	NN	O	progression	prep_of	32	SENT_133	[p9l1959t825r2138b900, p9l11t928r398b1028],
35	,	,	O	,	_	0	SENT_133	[p9l1959t825r2138b900, p9l11t928r398b1028],
36	the	DT	O	the	det	39	SENT_133	[p9l440t927r573b1006],
37	initial	JJ	O	initial	amod	39	SENT_133	[p9l609t927r866b1006],
38	response	NN	O	response	nn	39	SENT_133	[p9l902t953r1284b1028],
39	rate	NN	O	rate	nsubj	41	SENT_133	[p9l1320t944r1481b1006],
40	was	VBD	O	be	cop	41	SENT_133	[p9l1513t954r1676b1006],
41	similar	JJ	O	similar	_	0	SENT_133	[p9l1716t927r2023b1006],
42	to	TO	O	to	_	0	SENT_133	[p9l2056t944r2138b1006],
43	that	DT	O	that	prep_to	41	SENT_133	[p9l12t1055r184b1134],
44	for	IN	O	for	_	0	SENT_133	[p9l208t1055r332b1134],
45	all	PDT	O	all	predet	47	SENT_133	[p9l357t1055r462b1134],
46	the	DT	O	the	det	47	SENT_133	[p9l491t1055r624b1134],
47	patients	NNS	O	patient	prep_for	43	SENT_133	[p9l652t1056r1019b1156],
48	.	.	O	.	_	0	SENT_133	[p9l652t1056r1019b1156],

1	At	IN	O	at	_	0	SENT_134	[p9l1050t1063r1149b1134],
2	the	DT	O	the	det	3	SENT_134	[p9l1174t1055r1307b1134],
3	time	NN	O	time	prep_at	15	SENT_134	[p9l1337t1056r1530b1134],
4	the	DT	O	the	det	5	SENT_134	[p9l1560t1055r1693b1134],
5	study	NN	O	study	nsubjpass	7	SENT_134	[p9l1724t1055r1954b1156],
6	was	VBD	O	be	auxpass	7	SENT_134	[p9l1974t1082r2138b1135],
7	designed	VBN	O	design	dep	15	SENT_134	[p9l12t1183r395b1284],
8	(	CD	NUMBER	(	num	9	SENT_134	[p9l429t1183r670b1284],
9	April	NNP	DATE	April	dobj	7	SENT_134	[p9l429t1183r670b1284],
10	2005	CD	DATE	2005	num	9	SENT_134	[p9l699t1189r959b1279],
11	)	CD	NUMBER	)	dep	9	SENT_134	[p9l699t1189r959b1279],
12	,	,	O	,	_	0	SENT_134	[p9l699t1189r959b1279],
13	little	RB	O	little	advmod	15	SENT_134	[p9l993t1183r1191b1262],
14	was	VBD	O	be	auxpass	15	SENT_134	[p9l1215t1210r1378b1262],
15	known	VBN	O	know	_	0	SENT_134	[p9l1409t1183r1708b1263],
16	about	IN	O	about	_	0	SENT_134	[p9l1737t1183r1981b1262],
17	the	DT	O	the	det	19	SENT_134	[p9l2006t1183r2139b1262],
18	T79OM	NN	O	t79om	nn	19	SENT_134	[p9l8t1317r311b1390],
19	mutation	NN	O	mutation	prep_about	15	SENT_134	[p9l352t1312r809b1390],
20	}	CD	NUMBER	}	nsubjpass	15	SENT_134	[p9l352t1312r809b1390],
21	We	PRP	O	we	nsubj	24	SENT_134	[p9l846t1319r979b1390],
22	are	VBP	O	be	aux	24	SENT_134	[p9l1018t1338r1148b1390],
23	now	RB	DATE	now	advmod	24	SENT_134	[p9l1188t1337r1373b1390],
24	investigating	VBG	O	investigate	rcmod	20	SENT_134	[p9l1408t1312r1969b1412],
25	the	DT	O	the	det	26	SENT_134	[p9l2006t1311r2139b1390],
26	presence	NN	O	presence	dobj	24	SENT_134	[p9l10t1465r386b1540],
27	of	IN	O	of	_	0	SENT_134	[p9l420t1439r520b1518],
28	the	DT	O	the	det	31	SENT_134	[p9l535t1439r668b1518],
29	T	NN	O	t	nn	31	SENT_134	[p9l697t1445r759b1517],
30	790M	NN	O	790m	nn	31	SENT_134	[p9l763t1445r1001b1518],
31	mutation	NN	O	mutation	prep_of	26	SENT_134	[p9l1034t1440r1429b1518],
32	at	IN	O	at	_	0	SENT_134	[p9l1461t1456r1540b1518],
33	baseline	NN	O	baseline	prep_at	24	SENT_134	[p9l1568t1439r1944b1535],
34	,	,	O	,	_	0	SENT_134	[p9l1568t1439r1944b1535],
35	and	CC	O	and	_	0	SENT_134	[p9l1982t1439r2140b1518],
36	our	PRP$	O	we	poss	37	SENT_134	[p9l12t1593r160b1646],
37	findings	NNS	O	finding	nsubj	39	SENT_134	[p9l210t1567r583b1668],
38	are	VBP	O	be	cop	39	SENT_134	[p9l638t1593r769b1646],
39	similar	JJ	O	similar	conj_and	15	SENT_134	[p9l824t1567r1138b1646],
40	to	TO	O	to	_	0	SENT_134	[p9l1188t1584r1271b1646],
41	those	DT	O	those	prep_to	39	SENT_134	[p9l1326t1567r1563b1646],
42	reported	VBN	O	report	partmod	41	SENT_134	[p9l1616t1567r1991b1668],
43	by	IN	O	by	_	0	SENT_134	[p9l2045t1567r2144b1668],
44	Maheswaran	NNP	O	Maheswaran	agent	42	SENT_134	[p9l8t1695r563b1774],
45	et	FW	O	et	nn	46	SENT_134	[p9l598t1712r676b1774],
46	al.	FW	O	al.	tmod	42	SENT_134	[p9l705t1695r844b1774],
47	2	CD	NUMBER	2	dep	46	SENT_134	[p9l705t1695r844b1774],

1	Rafael	NNP	PERSON	Rafael	nn	2	SENT_135	[p9l20t1831r271b1913],
2	Rosell	NNP	PERSON	Rosell	_	0	SENT_135	[p9l316t1832r594b1927],
3	,	,	O	,	_	0	SENT_135	[p9l316t1832r594b1927],
4	M.D.	NNP	PERSON	M.D.	nn	6	SENT_135	[p9l639t1840r846b1913],
5	Miquel	NNP	PERSON	Miquel	nn	6	SENT_135	[p9l20t1961r311b2066],
6	Taron	NNP	PERSON	Taron	appos	2	SENT_135	[p9l346t1968r626b2056],
7	,	,	O	,	_	0	SENT_135	[p9l346t1968r626b2056],
8	Ph.D.	NNP	O	Ph.D.	appos	6	SENT_135	[p9l670t1961r900b2041],
9	.	.	O	.	_	0	SENT_135	[p9l670t1961r900b2041],

1	Catalan	NNP	ORGANIZATION	Catalan	nn	3	SENT_136	[p9l12t2110r259b2171],
2	Institute	NNP	ORGANIZATION	Institute	nn	3	SENT_136	[p9l293t2115r569b2171],
3	ofOnco	NNP	O	ofOnco	nsubj	4	SENT_136	[p9l593t2109r1006b2190],
4	|	VBD	O	|	_	0	SENT_136	[p9l593t2109r1006b2190],
5	ogy	NN	O	ogy	nn	6	SENT_136	[p9l593t2109r1006b2190],
6	Badalona	NNP	PERSON	Badalona	dobj	4	SENT_136	[p9l16t2194r343b2265],
7	,	,	O	,	_	0	SENT_136	[p9l16t2194r343b2265],
8	Spain	NNP	LOCATION	Spain	nn	9	SENT_136	[p9l372t2198r553b2273],
9	rrosell@iconcologia.net	NN	O	rrosell@iconcologia.net	appos	6	SENT_136	[p9l15t2278r825b2358],

1	Miguel	NNP	PERSON	Miguel	nn	3	SENT_137	[p9l20t2420r310b2526],
2	Angel	NNP	PERSON	Angel	nn	3	SENT_137	[p9l345t2420r589b2526],
3	Molina	NNP	PERSON	Molina	_	0	SENT_137	[p9l634t2420r956b2514],
4	,	,	O	,	_	0	SENT_137	[p9l634t2420r956b2514],
5	Ph.D.	NNP	O	Ph.D.	appos	3	SENT_137	[p9l1000t2420r1230b2500],
6	.	.	O	.	_	0	SENT_137	[p9l1000t2420r1230b2500],

1	USP	NNP	ORGANIZATION	USP	nn	5	SENT_138	[p9l15t2573r151b2630],
2	Dexeus	NNP	ORGANIZATION	Dexeus	nn	5	SENT_138	[p9l180t2574r419b2630],
3	University	NNP	ORGANIZATION	University	nn	5	SENT_138	[p9l449t2574r787b2648],
4	Institute	NNP	ORGANIZATION	Institute	nn	5	SENT_138	[p9l814t2574r1091b2630],
5	Barcelona	NNP	ORGANIZATION	Barcelona	_	0	SENT_138	[p9l16t2653r362b2724],
6	,	,	O	,	_	0	SENT_138	[p9l16t2653r362b2724],
7	Spain	NNP	LOCATION	Spain	appos	5	SENT_138	[p9l391t2657r572b2732],

1	1	LS	NUMBER	1	_	0	SENT_139	[p9l13t2856r62b2907],
2	.	.	O	.	_	0	SENT_139	[p9l13t2856r62b2907],

1	Inukai	NNP	PERSON	Inukai	nn	2	SENT_140	[p9l139t2848r352b2908],
2	M	NNP	O	M	_	0	SENT_140	[p9l390t2853r473b2920],
3	,	,	O	,	_	0	SENT_140	[p9l390t2853r473b2920],
4	Toyooka	NNP	PERSON	Toyooka	nn	5	SENT_140	[p9l515t2848r792b2923],
5	S	NNP	PERSON	S	appos	2	SENT_140	[p9l834t2852r886b2920],
6	,	,	O	,	_	0	SENT_140	[p9l834t2852r886b2920],
7	Ito	NNP	PERSON	Ito	nn	8	SENT_140	[p9l930t2853r1019b2907],
8	S	NNP	O	S	appos	2	SENT_140	[p9l1062t2852r1114b2919],
9	,	,	O	,	_	0	SENT_140	[p9l1062t2852r1114b2919],
10	et	FW	O	et	nn	11	SENT_140	[p9l1159t2861r1219b2907],
11	al.	FW	O	al.	appos	2	SENT_140	[p9l1255t2848r1330b2907],
12	.	.	O	.	_	0	SENT_140	[p9l1255t2848r1330b2907],

1	Presence	NN	O	presence	_	0	SENT_141	[p9l1374t2853r1663b2907],
2	of	IN	O	of	_	0	SENT_141	[p9l1704t2848r1781b2907],
3	epidermal	JJ	O	epidermal	amod	9	SENT_141	[p9l1809t2848r2140b2923],
4	growth	NN	O	growth	nn	9	SENT_141	[p9l10t2944r250b3020],
5	factor	NN	O	factor	nn	9	SENT_141	[p9l281t2944r474b3003],
6	receptor	NN	O	receptor	nn	9	SENT_141	[p9l501t2957r775b3019],
7	gene	NN	O	gene	nn	9	SENT_141	[p9l803t2963r955b3020],
8	T79OM	NN	O	t79om	nn	9	SENT_141	[p9l983t2949r1214b3003],
9	mutation	NN	O	mutation	prep_of	1	SENT_141	[p9l1245t2945r1546b3003],
10	as	IN	O	as	_	0	SENT_141	[p9l1576t2963r1641b3002],
11	a	DT	O	a	det	13	SENT_141	[p9l1673t2963r1707b3002],
12	minor	JJ	O	minor	amod	13	SENT_141	[p9l1735t2945r1939b3003],
13	clone	NN	O	clone	prep_as	9	SENT_141	[p9l1968t2944r2140b3003],
14	in	IN	O	in	_	0	SENT_141	[p9l10t3041r73b3098],
15	non-small	JJ	O	non-small	amod	18	SENT_141	[p9l99t3040r434b3099],
16	cell	NN	O	cell	nn	18	SENT_141	[p9l460t3040r572b3098],
17	lung	NN	O	lung	nn	18	SENT_141	[p9l597t3040r745b3116],
18	cancer	NN	O	cancer	prep_in	1	SENT_141	[p9l769t3059r999b3099],
19	.	.	O	.	_	0	SENT_141	[p9l769t3059r999b3099],

1	Cancer	NN	O	cancer	_	0	SENT_142	[p9l1029t3044r1258b3099],
2	Res	NNP	O	Res	dep	1	SENT_142	[p9l1281t3045r1396b3102],
3	2006	CD	DATE	2006	num	2	SENT_142	[p9l1423t3044r1950b3111],
4	;	:	O	;	_	0	SENT_142	[p9l1423t3044r1950b3111],
5	66:7854	CD	NUMBER	66:7854	num	6	SENT_142	[p9l1423t3044r1950b3111],
6	-8	CD	NUMBER	-8	dep	1	SENT_142	[p9l1423t3044r1950b3111],
7	.	.	O	.	_	0	SENT_142	[p9l1423t3044r1950b3111],

1	2	LS	NUMBER	2	_	0	SENT_143	[p9l9t3143r63b3194],
2	.	.	O	.	_	0	SENT_143	[p9l9t3143r63b3194],

1	Maheswaran	NNP	MISC	Maheswaran	nn	2	SENT_144	[p9l137t3136r561b3195],
2	S	NNP	O	S	_	0	SENT_144	[p9l602t3141r653b3207],
3	,	,	O	,	_	0	SENT_144	[p9l602t3141r653b3207],
4	Sequist	NNP	O	Sequist	nn	5	SENT_144	[p9l698t3137r937b3211],
5	LV	NNP	O	LV	appos	2	SENT_144	[p9l971t3141r1061b3207],
6	,	,	O	,	_	0	SENT_144	[p9l971t3141r1061b3207],
7	Nagrath	NNP	PERSON	Nagrath	nn	8	SENT_144	[p9l1102t3136r1373b3212],
8	S	NNP	O	S	appos	2	SENT_144	[p9l1414t3140r1465b3208],
9	,	,	O	,	_	0	SENT_144	[p9l1414t3140r1465b3208],
10	et	FW	O	et	nn	11	SENT_144	[p9l1509t3149r1567b3194],
11	al.	FW	O	al.	appos	2	SENT_144	[p9l1602t3136r1676b3195],
12	.	.	O	.	_	0	SENT_144	[p9l1602t3136r1676b3195],

1	Detection	NN	O	detection	_	0	SENT_145	[p9l1718t3137r2038b3195],
2	of	IN	O	of	_	0	SENT_145	[p9l2078t3136r2153b3195],
3	mutations	NNS	O	mutation	prep_of	1	SENT_145	[p9l10t3233r344b3291],
4	in	IN	O	in	_	0	SENT_145	[p9l369t3233r432b3290],
5	EGFR	NN	ORGANIZATION	egfr	prep_in	3	SENT_145	[p9l454t3237r617b3292],
6	in	IN	O	in	_	0	SENT_145	[p9l635t3233r698b3290],
7	circulating	VBG	O	circulate	prepc_in	5	SENT_145	[p9l722t3232r1082b3308],
8	lung	NN	O	lung	nn	11	SENT_145	[p9l1103t3232r1496b3308],
9	—	NN	O	—	nn	11	SENT_145	[p9l1103t3232r1496b3308],
10	cancer	NN	O	cancer	nn	11	SENT_145	[p9l1103t3232r1496b3308],
11	cells	NNS	O	cell	dobj	7	SENT_145	[p9l1518t3232r1681b3291],
12	.	.	O	.	_	0	SENT_145	[p9l1518t3232r1681b3291],

1	N	NN	O	n	nn	2	SENT_146	[p9l1708t3237r1764b3291],
2	EnglJ	NN	O	englj	nsubj	3	SENT_146	[p9l1786t3232r1978b3308],
3	Med	VBD	O	med	_	0	SENT_146	[p9l1999t3232r2140b3291],
4	2008	CD	DATE	2008	dobj	3	SENT_146	[p9l11t3332r562b3398],
5	;	:	O	;	_	0	SENT_146	[p9l11t3332r562b3398],
6	359:366	CD	NUMBER	359:366	number	7	SENT_146	[p9l11t3332r562b3398],
7	—	CD	NUMBER	—	dep	4	SENT_146	[p9l11t3332r562b3398],
8	77	CD	NUMBER	77	dep	7	SENT_146	[p9l11t3332r562b3398],
9	.	.	O	.	_	0	SENT_146	[p9l11t3332r562b3398],

1	Asymptomatic	JJ	O	asymptomatic	amod	2	SENT_147	[p9l170t3475r549b3538],
2	Reactivation	NN	O	reactivation	_	0	SENT_147	[p9l573t3475r886b3523],
3	of	IN	O	of	_	0	SENT_147	[p9l910t3473r1034b3537],
4	'	''	O	'	_	0	SENT_147	[p9l910t3473r1034b3537],
5	jC	NNP	O	jC	nn	6	SENT_147	[p9l910t3473r1034b3537],
6	Virus	NN	O	virus	prep_of	2	SENT_147	[p9l1053t3475r1188b3523],
7	in	IN	O	in	dep	2	SENT_147	[p9l1211t3475r1254b3522],
8	Patients	NNS	O	patient	pobj	7	SENT_147	[p9l1281t3475r1488b3523],
9	Treated	VBN	O	treat	partmod	8	SENT_147	[p9l1508t3474r1700b3523],
10	with	IN	O	with	_	0	SENT_147	[p9l704t3549r814b3597],
11	Natalizumab	NN	PERSON	natalizumab	prep_with	9	SENT_147	[p9l841t3549r1169b3597],

1	TO	TO	O	to	aux	3	SENT_148	[p10l93t53r137b74],
2	THE	DT	O	the	det	3	SENT_148	[p10l149t53r212b74],
3	EDITOR	NN	O	editor	csubj	23	SENT_148	[p10l228t53r358b74],
4	:	:	O	:	_	0	SENT_148	[p10l228t53r358b74],
5	Chen	NNP	PERSON	Chen	nsubj	14	SENT_148	[p10l373t44r457b75],
6	and	CC	O	and	_	0	SENT_148	[p10l469t44r529b75],
7	colleagues	NNS	O	colleague	nsubj	14	SENT_148	[p10l542t44r712b83],
8	(	CD	NUMBER	(	num	7	SENT_148	[p10l727t46r814b83],
9	Sept.	NNP	DATE	Sept.	tmod	7	SENT_148	[p10l727t46r814b83],
10	10	CD	DATE	10	num	9	SENT_148	[p10l830t46r866b75],
11	is	VBZ	O	be	cop	14	SENT_148	[p10l878t44r917b74],
12	—	JJ	O	—	amod	14	SENT_148	[p10l878t44r917b74],
13	groups	NNS	O	group	nn	14	SENT_148	[p10l957t46r1104b83],
14	“	NN	O	“	dep	3	SENT_148	[p10l957t46r1104b83],
15	and	CC	O	and	_	0	SENT_148	[p10l1114t44r1173b75],
16	large	JJ	O	large	amod	17	SENT_148	[p10l1183t44r1263b83],
17	studies	NNS	O	study	conj_and	14	SENT_148	[p10l1274t44r1385b75],
18	by	IN	O	by	_	0	SENT_148	[p10l1396t44r1433b83],
19	Biogen	NNP	ORGANIZATION	Biogen	nn	20	SENT_148	[p10l1441t44r1552b83],
20	Idec	NNP	ORGANIZATION	Idec	prep_by	3	SENT_148	[p10l1561t44r1627b75],
21	and	CC	O	and	_	0	SENT_148	[p10l1637t44r1696b75],
22	Elan	NNP	ORGANIZATION	Elan	prep_by	3	SENT_148	[p10l1706t44r1780b74],
23	sue	VBP	O	sue	_	0	SENT_148	[p10l95t95r172b128],
24	)	CD	NUMBER	)	number	25	SENT_148	[p10l95t95r172b128],
25	1	CD	NUMBER	1	nsubj	26	SENT_148	[p10l95t95r172b128],
26	describe	VBP	O	describe	ccomp	23	SENT_148	[p10l185t93r323b124],
27	an	DT	O	a	det	29	SENT_148	[p10l335t103r375b123],
28	increased	VBN	O	increase	amod	29	SENT_148	[p10l387t93r545b124],
29	prevalence	NN	O	prevalence	dobj	26	SENT_148	[p10l557t93r732b132],
30	of	IN	O	of	_	0	SENT_148	[p10l745t93r822b128],
31	]	NN	O	]	nn	33	SENT_148	[p10l745t93r822b128],
32	C	NN	O	c	nn	33	SENT_148	[p10l745t93r822b128],
33	virus	NN	O	virus	prep_of	29	SENT_148	[p10l834t93r916b124],
34	Pharmaceuticals5	NN	O	pharmaceuticals5	nn	36	SENT_148	[p10l956t93r1246b124],
35	(	CD	NUMBER	(	num	36	SENT_148	[p10l1262t93r1362b128],
36	Table	NNP	O	Table	dep	33	SENT_148	[p10l1262t93r1362b128],
37	1	CD	NUMBER	1	number	38	SENT_148	[p10l1377t95r1414b128],
38	)	CD	NUMBER	)	dep	36	SENT_148	[p10l1377t95r1414b128],
39	.	.	O	.	_	0	SENT_148	[p10l1377t95r1414b128],

1	DNA	NN	O	dna	nsubj	14	SENT_149	[p10l93t145r174b173],
2	in	IN	O	in	_	0	SENT_149	[p10l188t142r221b172],
3	19	CD	NUMBER	19	num	4	SENT_149	[p10l238t144r275b173],
4	patients	NNS	O	patient	prep_in	1	SENT_149	[p10l290t142r423b181],
5	With	IN	O	with	_	0	SENT_149	[p10l437t142r513b173],
6	multiple	JJ	O	multiple	amod	7	SENT_149	[p10l529t142r667b181],
7	sclerosis	NN	O	sclerosis	prep_with	4	SENT_149	[p10l683t142r824b173],
8	after	IN	O	after	_	0	SENT_149	[p10l840t142r918b172],
9	Data	NNS	O	datum	prep_after	7	SENT_149	[p10l1006t145r1084b172],
10	from	IN	O	from	_	0	SENT_149	[p10l1100t142r1182b173],
11	one	CD	NUMBER	one	num	13	SENT_149	[p10l1199t152r1258b173],
12	ongoing	JJ	O	ongoing	amod	13	SENT_149	[p10l1275t142r1414b181],
13	study	NN	O	study	prep_from	9	SENT_149	[p10l1430t142r1519b181],
14	showed	VBD	O	show	_	0	SENT_149	[p10l1534t142r1660b173],
15	no	DT	O	no	det	16	SENT_149	[p10l1676t152r1717b173],
16	in12	NN	O	in12	dobj	14	SENT_149	[p10l1735t142r1779b172, p10l95t193r133b221],
17	to	TO	O	to	_	0	SENT_149	[p10l147t198r179b222],
18	18	CD	DURATION	18	num	19	SENT_149	[p10l194t193r231b222],
19	months	NNS	NUMBER	month	prep_to	14	SENT_149	[p10l245t191r372b222],
20	of	IN	O	of	_	0	SENT_149	[p10l387t191r425b222],
21	treatment	NN	O	treatment	prep_of	19	SENT_149	[p10l432t197r596b221],
22	with	IN	O	with	_	0	SENT_149	[p10l606t191r682b222],
23	natalizumab	NN	O	natalizumab	prep_with	14	SENT_149	[p10l695t191r915b222],
24	.	.	O	.	_	0	SENT_149	[p10l695t191r915b222],

1	crease	NN	O	crease	_	0	SENT_150	[p10l957t201r1059b221],
2	in	IN	O	in	_	0	SENT_150	[p10l1078t192r1110b221],
3	the	DT	O	the	det	4	SENT_150	[p10l1129t191r1181b221],
4	prevalence	NN	O	prevalence	prep_in	1	SENT_150	[p10l1199t191r1375b230],
5	of	IN	O	of	_	0	SENT_150	[p10l1394t191r1433b222],
6	JC	NN	O	jc	nn	7	SENT_150	[p10l1441t193r1478b226],
7	virus	NN	O	virus	prep_of	1	SENT_150	[p10l1496t191r1579b222],
8	in	IN	O	in	_	0	SENT_150	[p10l1598t191r1630b221],
9	plasma	NN	O	plasma	prep_in	7	SENT_150	[p10l1648t191r1777b230],
10	,	,	O	,	_	0	SENT_150	[p10l1648t191r1777b230],
11	These	DT	O	these	det	13	SENT_150	[p10l93t240r190b270],
12	findings	NNS	O	finding	nn	13	SENT_150	[p10l206t240r348b279],
13	contrast	NN	O	contrast	conj_or	7	SENT_150	[p10l365t247r501b271],
14	with	IN	O	with	_	0	SENT_150	[p10l514t240r589b271],
15	results	NNS	O	result	prep_with	13	SENT_150	[p10l605t240r715b271],
16	from	IN	O	from	_	0	SENT_150	[p10l732t240r814b271],
17	other	JJ	O	other	amod	18	SENT_150	[p10l830t240r918b271],
18	urine	NN	O	urine	prep_from	15	SENT_150	[p10l957t240r1055b277],
19	,	,	O	,	_	0	SENT_150	[p10l957t240r1055b277],
20	or	CC	O	or	_	0	SENT_150	[p10l1084t250r1118b271],
21	peripheral	JJ	O	peripheral	amod	23	SENT_150	[p10l1143t240r1429b279],
22	—	NN	O	—	nn	23	SENT_150	[p10l1143t240r1429b279],
23	blood	NN	O	blood	prep_of	1	SENT_150	[p10l1143t240r1429b279],
24	mononuclear	JJ	O	mononuclear	amod	25	SENT_150	[p10l1455t240r1679b271],
25	cells	NNS	O	cell	dep	23	SENT_150	[p10l1705t240r1779b270],

1	N	NN	O	n	nn	3	SENT_151	[p10l587t364r601b379],
2	ENGLJ	NN	O	englj	nn	3	SENT_151	[p10l616t364r694b386],
3	MED	NN	O	med	_	0	SENT_151	[p10l708t364r760b379],
4	361	CD	NUMBER	361	num	6	SENT_151	[p10l771t358r846b386],
5	;	:	O	;	_	0	SENT_151	[p10l771t358r846b386],
6	25	CD	NUMBER	25	dep	3	SENT_151	[p10l771t358r846b386],
7	NEJM	NNP	O	NEJM	dep	6	SENT_151	[p10l882t364r1006b386],
8	,	,	O	,	_	0	SENT_151	[p10l882t364r1006b386],
9	ORG	NNP	O	ORG	nn	10	SENT_151	[p10l882t364r1006b386],
10	DECEMBER	NNP	DATE	DECEMBER	appos	7	SENT_151	[p10l1043t364r1171b379],
11	17	CD	DATE	17	num	10	SENT_151	[p10l1182t364r1212b385],
12	,	,	DATE	,	_	0	SENT_151	[p10l1182t364r1212b385],
13	2009	CD	DATE	2009	num	10	SENT_151	[p10l1224t364r1288b385],
14	2487	CD	DATE	2487	dep	3	SENT_151	[p10l1990t354r2067b376],

1	The	DT	O	the	det	4	SENT_152	[p10l752t421r803b445],
2	New	NNP	O	New	nn	4	SENT_152	[p10l812t422r874b445],
3	England	NNP	O	England	nn	4	SENT_152	[p10l884t421r994b452],
4	Journal	NNP	O	Journal	_	0	SENT_152	[p10l1003t421r1100b445],
5	of	IN	O	of	_	0	SENT_152	[p10l1110t421r1139b445],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_152	[p10l1146t421r1271b445],

